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ABSTRACT 	
The purpose of this study was to determine whether genotype of some obesity-
related genes (FABP2, PPARG, ADRB2, ADRB3) impacts health outcomes from 
participation in a 6-month weight loss program. Fifty-one overweight/obese women 
(41.8 ± 12.1 yrs, 35.3 ± 8.0 kg/m2) were randomly assigned to diet based on genotype, 
true or false match. Dietary intervention included two hypocaloric (week 1: 1400 kcal/d, 
weeks 2-24: 1500 kcal/d), moderate protein (45% kcal from protein) diets with 
variations in carbohydrates and fat (LC- 20:35, MC- 30:25). Participants performed a 
resistance-exercise program four days/week, and 10,000 steps/day three days/week. 
Anthropometrics, body composition, REE, dietary data, biochemical markers, and 
psychosocial evaluation were collected monthly. VO2peak, muscular strength and 
endurance were assessed at baseline, 3- and 6-months. All measures were analyzed with 
repeated measures MANOVA. Significant genotype effects and trends favoring false 
matches were observed for body weight (F-5.6±5.0, T-5.0±5.0 kg, p=0.10), fat free mass 
(F-0.4±2.3, T-0.8±2.3 kg, p=0.09), android total mass (F-849.1±882.8, T-669.7±855.4 
grams, p=0.05), android fat mass (F-627±583, T-459±480 grams, p=0.07), gynoid fat 
free mass (F+3.0±665, T-199±534 grams, p=0.09), and fasting insulin (T+1.9±5.3, 
F+0.2±5.1 microIU/mL, p=0.04). Significant time x genotype interactions and trends 
favoring false were observed for triglycerides (T-9.9±62.3, F-35.5±49.1 mg/dL, p=0.05). 
Genotype effect favoring true was observed for android fat free mass (T-210.5±451.7, F-
222.0±463.8 grams, p=0.04), gynoid total mass (T-878±978, F-852±1073 grams, 
p=0.09), and hip circumference (T-5.1±5.5, F-4.9±3.7 cm, p=0.07). Significant genotype 
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x diet interaction and trend was observed in favor of true MC for LDL (TMC-15.8±26.7, 
FMC-8.6±34.2, FLC+3.7±28.1, TLC+10.1±26.3 mg/dL, p=0.02) and cholesterol (TMC-
26.0±32.1, FMC-23.5±32.0, FLC+7.0±31.8, TLC+8.5±35.8 mg/dL, p=0.06). Overall, 
false matches experienced greater improvements in body composition, fitness, and 
biochemical markers.  
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BMI Body Mass Index  
CHO Carbohydrate 
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CHAPTER I 
INTRODUCTION AND RATIONALE 
 
Background 
 In the United States, two-thirds of all adults are classified as overweight or 
obese.1 Currently, obesity is attributed to an interaction among multiple components, 
including physiological, metabolic, behavioral, social, and genetic factors.2 The latter 
has received significant attention as of late, with new findings from Genome Wide 
Association Studies identifying possible candidate genes related to the cause of obesity.3-
6 Identification of candidate genes associated with obesity is useful in determining both 
pharmacological treatment and optimal dietary intervention for weight loss. 
Dietary prescription based on genotype is an example of genetic profiling. 
Genetic profiling is used frequently in oncology to help determine treatment routes and 
predict clinical outcomes.7 Regarding obesity, the use of genetic profiling as a method to 
dictate treatment is a novel idea in its infancy.  
Few weight loss interventions to date have assigned dietary prescriptions based 
on genotype.7-9 Among the investigations conducted, the genetic profile used in the trial 
by Dopler-Nelson and colleagues demonstrated the most effective results.9 However, 
genotype matching to dietary intervention in this trial was retrospective. Therefore more 
research is warranted prospectively testing the genetic profile used in Dopler-Nelson and 
colleagues trial (FABP2 (rs1799883), PPARG2 (rs1801282), ADRB3 (rs4994C3), 
ADRB2 (rs1042713 and rs1042714)) in relation to dietary prescription and health 
  
 
2 
outcomes from weight loss interventions to validate the profile for use in a clinical 
setting. 
Statement of the Problem  
 Will prospective matching to dietary intervention based on variants within the 
following genetic profile, FABP2 (rs1799883), PPARG2 (rs1801282), ADRB3 
(rs4994C3), ADRB2 (rs1042713 and rs1042714), demonstrate improved health 
outcomes in apparently healthy, sedentary, overweight/obese women assigned to their 
diet group based on genotype (true match) in comparison to participants assigned to their 
diet group based on the opposite of their genotype (false match)?  
Purpose 
 The purpose of this study was to determine if participants truly matched to diet 
intervention based on genotype demonstrated greater health outcomes in comparison to 
participants falsely matched to diet intervention based on genotype.  
General Study Overview 
 Fifty-one, overweight or obese, apparently healthy, sedentary women were 
matched to a diet intervention based on variations in allele patterns within the following 
genetic profile: FABP2 (rs1799883), PPARG2 (rs1801282), ADRB3 (rs4994C3), 
ADRB2 (rs1042713 and rs1042714). DNA was collected from buccal cheek swabs and 
samples were sent out to Interleukin Genetics (Waltham, Ma) for genotyping. Once 
genotyping results were obtained, participants were randomly assigned to either a dietary 
intervention that aligned with their genotype (true match) or a dietary intervention that 
did not align with their genotype (false match).  
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 The two diets prescribed in this investigation varied in carbohydrate (CHO) 
content, such that one diet was a moderate CHO diet (30% kcal CHO) and the other was 
a low CHO diet (20% kcal CHO).10-12 Both diets were adequate in fat content, 25% kcal 
fat in moderate CHO diet and 35% kcal fat in low CHO diet, and moderate in protein 
content, 45% kcal from protein.11,12 The diets were also hypocaloric in nature, 1400 
kcal/d prescribed for week one and 1500 kcal/d prescribed for weeks two through 24. 
The variation in CHO and fat content is consistent with previous weight loss 
interventions suggesting similar variations in relation to candidate genes within the 
genetic profile.13-25 Additionally, the use of a moderate protein diet in conjunction with 
the Curves exercise program (Curves International, Waco TX) is consistent with 
previous weight loss interventions conducted in the Exercise and Sport Nutrition 
Laboratory.26-28 
 Along with a dietary intervention, the exercise intervention used was the Curves 
exercise program (Curves International, Waco TX). The Curves exercise program 
consisted of a circuit-style training regimen including hydraulic resistance machines 
interspersed with calisthenic exercise or Zumba dance. Participants completed four, 30-
minute, Curves workouts, including one of the four workouts interspersed with Zumba 
dance. In addition to exercise on the Curves circuit, participants were instructed to 
achieve 10,000 steps per day on the days they were not exercising on the Curves circuit 
(three days per week). A pedometer was provided to assist with tracking step count.  
The dependent variables included the following: diet assignment; body weight, 
body composition as determined with the Hologic Discovery W QDR series Dual 
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Energy X-ray Absorptiometry (Waltham, Ma); resting energy expenditure and peak 
oxygen consumption with the Parvo Medics TrueMax 2400 Metabolic Measurement 
System (Sandy, UT); waist and hip circumference; resting heart rate and blood pressure; 
lower and upper body maximal strength and endurance; serum panels to determine 
fasting insulin, glucose, HOMA-IR, glucose to insulin ratio, and blood lipid profile; 
dietary intake via four-day food logs; step count from the pedometer via weekly physical 
activity log; and psychosocial evaluation. All measures were collected monthly from 
baseline to completion of six months with the exception of peak oxygen consumption, 
and lower and upper body muscular strength and endurance, which were measured at 
baseline, end of three months and six-months. Exercise compliance at the Curves circuit 
was measured daily via circuit attendance and collection of peak and average heart rate 
during each workout.  
 Data were analyzed with SPSS statistical software package, version 22 
(Chicago, IL).  ANOVA or MANOVA with repeated measures was used to assess the 
data. Data is presented as mean ± standard deviation. This study was funded by 
Interleukin Genetics (Waltham, MA) and Curves International, (Waco, TX).  
Hypotheses 
H1: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will be observed among body composition variable.  
H2: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will be observed for visceral adipose tissue depots.  
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H3: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will be observed for fat deposition.  
H4: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will be observed among anthropometric variables.  
H5: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will be observed for resting energy expenditure.  
Ho6: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will not be observed for cardiorespiratory fitness. 
Ho7: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will not be observed for muscular strength.  
Ho8: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will not be observed for muscular endurance.  
H9: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will be observed among blood lipids.  
Ho10: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will not be observed among markers related to insulin 
resistance. 
Ho11: Statistically significant interactions (time x genotype and/or time x genotype x 
diet) in favor of true matches will not be observed among variables related to 
psychosocial evaluation. 
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Delimitations 
The following guidelines will be followed: 
1. One hundred and ninety one sedentary, apparently healthy women, between the 
ages of 18 and 60 years, with a BMI greater than 22 kg/m2 will be recruited from 
College Station/Bryan and Texas A & M University.  
2. Participants have not participated in a planned exercise program within three 
months prior to screening for eligibility to participate in this weight loss study. 
3. Participants were not currently exercising more than 30 minutes per day, three 
times per week, at the time of screening. 
4. Participants did not experience a weight change of ± 7 pounds within the three 
months prior to screening for eligibility to participate in this weight loss study. 
5. Participants were not pregnant or nursing during the preceding 12 months, nor 
were they planning to become pregnant during the proceeding 12 months at time 
of screening for eligibility to participate in the study. 
6. Participants did not have any uncontrolled metabolic disorders. 
7. Participants were not currently taking thyroid, hyperlipidemic, hypoglycemic, 
anti-hypertensive, or androgenic medications prior to the start of the study. 
8. Within the three months prior to the start of the study, participants were not 
taking ergogenic levels of nutritional supplements that may have affected muscle 
mass, anabolic/catabolic hormones levels, or weight loss.  
9. All individuals were willing to participate in a regular, moderate, exercise 
program.  
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10. All eligible participants attended a familiarization session in the Exercise and 
Sport Nutrition Laboratory, where they were briefed on the rationale, testing 
protocols, and requirements of the study. After reviewing the informed consent, 
all interested participants signed the informed consent, completed a questionnaire 
related to subjective rating of carbohydrate intolerance (carbohydrate intolerance 
questionnaire), and completed a general health screening form for review by a 
research nurse. After paperwork was complete, height, weight, resting heart rate, 
blood pressure, and buccal cheek swab samples were collected.  
Limitations 
1. Recruitment of participants in this study is limited to the Bryan/College Station 
area of Texas. 
2. The Eating Satisfaction Survey, included within the psychosocial questionnaires 
provided, has yet to be validated.   
3. Dietary data collected was self-reported via four-day food logs. 
Assumptions 1. Participants will honestly and accurately answer all screening questions to 
determine eligibility for participation in the study. 2. Participants will honestly and accurately complete the general health screening 
form and carbohydrate intolerance questionnaire.  3. Prior to each testing session, participants will fast for 10-12 hours, abstain 
alcohol consumption and non-steroidal anti-inflammatory use for 24 hours, and 
refrain from exercise for 48 hours. 
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4. Participants will honestly and accurately complete the four-day food records and 
one-week activity log upon submission at each monthly testing session. 5. Participants will comply with their assigned diet regimen and exercise protocol.  6. The sample population will be normally distributed. 7. All testing procedures will be performed consistently among lab personnel.  
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CHAPTER II 
LITERATURE REVIEW* 
 
Excessive energy intake, poor diet quality, and insufficient energy expenditure is 
directly associated with weight gain resulting in obesity and adverse health outcomes. It 
is clear a single cure-all approach for weight loss does not exist; thus more efforts in 
personalized nutrition via genetic profiling have been investigated. The purpose of this 
literature review is to present the prevalence, health consequences, and etiology 
associated with obesity, demonstrate the relationship between genetics and obesity, 
explain how genetic profiling may improve weight loss outcomes, and identify five 
potential candidate genes for use in genetic profiling to promote weight loss and improve 
health outcomes.  
Prevalence of Obesity 
The obesity epidemic has gained the national spotlight regarding the prevalence, 
health consequences, and contributing factors of the disease. According to the most 
recent data from the National Health and Nutrition Examination Survey (NHANES) 
2011-2012, in the United States more than two-thirds of adults aged 20 years and older, 
68.5%, are classified as overweight or obese (BMI > 24.9 kg/m2), with one-third alone,  
 
 
 
*A portion of this chapter is reprinted with permission from “Genetic Profiling for 
Weight Loss: Potential Candidate Genes” by Adriana Coletta and Richard B. Kreider, 
2015. Bioenergetics, 4, Copyright 2015 Coletta A, et al.   
 
  
 
10 
34.9%, classified among the three grades of obesity (grade 1 = 30-34.9 kg/m2, grade 2 = 
35-39.9 kg/m2, grade 3 = ≥ 40 kg/m2).1 Obesity, including excess accumulation of 
visceral adipose tissue, is associated with increased risk of cardiovascular and metabolic 
diseases and conditions.29-33  
Health Consequences and Obesity 
 
Cardiovascular  
 
According to the Centers for Disease Control, annually, one in four deaths in the 
United States is attributed to heart disease.34 A positive relationship has been 
demonstrated between BMI and risk of coronary artery disease, atherosclerosis, and 
heart failure.35-37 In a prospective, international, multicenter investigation conducted by 
Labounty and colleagues36, increased BMI demonstrated a stronger association with 
coronary artery disease in comparison to smoking, dyslipidemia, type 2 diabetes and 
hypertension. Investigators concluded that a “strong and consistent” relationship exists 
between increased BMI and the severity, extent, and prevalence of coronary artery 
disease.36  
Kenchaiah and colleagues37, also found a significant association between 
increased BMI and heart failure risk. Women classified as overweight demonstrated a 
50% increased risk for heart failure in comparison to normal weight women, whereas, 
risk of heart failure in obese women doubled in comparison to normal weight women.37 
Outcomes for increased risk differed in men; thus, one may conclude that women 
classified as overweight or obese are at greater risk of heart failure in comparison to 
overweight or obese men.   
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The positive relationship between obesity and risk of heart disease and heart 
failure may be attributed to obesity-induced dyslipidemia. Dyslipidemia may be 
characterized as increased plasma triglycerides (TG) and free fatty acids, decreased 
high-density lipoprotein levels (HDL), and an increase in low-density lipoprotein levels 
(LDL).38,39 According to a recent review conducted by Franssen and colleagues38, 
dyslipidemia associated with obesity has consistently demonstrated a positive 
relationship with risk for heart disease and is considered a contributing risk factor.  
Along with dyslipidemia, in comparison to lean patients, obese patients are more 
likely to present with hypertension.40 Chronic hypertension may result in damage to the 
heart and coronary arteries, which increases one’s risk of developing atherosclerosis, 
heart disease, heart failure, heart attack and stroke. 41 Multiple investigations have 
demonstrated a relationship between weight loss in obese individuals and reduction in 
antihypertensive medication and blood pressure.40,42-45 Taken together obesity increases 
one’s risk of dyslipidemia and hypertension, which may lead to adverse cardiovascular 
conditions.  
Endocrine and Renal  
 Along with cardiovascular conditions, onset of obesity is associated with adverse 
endocrine and renal conditions. Insulin resistance and subsequent onset of type 2 
diabetes is directly associated with obesity, in particular increased visceral adiposity.46,47 
The combination of visceral adiposity and an obese state may be attributed to the 
following mechanisms: adipocytes become resistant to the anti-lipolytic effect of insulin, 
leading to increased plasma free fatty acids, resultant hepatic gluconeogenesis, muscle 
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and hepatic insulin resistance and impaired insulin secretion; further over accumulation 
of visceral fat cells produce adipokines associated with inducing insulin resistance, 
inflammation, and formation of atherosclerotic plaques.47 Thus obesity may result in 
type 2 diabetes and, if not pre-existing, lead to the development of dyslipidemia and 
atherosclerosis. 
If left untreated or poorly controlled, chronic hyperglycemia may develop into 
neuropathy and lead to amputation, retinopathy and result in blindness, and/or 
nephropathy and result in chronic kidney disease. If further noncompliance or poor 
control continues with chronic kidney disease, this increases risk of end stage renal 
disease.48,49  
Etiology of Obesity 
Originally, the onset of obesity was solely attributed to a positive energy balance 
such that energy intake exceeded energy expenditure of basal metabolic needs, thermic 
effect of food, lifestyle and physical activity. Currently, obesity is attributed to an 
interaction among multiple factors, including physiological, metabolic, behavioral, 
social, and genetic factors.2 Attention to genetic factors has gained recent attention as of 
late and has demonstrated notable relationships that may contribute to the epidemic.  
Genetics and Obesity 
 There are two types of genetic conditions related to obesity, monogenic and 
polygenic obesity. Monogenic obesity is classified as rare genetic variants that result in 
extreme measures of obesity.50 In this form of obesity, a causative effect is demonstrated 
such that one gene is considered the culprit of the condition.51 Prader-Willi, syndrome is 
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an example of a condition within monogenic obesity.52 Examples of genetic variants 
associated with monogenic obesity include single nucleotide polymorphisms (SNPs) in 
the melanocortin-4 receptor (MC4R), propiomelanocortin (POMC), leptin gene and 
leptin receptor gene.50-52  
In contrast to monogenic obesity, polygenic obesity is classified as a summation 
of effects from multiple SNPs.50 Polygenic obesity is referred to as common obesity and 
consists of the majority of cases of obesity. The discovery of polygenic obesity may be 
attributed to the start of genome-wide association studies (GWAS). The method within 
GWAS is unbiased and thorough, enabling determination of associations between target 
disease phenotypes and common variations in the genome.51 This method scans a set of 
SNP markers from 0.1 to 5 million in size and tags SNPs that demonstrate variation in 
haplotypes within a target region. From the tagged SNPs, one may determine where 
variations occur within the genome.51  
With use of GWAS, identification of countless candidate genes associated with 
BMI classification of obesity, unfavorable blood lipid profiles and body fat distribution 
have been identified.3-6 This information enables research within the areas of 
nutrigenomics and nutrigenetics. Nutrigenomics focuses on how diet and other lifestyle 
factors influences the expression of genes over time.53 The influence of baseline 
genotype on the response to caloric restriction within a weight loss program is 
considered nutrigenetics, also commonly referred to as genetic profiling.53  
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Genetic Profiling (Nutrigenetics) 
 The concept of genetic profiling to classify or predict clinical outcomes and 
disease states is used frequently with microarray analyses in oncology.7 Within a clinical 
setting, genotypes associated with metabolism, transport of nutrients, removal of toxins, 
and protection from antioxidants are analyzed to determine a pattern of baseline genetic 
variation.8 Determining baseline variation in candidate genes provides insight regarding 
clinical intervention, diet, and exercise.8 This practice is relatively new in the arena of 
weight loss, with few studies to date assessing baseline genetic profile in relation to 
health outcomes after participating in a weight loss intervention.7-9 (Appendix A) 
 In a retrospective analysis conducted by Mutch and colleagues7, a smaller sample 
size from a larger European multicenter study, the Nutrient-Gene Interactions in Human 
Obesity-Implications for Dietary Guidelines Trial (NUGENOB; www.nugenob.org), 
was assessed in regards to baseline genotype and response to the weight loss 
intervention. Briefly, within the NUGENOB 10-week intervention, 771 obese (average 
BMI ~ 35 kg/m2) participants, with an average age of approximately 35 years old, were 
randomly assigned to a hypocaloric diet (~600 kcal deficit) consisting of either a low fat, 
high carbohydrate (CHO) diet (20-25% kcal fat, 60-65% kcal CHO, 15% kcal protein), 
or a moderate fat, low CHO diet (40-45% kcal fat, 40-45% kcal CHO, 15% kcal 
protein). Three-day weighed food logs were collected at baseline and 10 weeks, and 
participants were in weekly contact with a Registered Dietitian (RD) to assist with 
dietary compliance.  
Mutch and colleagues7 selected 53 participants from the NUGENOB trial who 
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were closely matched in baseline characteristics. This smaller sample of participants 
were then classified as responders or non-responders based on their success in the 
NUGENOB intervention. Responders exhibited an 8-10 kg weight loss by the end of the 
intervention, whereas non-responders exhibited less than four kilograms of weight loss. 
Genotype was determined from microarray analysis of adipose biopsies collected at the 
start of the study. The following candidate genes were identified as having significantly 
different allele patterns between responders and non-responders at baseline: 
transmembrane protein 132A (TMEM132A), quinolinate phosphoribosyltransferase 
(QPRT), claudin 5 (CLDN5), prostaglandin D2 synthase (PTGDS), endothelial cell 
adhesion molecule (ESAM), fibromodulin (FMOD), family with sequence similarity 69 
B (FAM69B), interferon alpha-inducible protein 27 (IF127).7 Taken together, these 
findings suggest that the identified candidate genes are associated with success in the 
aforementioned weight loss intervention.7  
 Similarly, Dopler-Nelson and colleagues9 retrospectively categorized participants 
to their dietary interventions, i.e. true match to diet or false match to diet, based on 
baseline genotype in a smaller sample from a large, 12-month, randomized controlled 
trial, The AtoZ Weight Loss Trial.9,54 Summarily, within the AtoZ Weight Loss Trial, 
311 obese (average body fat percentage ~40%) participants, with an average age of 
about 40 years old, were randomly assigned to one of the following commercial weight 
loss programs: Atkins: < 20 g/d CHO for 2-3 mo, then < 50 g/d CHO; Zone: 40% kcal 
CHO, 30% kcal fat, 30% kcal protein; LEARN: 55-60% kcal CHO and < 10% kcal 
saturated fat; Ornish: < 10% kcal fat).54 Weekly dietary education was provided for two 
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months by an RD. Three-day food records were collected at baseline, and then randomly 
around two, six, and twelve months. Additionally, anthropometrics, body composition, 
blood pressure, and blood sample were collected at baseline, two, six, and twelve 
months.54  
 Dopler-Nelson and colleagues9 contacted all participants in the AtoZ Weight 
Loss Trial regarding retrospective genetic analysis. Of all 311 participants contacted, 
101 individuals participated in the retrospective genetic profiling study. Genotyping was 
determined via buccal cheek swabs to assess five genetic variants among the following 
four candidate genes: fatty acid binding protein (FABP2, rs1799883), peroxisome-
proliferator activated-receptor gamma 2 (PPARG2, rs1801282), beta-3 adrenergic 
receptor (ADRB3, rs4994C3), beta-2 adrenergic receptor (ADRB2, rs1042713 and 
rs1042714). Findings determined that individuals who were truly matched to their 
dietary intervention based on genotype experienced a 5.3 percent loss in body weight 
(BW) over 12-months versus 2.3 percent BW in false matches (p < 0.05).9 True matches 
to the programs lowest in CHO (Atkins) and fat (Ornish) experienced 6.8% total weight 
loss in comparison to 1.4% in false matches. Additionally, true matches experienced a 
significant reduction in waist circumference (p=0.01) and triglycerides (p=0.007), and an 
increase in HDL (p=0.01).  
In addition to the retrospective analyses, Arkadianos and colleagues8 conducted 
the only investigation to our knowledge where participants were matched prospectively 
to a dietary intervention based on genotype at baseline. Ninety-three patients from the 
Dr. Arkadianos Clinic participated in an intervention approximately 11-months in 
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length. All participants followed a low saturated fat, low glycemic index, Mediterranean-
style diet. With typical macronutrient distribution range of the Mediterranean diet 
consisting of approximately 38% kcal CHO, 46% kcal fat, and 16% kcal protein.8 Fifty 
obese (22 female, 28 male, average BMI 32 kg/m2) participants, aged approximately 45 
years old, received specific alterations in their dietary prescription based on genetic 
variants within the candidate gene of interest (nutrigenetic group), whereas 43 
participants (18 female, 25 male, average BMI 32 kg/m2) simply followed the prescribed 
Mediterranean-style diet (control group). In addition to diet, exercise routines were 
provided and consistent among all participants. Participants attended regular 
appointments with their physician at the clinic where BW was measured and a fasting 
blood sample was collected at baseline and completion.8 Genotyping was determined by 
Buccal cheek swabs. Results from buccal cheek swabs included variants among the 
following candidate genes: 5,10-methylenetetrahydrofolate reductase (MTHFR, 
rs1801131, 677C>T), 5-methyltetrahydrofolate-homocysteine methyltransferase 
reductase (MTRR, 66A>G), 5-methyltetrahydrofolate-homocysteine methyltransferase 
(MTR, 275A>G), cystathione-beta-synthase (CBS, 699C>T); glutathione s-transferase 
MI (GSTMI, deletion), glutathione s-transferase theta 1 (GSTT1, deletion), glutathione 
s-transferase pi (GSTP1, 313A>G, 341C>T); SOD2 (-28C>T), SOD3 (760C>G), nitric 
oxide synthase (NOS3, 894G>T); vitamin D receptor (VDR, CTaqIT, TBsmIC, 
TFokIC), collagen type 1 alpha 1 (COLIA, G SpI T); tumor necrosis factor alpha 
(TNFalpha, -308G>A), interleukin 6 (IL6, 1595C>G), nitric oxide synthase 3 (NOS3, 
894G>T); cholesteryl ester transfer protein (CETP, 279G>A), lipoprotein lipase (LPL, 
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1595C>G), apolipoprotein C-3 (APOC3, 3175C>G); angiontensin I convertin enzyme 
(ACE, INS/DEL), and peroxisome-proliferator activated-receptor gamma 2 (PPARG2, 
Pro12Ala).8  
There were no significant differences among participants in age, sex, BMI, 
fasting blood lipids and blood glucose at baseline. Upon completion of the study, change 
in BMI between approximately three to ten months of the intervention was not 
significant; however, after about ten months, BMI decreased 5.6% (1.93 kg/m2) in the 
nutrigenetic group versus a 2.2% gain (0.51 kg/m2) in the control group (p < 0.023). 
After 90 days, among the participants with pre-diabetes, 57% of individuals in the 
nutrigenetic group and 25% of individuals in the control group demonstrated a 
significant reduction in fasting blood glucose (p < 0.046).8 Overall these findings 
support use of genetic profiling to personalize nutrition and optimize weight loss and 
maintenance in comparison to random assignment to a diet for weight loss. Additionally, 
findings suggest benefits for use of genetic profiling in patients with pre-diabetes such 
that these patients experience improved insulin sensitivity when genetically matched to a 
diet to promote weight loss.  
As previously mentioned, few investigations have assessed the relationship 
between baseline genotype and weight loss success after participation in an intervention. 
Candidate genes assessed among investigations have been relatively inconsistent. More 
research assessing a consistent group of candidate genes will be helpful to determine if 
genetic profiling is analytically and clinically valid.55 Between the investigations 
retrospectively matching genotype to diet, Dopler-Nelson and colleagues demonstrated 
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the most practical intervention and genetic profile while demonstrating clear significant 
effects.9 In the one investigation prospectively matching genotype to diet, significant 
effects were not exhibited until after about ten months of intervention.8 Considering the 
profound results found with the genetic profile used by Dopler-Nelson and colleagues, 
further research with use of this genetic profile is warranted. The following section will 
review candidate genes within the genetic profile suggested by Dopler-Nelson and 
colleagues (FABP2, rs1799883; PPARG2, rs1801282; ADRB3, rs4994C3; ADRB2, 
rs1042713 and rs1042714), specifically in relation to association with obesity, weight 
loss interventions, and potential use in genetic profiling to optimize nutrition for weight 
loss. (Appendix B) 
Candidate Genes 
FABP2 (rs1799883) 
Association with Obesity 
 Intestinal fatty acid binding protein 2 (FABP2) is a protein located in the cytosol 
of intestinal epithelial cells and is associated with long-chain fatty acid metabolism.56 At 
rs1799883 a transition occurs at codon 54 resulting in replacement of alanine (Ala) with 
threonine (Thr).57 The wild-type allele pattern for FABP2 is Ala/Ala, whereas the 
mutant-type is Ala/Thr or Thr/Thr. In most populations, the allelic frequency of Thr at 
codon 54 is 30%.57 Multiple investigations have demonstrated differences in baseline 
biochemical markers related to glucose and lipid metabolism favoring the wild-type 
allele pattern.57-59 All of these investigations conducted genotyping with peripheral 
leukocytes.  
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In an investigation assessing 122 overweight and obese (BMI > 25 kg/m2) men 
and women (average age 48 ± 16 years) where diet was controlled prior to collection of 
biochemical markers, those with the mutant-type allele pattern demonstrated 
significantly higher circulating levels of fasting glucose and insulin.59 Additionally, in 
another investigation assessing 55 morbidly obese men and women, those with mutant-
type allele pattern had significantly higher levels of fasting insulin, HOMA, leptin, and 
lower levels of adiponectin.57  
 Along with this, Albala and colleagues58 compared baseline FABP2 rs1799883 
genotype and fasting levels of glucose, insulin, HOMA, blood lipids, and inflammatory 
markers between obese and normal weight individuals. Thirty-three obese women (BMI 
> 30 kg/m2) were compared to 30 normal weight women (BMI 18.5-24.9 kg/m2), all 
with an average age of about 37 years old. Regarding genotype, a significant difference 
in the number of obese females carrying the mutant-type allele pattern was demonstrated 
in comparison to normal weight women. As expected, obese women had significantly 
higher levels of fasting glucose, insulin, HOMA, triglycerides, total cholesterol, and 
TNFα in comparison to normal weight women. In obese participants, those homozygous 
for the Thr allele, one of the mutant-type allele patterns, demonstrated significantly 
higher levels of insulin, TNFα, and leptin.58  
Collectively, evidence suggests that obese individuals are more likely to contain 
the mutant-type allele patterns of FABP2 at rs1799883. Consequently, the mutant-type 
allele patterns demonstrate an association with markers of insulin resistance and 
abnormal lipid profile. Thus assessment of baseline allelic variants in FABP2 rs1799883 
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in relation to health outcomes after a weight loss intervention is justified to determine 
optimal interventions, especially in individuals with the mutant-type allele pattern.  
Weight Loss Interventions 
Multiple investigations have demonstrated varying health outcomes after 
implementation of diet and exercise intervention for weight loss in individuals 
containing the FABP2 rs1799883 mutant-type allele patterns.13-16,60 In a two-month 
randomized, clinical trial conducted by de Luis and colleagues14, 204 apparently healthy, 
obese (average BMI 34.3 ± 4.8 kg/m2) men and women (50 males and 154 females), 
with an average age of 46.5 ± 15.7 years, were randomly assigned to either a hypocaloric 
moderate fat diet (1500 kcal/d, 27% kcal fat, 52% kcal CHO, 20% kcal protein) or 
hypocaloric low CHO diet (1507 kcal/d, 36% kcal fat, 38% kcal CHO, 26% kcal 
protein). Aerobic exercise consisting of 60 minutes per day, three days per week was 
encouraged. Three-day food records were collected at baseline and two-months to 
determine dietary compliance. Anthropometric measurements and blood samples were 
collected at baseline and two months. Genotyping was determined from peripheral 
leukocytes. Overall, from baseline to two months all participants experienced significant 
loss in BW and fat mass (FM) (p < 0.05). Regardless of diet group, a significant 
reduction in cholesterol, TG, insulin, and leptin was demonstrated in the wild-type allele 
pattern, with no significant changes in mutant-type allele pattern. However, participants 
with the mutant-type allele pattern who followed the low CHO diet experienced a 
significant reduction in FM (p < 0.05).14  
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 Similarly, Martinez-Lopez and colleagues13 also conducted a two-month weight 
loss intervention utilizing a moderate fat diet in 109 overweight and obese (BMI > 25 
kg/m2) men and women (20 male, 89 female), with mean age of 38.6 ± 11.3 years. The 
diet consisted of 1000 kcal/d for women and 1200 kcal/d for men, with 30% kcal from 
fat, 55% kcal CHO, 15% kcal protein.  Additionally, participants were required to 
consume less than 200 mg dietary cholesterol per day, 25 grams per day of fiber and two 
grams per day from plant stanols/sterols. Exercise was not included in this intervention. 
To assess dietary compliance, an RD collected 24-hour dietary recalls at baseline, one 
month, and two months. Anthropometric measurements and blood samples were 
collected at baseline, one month, and two months. Genotyping was derived from 
peripheral leukocytes. Significant reductions in BW, BMI, body fat percentage (BF%), 
waist circumference (WC), waist-to-hip ratio (WHR), systolic blood pressure, fasting 
glucose, TG, total cholesterol, high-density lipoprotein (HDL), very low-density 
lipoprotein (VLDL), and insulin was exhibited in all participants (p < 0.05). 
Additionally, a significantly greater reduction in BW, BMI, WC, WHR, and c-reactive 
protein was demonstrated in individuals with the mutant-type allele patterns (p < 0.05).13  
 Along with this, de Luis and colleagues16,60 conducted two, three-month weight 
loss investigations testing varying fat content within the dietary interventions in order to 
determine the influence of genotype and response to treatment. In the first investigation, 
111 obese participants, with average BMI of 30.7 ± 7.1 kg/m2 and an average age of 
49.7 ± 10.1 years, consumed a diet consisting of 1459 kcal/d, with 34.4% kcal fat, 45.7% 
kcal CHO, 19.9% kcal protein. Fat content was further divided into 21.8% kcal from 
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saturated fat, 55.5% from monounsaturated fats (MUFA), and 22.7% from 
polyunsaturated fats (PUFA) (seven grams per day omega-6 fatty acids and two grams 
per day omega-3 fatty acids).16 Two to three hours of walking per week was encouraged 
as aerobic exercise. Dietary intake was assessed via three-day food records at baseline 
and three months, and weekly dietary monitoring by an RD via phone call. 
Anthropometric measurements and blood samples were collected at baseline and three 
months. Genotyping was determined via peripheral leukocytes. All in all a significant 
decrease in BW, BMI, fat free mass (FFM), and systolic blood pressure were 
demonstrated in all participants from baseline to three months (p < 0.05). Individuals 
with the mutant-type allele pattern experienced greater reductions in BMI, BW, FFM, 
FM, and WC (p < 0.05). Interestingly only individuals with the mutant-type allele 
patterns demonstrated significant decrease in total cholesterol, LDL, insulin and HOMA 
after three months (p < 0.05).16  
 In the second investigation, 122 apparently healthy, obese (average BMI 37.4 ± 
6.1 kg/m2, average age 47.8 ± 11.9 years) males and females were assessed.60 The 
dietary protocol was slightly different from the aforementioned protocol such that higher 
amounts of MUFAs were included as opposed to PUFAs. The diet was composed of 
1342 kcal/d, 34.1% kcal fat, 46.6% kcal CHO, 19.2% kcal protein. Fat content was 
further divided into 21.7% kcal from saturated fat, 67.5% kcal as MUFA and 10.8% kcal 
PUFA. Three-day food records were collected at baseline and three months to determine 
dietary compliance. Exercise, genotyping, and measurement protocols were identical to 
the previously mentioned trial.16 In this trial all participants demonstrated a significant 
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decrease in BW, BMI, and WC (p < 0.05). In contrast to the previously mentioned 
investigation, individuals with the wild-type allele pattern demonstrated significant 
reduction in FM, along with fasting insulin and leptin levels (p < 0.05).60  
 Finally, in another three-month weight loss intervention conducted by de Luis 
and colleagues15, 69 apparently healthy, obese participants (average BMI 34.1 ± 5.1 
kg/m2), with an average age of 45.5 ±  16.6 years, consumed a hypocaloric diet 
consisting of 1520 kcal/d, 25% kcal fat, 52% kcal CHO, 23% kcal protein. Aerobic 
exercise was encouraged for 60 minutes at least three days per week. Three-day food 
records were collected at baseline and three-months to determine dietary compliance. 
Anthropometric measurements, blood sample, and maximal oxygen consumption was 
measured at baseline and three months. All Genotyping was determined via peripheral 
leukocytes. All participants demonstrated a significant reduction in BW, BMI, WC, and 
increase in oxygen consumption between baseline and three months (p < 0.05). 
Individuals with the wild-type allele pattern demonstrated a greater decrease in FM, 
LDL and leptin levels in comparison to those with the mutant-type allele pattern (p < 
0.05). However, individuals with the mutant-type allele pattern demonstrated more 
significant reduction in fasting glucose at three months (p < 0.05).15  
 Overall, health outcomes from weight loss interventions in relation to FABP2 
rs1799883 genotype have been variable.  Among the two-month weight loss 
interventions, de Luis and colleagues14  demonstrated greater reductions in biochemical 
markers related to lipid and CHO metabolism in carriers of the wild-type allele pattern, 
yet greater reductions in fat mass in individuals with the mutant-type allele pattern. 
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Similarly Martinez-Lopez and colleagues13  demonstrated favorable outcomes in 
anthropometrics in individuals carrying the mutant-type allele pattern, but biochemical 
changes were not significantly different between genoytpe. It is possible the degree of 
caloric restriction may have influenced the minor variations in results, i.e. ~1500 kcal/d 
versus 1000-1200 kcal/d. In the three-month weight loss interventions, varying 
responses in relation to genotype were demonstrated pending on the type of fat included 
in the diet, MUFA versus PUFA.16,60 Additionally, when fat content was not controlled, 
mutant-type allele pattern was associated with improvements in fasting glucose, whereas 
wild-type allele pattern was associated with improvements in LDL cholesterol, FM, and 
fasting leptin levels.15 Considering these findings, it is evident that varying dietary 
compositions elicit different outcomes pending FABP2 rs1799883 genotype. 
FABP2 rs1799883 and Genetic Profiling 
 The mutant-type allele pattern at rs1799883 of FABP2 has been associated with 
adverse glucose and lipid metabolism.57-59 Additionally, this genotype is more prevalent 
in obese individuals.57-59 Collectively, when considering dietary prescription to optimize 
weight loss, evidence supports a lower CHO, moderate fat, and adequate protein diet to 
improve markers of body composition in overweight and obese individuals carrying the 
mutant-type allele patterns.13-16 Furthermore, a moderate CHO, lower fat, and adequate 
protein diet may be helpful for individuals with the wild-type allele pattern to improve 
body composition and fasting blood lipid levels.15 Considering this, use of FABP2 
rs1799883 may be useful as a marker within a genetic profile to optimize nutrition for 
weight loss.  
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PPARG2 (rs1801282) 
Association with Obesity 
 Peroxisome proliferator-activated receptor gamma-2 (PPARG2) is an isoform of 
the peroxisome proliferator-activated receptor gamma gene and consists of an additional 
28 amino acids at its amino terminus.61 PPARG2 is primarily located in adipocytes and 
plays an important role in adipocyte differentiation.62-64 A missense mutation in 
PPARG2 occurs at codon 12 of exon B in rs1801282 and consists of a transition of 
alanine (Ala) for proline (Pro).64 The wild-type allele pattern for PPARG2 is Pro/Pro, 
whereas the mutant-type is Pro/Ala or Ala/Ala. In contrast to FABP2 rs1799883, the 
allelic frequency of Ala varies among populations; for example, the frequency among 
Caucasians is about 11%, whereas the frequency among Asians is about 9%.65,66 A 
strong association between mutant-type allele patterns and more favorable body 
composition, blood lipid profile, and insulin sensitivity has been demonstrated in 
normal-weight, middle-aged and elderly men and women in comparison to individuals 
with the wild-type allele pattern.61,64 Interestingly, the opposite association has been 
demonstrated in overweight/obese individuals.65-68  
In an investigation conducted by Cole and colleagues65, baseline PPARG2 
rs1801282 genotype, anthropometric, and biochemical measurements were assessed in 
921 overweight/obese (BMI > 28 kg/m2), middle-aged (38-40 years old) Mexican- 
Americans who were part of a population-based family study of atherosclerotic risk 
factors associated with atherosclerosis (San Antonio Family Heart Study). BMI, WC, 
WHR, body composition via bioelectrical impedance, and a fasting blood sample were 
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collected. Genotyping was determined from peripheral leukocytes. Overall, mutant-type 
allele patterns demonstrated significantly higher BMI (p=0.011), WC (p=0.028), and 
leptin levels (p=0.021) in comparison to individuals with the wild-type pattern.65  
Similarly, Kim and colleagues66  assessed 1,051 overweight (BMI of 25.6 ± 0.12 
kg/m2) Korean women aged 27 ± 0.2 years old. Body composition measures were 
collected via bioelectrical impedance, and fat distribution measures via CT scan for 471 
of the participants. Blood samples were collected to determine blood lipid profile and 
genotyping. Individuals with the mutant-type allele pattern had significantly higher BW 
(p=0.012), BMI (p=0.012), WHR (p=0.001), BF% (p=0.025), abdominal fat area, 
abdominal subcutaneous fat, and visceral fat (p=0.001).  
Along with investigations exclusively in overweight and obese individuals, 
Robitaille and colleagues68 assessed normal weight, overweight, and obese individuals 
from a cohort of the Quebec family study including 720 adults (313 men and 407 
women), with an average age of approximately 44 years old, of French-Canadian 
descent. Body composition via CT scan, WC, and a blood sample were collected. 
Genotyping was determined from lymphoblastoid cell lines. When adjusted for age and 
gender, regardless of baseline weight status, individuals with mutant-type allele pattern 
exhibited higher BMI (p=0.04), FM (p=0.009), WC (p=0.03), visceral adipose tissue 
(p=0.01), and subcutaneous adipose tissue (p=0.001).68  
Similarly, Milewicz and colleagues67  compared overweight/obese women to 
normal weight counterparts within 318 postmenopausal women, 50-60 years old. Body 
composition determined by DXA scan, BW, WC, and blood sample were collected. 
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Genoytping was determined via peripheral leukocytes. In comparison to normal weight 
individuals, obese individuals with mutant-type allele pattern demonstrated higher total 
cholesterol (p < 0.001), LDL (p < 0.001), and TG (p < 0.001). Aside from these findings, 
no other significant differences between weight status or genotype among BW and body 
composition measures were observed.67  
Furthermore, from a longitudinal perspective, a retrospective population study 
was conducted assessing genotype and weight change throughout the life cycle in 311 
participants (145 men and 166 women).69 Weight was measured at birth, seven years of 
age, 20 years of age, and the age of the study, which was approximately 41 years. 
Genotyping was determined from peripheral leukocytes. Individuals homozygous for the 
mutant-type allele pattern (Ala/Ala) demonstrated higher birth weight (p=0.031), weight 
at seven years of age (p=0.016), and weight at study age (p=0.073). Individuals with 
either mutant-type allele pattern demonstrated significantly higher ponderal index (birth 
weight in kg/birth length in m3) (p=0.04) and waist circumference at study age 
(p=0.04).69  
Jointly, a strong association has been demonstrated between PPARG2 rs1801282 
mutant-type allele pattern in relation to degree of obesity, fat deposition, and adverse 
blood lipid profile in overweight/obese individuals.65-68 When comparing 
overweight/obese individuals to normal weight individuals, those with the mutant-type 
allele pattern, regardless of weight status, demonstrated higher BW and adverse 
parameters of body composition.68 Additionally, in the post-menopausal age group, 
when comparing normal weight to overweight/obese women, overweight/obese women 
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with the mutant-type allele pattern demonstrated significantly greater markers of blood 
lipids.67 Moreover, findings from a longitudinal, retrospective study suggests the mutant-
type allele pattern in PPARG2 rs1801282 may serve as a predictor for weight gain 
throughout the life cycle. These findings support increased susceptibility to 
overweight/obese weight status, adverse body composition and abnormal blood lipid 
profiles in individuals carrying the mutant-type allele pattern of PPARG2 rs1801282; 
thus further research is warranted in this population to determine optimal intervention to 
promote weight loss, improved body composition and blood lipid profile.  
Weight Loss Interventions 
 In spite of the aforementioned findings, few investigations have assessed the 
association between baseline PPARG2 rs1801282 genotype and response to weight loss 
interventions. In an investigation conducted by Lindi and colleagues20, 490 
overweight/obese men and women (average BMI 31.1 ± 4.6 kg/m2, aged 40-68 years 
old) with pre-diabetes were assessed for baseline PPARG2 rs1801282 genotype in 
relation to health outcomes after participating in the Finnish Diabetes Prevention Study. 
Briefly, the Finnish Diabetes Prevention Study included 522 participants who were 
randomized into a control group or lifestyle intervention group.70 A diet consisting of 
less than 30% calories from fat, less than 10% calories from saturated fat and 15 grams 
of fiber consumed per 1000 calories was prescribed, with no specific instruction 
regarding total caloric intake, and macronutrient range for CHO and protein. Participants 
met with an RD for dietary education/counseling seven times within the first year and 
every three months over the last two years. Additionally, 30 minutes of exercise per day 
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was encouraged. Dietary data from three-day food records, anthropometric 
measurements, and a blood sample was collected at baseline and at three years. 
Genotyping was determined via peripheral leukocytes.70  
At three years, within the control group, participants homozygous for Ala allele 
had significantly greater chance of developing type 2 diabetes, a 2.36 fold odds ratio, in 
comparison to individuals with the wild-type allele pattern.20 In the intervention group, 
while the risk of developing type 2 Diabetes was higher in individuals homozygous for 
Ala in comparison to those with the wild-type allele pattern, the difference in risk was 
not significant. Moreover, within the intervention group, individuals homozygous for 
Ala allele experienced a significant reduction in body weight in comparison to those 
with the wild-type allele pattern (p=0.043). While not statistically significant, 
heterozygotes for Ala also exhibited greater reduction in body weight in comparison to 
individuals with the wild-type allele pattern.20  
 Along with this investigation in patients with pre-diabetes, Franks and 
colleagues18 demonstrated similar findings in the Diabetes Prevention Program 
conducted in the United States. Briefly, the U.S Diabetes Prevention Program was a 
multi-centered, randomized controlled trial.71 Participants were randomized to a control 
group, a medication group, and a lifestyle intervention. The medication group received 
850 mg twice daily of metformin along with annual individual meetings, 20-30 minutes 
in length, emphasizing consumption of healthy diet and participation in a regular 
exercise program. The lifestyle intervention included a 16-session curriculum covering 
diet, exercise, and behavior modification. The curriculum included individual meetings 
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with study personnel for the first 24 weeks, then monthly sessions thereafter for the 
remainder of the study. Participation in 150 min of physical activity per week was 
prescribed.71 Further, in both groups dietary prescription was based on the National 
Cholesterol Education Program step 1 diet (500-1000 kcal/d reduction, 55% kcal CHO, 
< 30% kcal fat with 8-10% kcal from saturated fat, ~15% kcal protein, and < 300 mg/d 
cholesterol).  
Franks and colleagues18 reported on data collected in one year of the program in 
3,234 obese (average BMI 34.1 kg/m2, average age of 51 years) men and women. 
Genotyping for all participants was determined via peripheral leukocytes. Consistent 
with previously mentioned findings, individuals with mutant-type allele pattern 
demonstrated significant reduction in body weight in the drug group (p=0.01) and 
lifestyle intervention (p=0.04) in comparison to individuals with the wild-type allele 
pattern.18 
In addition, Curti and colleagues21 assessed baseline genotype of PPARG2 
rs1801282 along with FTO rs9939609 and PPARG ApoA1 -75G/A in a 9-month weight 
loss intervention in 18-80 year old, apparently healthy, overweight/obese (BMI 30.4 ± 
0.48 kg/m2) males and females. Participants received lifestyle coaching every three 
months consisting of dietary education/counseling for a healthy diet, and encouragement 
for participation in greater than 150 minutes per week of physical activity. At baseline 
and nine months, 24-hour food recalls were collected to determine dietary compliance, 
physical activity was assessed with the International Physical Activity Questionnaire, 
and BW, BMI, blood pressure, WC, and blood samples were collected. Genotyping was 
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determined from whole blood samples. Regarding PPARG2 rs1801282 genotype, 
outcomes demonstrate a significant reduction in blood pressure favoring the mutant-type 
allele patterns (p < 0.001). All participants experienced a significant reduction in BW (P 
< 0.001), WC (p=0.01), fasting blood glucose (p=0.041), fasting insulin (p < 0.001), 
apolipoprotein B (p < 0.001), and increased HDL (p < 0.001).21 Favorable trends for the 
mutant-type allele pattern were demonstrated for WC and fasting blood glucose, whereas 
favorable trends for the wild-type allele pattern were demonstrated for fasting insulin. 
 Similarly, Garaulet and colleagues19 assessed baseline PPARG2 rs1801282 in 
relation to weight loss outcomes in 1465 apparently healthy, overweight/obese (BMI 25-
40 kg/m2), males and females, aged 20-65 years old. Length of the study was 
individualized depending on how long it took each participant to reach goal weight. 
Individual goal weight was determined considering a weight loss of 0.5-1 kg per week. 
The Harris-Benedict Equation was used to calculate energy needs including an activity 
factor; for weight loss, 600 kcals were deducted from the predicted energy needs to 
promote weight loss. In addition, participants were instructed to consume 50% of their 
kcal from CHO, 35% kcal fat (< 10% kcal saturated fat, 20% MUFA), and 15-20% kcal 
protein. Overall this resulted in a 1200-1800 kcal diet for women and 1500-2000 kcal 
diet for men. Participants met with an RD weekly for group education sessions. The 
exercise intervention included 10,000 steps per day along with daily physical activity of 
moderate-intensity for 30 minutes or more. Dietary data was collected via 24-hour diet 
recalls; BW, body composition via bioelectrical impedance, WC, HC, and blood 
pressure were measured at start and finish of each individual’s study time. Genotyping 
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was determined from whole blood samples. Overall, a significant interaction between 
heterozygote carriers, a mutant-type allele pattern, was demonstrated between fat intake 
and weight loss (p < 0.001). When consuming a lower fat diet, individuals with the 
mutant-type allele patterns demonstrated greater percentage of weight loss from baseline 
in comparison to those with the wild-type allele pattern (p=0.286); additionally, when 
consuming a higher fat diet (> 42.6% kcal fat), those with the mutant-type pattern 
demonstrated less weight loss from baseline in comparison to individuals with the wild-
type pattern (p=0.037).19  
 Finally, Nicklas and colleagues72 conducted an 18 month trial, including six 
months of weight loss intervention followed by 12 months of follow up in 70 
postmenopausal (average age 61 years old), apparently healthy, obese (average BMI ~31 
kg/m2) women. For the six-month weight loss intervention, participants were instructed 
to reduce caloric intake by 250-350 kcal/d, with no specific instruction regarding 
macronutrient distribution. In addition, participants attended weekly group meetings 
with an RD for dietary instruction, education, and counseling. Along with the dietary 
component, the exercise component included walking on a treadmill at 50-60% 
measured heart rate reserve one day per week in the investigator’s laboratory, and 
walking two days per week outside of the lab. Measures at baseline and six months 
include the following: BW, body composition via DXA scan, maximal oxygen uptake, 
resting metabolic rate via indirect calorimetry, and blood sample. Genotyping was 
determined from whole blood samples. Of all the measures collected, significant 
reductions from baseline to six months were only exhibited in BW, fasting glucose and 
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insulin favoring individuals with the wild-type allele pattern (p < 0.001). Individuals 
with the mutant-type allele pattern also demonstrated significant reduction in fat 
oxidation.72 
 As for the 12-month follow up portion of the study, for the first six months of 
this time participants attended group sessions with an RD bi-weekly to discuss healthy 
lifestyle change. Participants were encouraged to continue progress for the last six 
months and return for BW measurements after six months.72 Upon completion of the12 
month maintenance period, incidence of weight regain was significantly higher in 
women with the mutant-type allele pattern (5.4 ± 0.8 kg in mutant-type versus 2.8 ± 0.4 
kg in wild-type, p < 0.01).72  
 Among all weight loss interventions conducted, the majority of evidence 
supports greater reductions in BW, improvements in body composition, and 
improvements in fasting blood glucose associated with PPARG2 rs1801282 mutant-type 
allele pattern in both apparently healthy overweight/obese individuals and 
overweight/obese individuals with pre-diabetes. 18-21,72 In contrast, Nicklas and 
colleagues72 demonstrated significant reduction in BW, fasting blood glucose, and 
insulin levels favoring individuals with the mutant-type allele pattern. Differences in 
health outcomes regarding genotype may be attributed to length of intervention and/or 
degree of caloric restriction, suggesting individuals with the wild-type allele pattern may 
improve health outcomes in a shorter period of time with less caloric restriction, whereas 
those with the mutant-type allele pattern may require longer interventions with a more 
intense dietary protocol.  
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PPARG2 rs1801282 and Genetic Profiling 
 The role of PPARG2 in adipocyte differentiation and fat metabolism is supported 
by significant associations demonstrated between baseline genotype and degree of 
obesity, body composition, and blood lipid profile in overweight/obese indivudals.65-68 
Regarding weight loss, the majority of investigations demonstrated greater outcomes in 
individuals with the mutant-type allele pattern.18-21 These investigations included similar 
exercise prescriptions, emphasizing at least 30 minutes per day, five days per week, of 
cardiovascular activity. In addition, dietary prescription consisted of a hypocaloric, 
lower-fat, moderate CHO, and adequate protein diet specifically in individuals carrying 
the mutant-type allele pattern of PPARG2 rs1801282. Therefore, preliminary evidence 
supports the use of baseline PPARG2 rs1801282 genotype to optimize dietary 
prescription within a weight loss program. 
ADRB3 (rs4994) 
Association with Obesity 
 Beta-3-adrenergic receptor (ADRB3) is located primarily in adipocytes and plays 
a role in lipid metabolism and thermogenesis.73,74 A missense mutation in rs4994 at 
codon 64 results in the replacement of tryptophan for arginine.74 The wild-type allele 
pattern of ADRB3 is homozygous for tryptophan, Trp/Trp, whereas the mutant-type 
allele patterns include arginine and can be homozygous, Arg/Arg, or heterozygous, 
Trp/Arg.  
In a quantitative meta-analysis conducted in over 9000 participants across 
diverse populations, regardless of weight classification, heterozygous carriers of the 
  
 
36 
mutant-type allele pattern exhibited a significantly greater BMI in comparison to 
individuals with the wild-type allele pattern.74 Along with this, more recent 
investigations comparing normal weight to overweight/obese males and females have 
also demonstrated increased BF%, visceral adipose tissue (VAT), WC, WHR, decreased 
HDL levels, and impaired glucose tolerance in carriers of the mutant-type allele 
patterns.75-77  
Furthermore, in an investigation comparing 131 obese (BMI > 30 kg/m2), 
premenopausal women to 256 age-matched non-obese women, the obese individuals 
with the mutant-type allele pattern exhibited significantly higher fasting BG, total 
cholesterol, TG, and lower HDL in comparison to obese individuals with wild-type 
allele pattern.78 Interestingly, no significant differences for body composition, fat 
distribution, blood pressure, fasting BG, insulin, and blood lipid levels were 
demonstrated between genotype in non-obese weight participants.78    
 Overall, a strong association has been demonstrated between ADRB3 rs4994 
mutant-type allele patterns and adverse health effects in overweight/obese individuals. 
Considering this strong association, along with ADRB3’s role in lipid metabolism, 
research is warranted assessing health outcomes from a weight loss intervention in 
relation to ADRB3 rs4994 genotype. 
Weight Loss Interventions 
 While multiple investigations have assessed baseline ADRB3 rs4994 genotype in 
relation to health outcomes after participation in a weight loss intervention, findings 
regarding genotype are mixed. In an investigation conducted by Rawson and 
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colleagues79, 34 obese (BMI > 30 kg/m2), postmenopausal (average age 57 years), 
Caucasian women were prescribed a 1200-calorie diet based on the step two diet plan 
from the National Cholesterol Education Program (500-1000 kcal/d reduction, 55% kcal 
CHO, < 30% kcal fat with < 7% kcal from saturated fat, ~15% kcal protein, and < 200 
mg/d cholesterol).80 An exercise component was not included in this intervention. 
Length of study was dependent on how long it took each participant to reach her goal 
weight, which was based on the Metropolitan Life Insurance Tables. Average length of 
study for participants was approximately 13.5 months. Measures from baseline to 
completion of the study included BW and body composition via doubly labeled water 
technique. Genotyping was determined from peripheral leukocytes. Interestingly, all 
participants experienced a significant reduction in body mass, BMI, BF%, FFM, and FM 
from baseline to completion (p < 0.05), with no genotype x time interactions observed.79  
 In addition, Shiwaku and colleagues81 also did not find significant differences in 
health outcomes between ADRB3 rs4994 genotype and health outcomes after 
participation in a weight loss intervention. Seventy-six apparently healthy, normal and 
overweight (BMI > 21 kg/m2) Japanese women aged 35-69 years old participated in a 
three-month weight loss program that included individualized dietary counseling 
promoting caloric restriction from baseline dietary intake, with no specific prescription 
regarding macronutrient intake. The exercise component of the program consisted of 
7,000 steps per day measured with a pedometer. Additionally, participants attended 
supportive group therapy sessions with study personnel emphasizing implementation of 
healthy lifestyle habits.81 Body composition measurements, BW, and a blood sample 
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were collected at baseline and three months. Genotyping was determined from 
peripheral leukocytes. As mentioned previously, no significant differences in ADRB3 
rs4994 genotype were demonstrated in anthropometric measures or biochemical markers 
from baseline to three-months; all participants exhibited significant reductions in WC, 
HC, tricep skinfold measurement, blood pressure, BW, HDL LDL to HDL ratio, and 
phospholipids from baseline to completion of the study (p < 0.05).81  
 Similarly, Tahara and colleagues82 conducted a three-month behavioral weight 
loss intervention in 57 apparently healthy, normal and overweight/obese Japanese men 
(BMI > 23 kg/m2), with an average age of 48 years old. The dietary intervention 
consisted of individual meeting(s) with an RD at least once during the study for dietary 
counseling to promote consumption of a healthier, lower calorie diet in comparison to 
baseline diet. Additionally, the exercise intervention included 10,000 steps per day 
measured with a pedometer. Corresponding with the previously mentioned trial,79 a 
behavioral intervention was also included in this trial. The behavioral intervention 
consisted of three group meetings (baseline, mid-point, and completion of the study) 
emphasizing healthy lifestyle habits. In order to determine compliance with the diet and 
exercise interventions, a battery of questionnaires were provided at completion of the 
study. Additionally, BW and WC were measured once per week throughout the duration 
of the study, and genotyping was determined via peripheral leukocytes. Consistent with 
aforementioned studies,79,81 while all participants experienced significant reductions in 
anthropometric measures from baseline to three-months (p < 0.05), no significant 
differences were identified between ADRB3 rs4994 genotype.82  
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 Furthermore, Bea and colleagues83 retrospectively assessed baseline genotype of 
three common mutations of beta-adrenergic receptor (ADRB2, ADRA2B, ADRB3) in 
response to health outcomes from a block-randomized controlled lifestyle intervention. 
This investigation is different from previously mentioned trials79,81,82 such that there was 
no dietary component within the weight loss intervention, solely an exercise component.  
This secondary analysis included 148 apparently healthy, normal and overweight/obese 
(BMI > 21 kg/m2) postmenopausal women, with an average age of 56 years. The 
lifestyle intervention was 12-months in length, where participants were randomized at 
baseline to an exercise group or control group. The exercise intervention consisted of 
high-intensity resistance training and moderate impact weight-bearing exercise for 75 
minutes, three days per week. Individuals completed two sets of six to eight repetitions 
at 70-80% one repetition maximum (1 RM). Participant’s 1 RM was adjusted every six 
to eight weeks as strength improved. Body composition was measured via DXA at 
baseline and 12 months. Genotyping was determined from buccal cheek swabs. 
Regarding ADRB3 rs4994 polymorphism, as reported in previous studies with dietary 
and/or lifestyle interventions, no significant differences were exhibited between ADRB3 
rs4994 genotype and changes in body composition from baseline to 12 months. 
Additionally, all ADRB3 rs4994 genotypes lost significant and equivalent BF%.83  
 In contrast to the previously mentioned studies demonstrating no significant 
differences between ADRB3 rs4994 genotype after diet, exercise, and/or behavioral 
intervention,79,81-83 some investigations have found significant differences between 
ADRB3 genotype and health outcomes after a weight loss intervention.17,22,23 Phares and 
  
 
40 
colleagues22 conducted a six-month weight loss intervention within 70 apparently 
healthy, overweight (average BMI 28 kg/m2), Caucasian men and women (29 men, 41 
women), aged 50-75 years old. The dietary intervention was not hypocaloric, but 
included a macronutrient distribution range recommended by the American Heart 
Association (55% kcal CHO, 30% kcal fat, 15% kcal protein). The exercise intervention 
consisted of endurance exercise three days per week and progressed in intensity and 
duration for the first ten weeks of the trial, i.e. 50-70% individual VO2max starting with 
20 minutes of exercise and progressing to 40 minutes. For the last 14 weeks, participants 
trained at 70% VO2max for 40 minutes and also included 45-60 minutes of walking on 
one day during the weekend. Dietary compliance was measured from three-day food 
records collected at baseline, two, four, and six months. Measures at baseline included 
blood sample for genotyping, VO2max, oral glucose tolerance test, and body 
composition via DXA scan. At six months, body composition was measured once more. 
Regarding the ADRB3 rs4994 genotype, while all participants exhibited a significant 
reduction in BF%, FM, and percent trunk mass from baseline to six months, individuals 
with the mutant-type allele pattern demonstrated greater reduction in BF% (P=0.027), 
FM (p=0.037), and percent trunk fat (p=0.03) in comparison to individuals with the 
wild-type allele pattern.22 
 Although Phares and colleagues22 exhibited a significant difference between 
ADRB3 rs4994 genotype in favor of the mutant-type allele pattern, other investigations 
have demonstrated the opposite.17,23 In a three-month weight loss intervention conducted 
by Lee and colleagues23, 80 apparently healthy, overweight (BMI 25-30 kg/m2), 
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Japanese women, aged 40-69 years old, attended weekly dietary counseling sessions 
with an RD regarding reduction of baseline energy intake. In addition, participants 
completed 60 minutes of supervised, moderate-intensity, aerobic exercise weekly along 
with 10,000 steps per day as measured with a pedometer. Dietary compliance was 
measured with two-day food records collected at baseline and three months. 
Additionally, BW, tricep and subscapular skinfold thickness, WC, BF% as determined 
by the Brozek equation, and a blood sample was retrieved at baseline and three months. 
Genotyping was determined from peripheral leukocytes. Overall, while all participants 
experienced a significant reduction in BW, BMI, BF%, WC, and total cholesterol from 
baseline to three months (p < 0.01), participants with the wild-type allele pattern also 
demonstrated significant reductions in HDL (p < 0.05), LDL (p < 0.05), and TG (p < 
0.01). Moreover, participants with the wild-type allele pattern demonstrated greater 
reductions in BW and BMI (p < 0.01). 
 Similarly, a more recent three-month investigation was conducted in 260 
apparently healthy, obese (average BMI 37 kg/m2) men and women (55 men, 166 
women), with an average age of approximately 45 years old.17 Participants were 
randomized into two hypocaloric diet groups with similar macronutrient distributions 
(approximately 1400 kcal/d, 45% kcal CHO, 35% kcal fat, 20% kcal protein). The 
difference between diet groups remained in the content of MUFA versus PUFA. The 
MUFA group included a dietary prescription of 67.5% fat calories as MUFA and 10.8% 
fat calories as PUFA, while the PUFA group included 55.5% fat calories from MUFA 
and 22.7% fat calories from PUFA. The exercise intervention consisted of 60 minutes 
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per day of aerobic activity, three days per week. At baseline and three months, the 
following measures were collected: three-day food records, BW, blood pressure, body 
composition via bioelectrical impedance, and a blood sample. Additionally, genotyping 
was determined by peripheral leukocytes. As demonstrated in previous investigations, all 
participants experienced significant reductions in BMI, BW, FM, and WC from baseline 
to completion (p < 0.05), regardless of genotype or diet group. Individuals with the wild-
type allele pattern following the PUFA diet also demonstrated a significant reduction in 
BG, insulin, HOMA, TC, LDL, and TG from baseline (p < 0.05). When comparing 
genotypes within the diet groups, reductions in WC were significantly greater in mutant-
type following the MUFA diet (p < 0.05), whereas reductions in BMI were greater in 
wild-type allele pattern (p < 0.05). In the PUFA diet, participants with the mutant-type 
allele pattern exhibited greater reductions in BW, WC, and fasting insulin (p < 0.05), 
whereas participants with the wild-type allele pattern exhibited greater reductions in 
BMI, FM, WHR, and calculated HOMA (p < 0.05).17 
 Conclusively, evidence exists regarding baseline ADRB3 rs4994 genotype and 
response to weight loss interventions. Among investigations that demonstrated no 
significant differences between baseline genotype and response to intervention, this may 
be attributed to less-rigorous diet and exercise protocols.79,81-83 For example, half of 
these investigations did not include a specific dietary prescription, rather dietary 
counseling with the objective of reducing overall energy intake.81,82 Furthermore, while 
Rawson and colleagues included a specific dietary prescription, no exercise intervention 
was included; the opposite was done in the investigation for Bea and colleagues.79,83 
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Therefore, evidence suggests inclusion of a specific dietary and exercise prescription is 
necessary to determine if a relationship exists between baseline ADRB3 rs4994 
genotype and health outcomes after a weight loss intervention.  
Among the interventions that have demonstrated significant differences between 
genotype, the findings are inconsistent.17,22,23 Within the investigation that demonstrated 
health outcomes in favor of the mutant-type allele pattern, these results may be attributed 
to lack of caloric restriction within the intervention.22 Additionally, since this 
investigation was six-months in length in comparison to three-months in the 
investigations favoring the wild-type allele pattern, it is possible that the mutant-type 
allele pattern may be associated with long-term benefits, whereas the wild-type allele 
pattern is associated with acute response to weight loss intervention. Thus current 
evidence suggests that individuals with the wild-type allele pattern may experience 
greater health outcomes in comparison to the mutant-type allele pattern when following 
a hypocaloric, moderate fat diet, and participating in 60 minutes of moderate to high 
intensity aerobic activity three days per week for at least three months.  
ADRB3 rs4994 and Genetic Profiling 
 A strong association has been demonstrated between the mutant-type allele 
pattern of ADRB3 rs4994 and prevalence of obesity.74-76,78,84 Considering ADRB3’s 
exclusive location in adipocytes and primary role in lipid metabolism, dietary 
manipulation of fat intake specifically may be useful in improving health outcomes in 
individuals participating in a weight loss intervention. Among weight loss interventions, 
current evidence suggests the necessity of a specific dietary and exercise component 
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within the investigation to promote weight loss. Regarding the dietary component, 
evidence suggests a hypocaloric, moderate CHO, higher fat, adequate protein diet to 
promote improvements in body composition in individuals with the mutant-type allele 
pattern. Further, increase PUFA content within the diet may improve body composition 
and biochemical markers related to glucose and lipid metabolism in individuals with the 
wild-type allele pattern. Regarding the exercise component, it appears as though 
participation in 60 minutes of moderate to high intensity aerobic activity three days per 
week for at least three months is necessary. 
ADRB2 (rs1042713 and rs1042714) 
Association with Obesity 
Beta-2-adrenergic receptor (ADRB2) is a G-protein coupled receptor that is 
widely distributed across the body in adipocytes.85 The influence of catecholamines on 
the adrenergic receptors, specifically ADRB2, modulates lipolysis and lipogenesis.86 
Two of the most common genetic mutations associated with ADRB2 occur at codon 16 
and 27.86 At codon 16 (rs1042713), arginine (Arg) replaces glycine (Gly). The allele 
pattern homozygous for glycine (Gly/Gly) is considered the wild-type allele pattern, 
whereas the allele patterns including arginine (Arg/Gly, Arg/Arg) are considered the 
mutant-type. The frequency of the mutation varies depending on the population. For 
example, allelic frequency of arginine in Europeans is about 51-64% whereas the 
frequency in East Asians is 71-85%. Additionally the frequency of mutation is most 
common in women.86 At codon 27 (rs1042714), glutamic acid (Glu) replaces glutamine 
(Gln).86 Thus homozygous carriers of glutamine (Gln/Gln) contain the wild-type pattern, 
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and carriers of glutamic acid (Glu/Gln, Glu/Glu) are considered mutant-type. At the 
global level, the frequency of the mutation is about 30%.86  
Considering the high frequency of mutation at codons 16 and 27, role in lipid 
metabolism, and subsequent influence on energy expenditure, ADRB2 genotype at 
codons 16 and 27 may serve importance in relation to weight status.87 Current evidence 
suggesting an association between ADRB2 and obesity is mixed. Two meta-analyses 
assessing men and women of varying populations, ages, and weight classifications did 
not demonstrate any significant associations between mutations of ADRB2 at codon 16 
or 27 and increased risk of obesity or adverse health markers associated with obesity.86,88 
In contrast, regarding the mutation at codon 16 (rs1042713), two investigations, 
conducted in men and women demonstrated a significant association between the wild-
type allele pattern and prevalence of obesity.89,90 Additionally, a significantly higher 
BMI, WC, HC, WHR, total cholesterol, LDL, TG, leptin and insulin levels were 
demonstrated in individuals with the wild-type allele pattern.90 Along with these 
findings, two longitudinal studies, one over a six year time period and one over a 23 year 
time period, conducted in men and women, demonstrated a significant association 
between obesity in men carrying the wild-type allele pattern, and obesity in women 
carrying the mutant-type allele pattern.87,91 In a five year longitudinal study conducted in 
individuals who were normal weight at baseline, significant increases in BMI, WHR, 
FM, and BP were exhibited after five years in men and women carrying the glycine 
allele, which is part of the wild-type and heterozygous mutant-type allele patterns.92  
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Furthermore, the mutation at codon 27 (rs1042714) has also shown significant 
associations with obesity. In two recent meta-analyses, the presence of the mutant-type 
allele pattern demonstrated a significant association with obesity risk, with increased risk 
in Asians, Pacific Islanders, and American Indians.86,88 In investigations comparing 
normal weight to overweight/obese individuals, regardless of weight, individuals 
homozygous for the mutant-type allele pattern demonstrated significantly (p < 0.05) 
higher BMI,85,89,93 WC and HC,85 TG,85,89,93 fasting leptin and insulin,85 and incidence of 
type 2 diabetes.89 Moreover, a higher risk of obesity was demonstrated in individuals 
homozygous for the mutant-type allele pattern.89,93 In the previously mentioned five year 
longitudinal study, significant increases in BMI, WHR, FM, and BP were exhibited after 
five years in men and women carrying the mutant allele patterns.92  
Interestingly, only one investigation to date has assessed an interaction between 
the aforementioned mutations in ADRB2. Prior and colleagues94 exhibited significantly 
greater BMI, weight, BF%, intra-abdominal fat, fasting BG, and 120 minute post-
prandial glucose in obese, middle-aged women with the glycine allele at codon 16 
(Gly16) and glutamine allele at codon 27 (Gln27).94Additionally, individuals with Gly16 
and glutamic acid at codon 27 had the lowest oxygen consumption during a submaximal 
exercise test. These findings suggest individuals with the wild-type allele pattern of both 
ADRB2 polymorphisms or heterozygous mutant-type allele pattern of the mutation at 
codon 27 may be at greater risk of obesity and adverse health markers associated with 
obesity.  
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Overall, current evidence suggests an association between obesity and carriers of 
the glycine allele at codon 16 (wild-type or heterozygous mutant-type) and glutamic acid 
allele at codon 27 (heterozygous or homozygous mutant-type). The only investigation to 
date demonstrating a synergistic effect between these mutations in ADRB2 suggests 
prominent adverse health effects in the presence of the glycine allele at codon 16.94 Due 
to the aforementioned associations with obesity and known role of ADRB2 in regards to 
thermogenesis and lipid metabolism, further research regarding ADRB2 genotype at 
codon 16 and 27 in relation to success in a weight loss intervention is warranted.  
Weight Loss Interventions 
 Few investigations have assessed the relationship between baseline genotype of 
the common mutations of ADRB2 and health outcomes from a weight loss intervention. 
Regarding the mutation at codon 27, Bea and colleagues83, as previously mentioned with 
respect to ADRB3, demonstrated significant increases in lean soft issue in individuals 
with the mutant-type allele patterns. As demonstrated among weight loss trials related to 
ADRB3, the exercise intervention included in Bea and colleagues trial is the most 
rigorous prescription among all of the studies assessing baseline ADRB2 polymorphisms 
in response to a weight loss intervention.  
 The remaining weight loss trials assessing health outcomes in relation to baseline 
ADRB2 genotype at codon 16 and 27 consist primarily of dietary interventions, with 
some guidance/encouragement for participation in regular physical activity. In a 12-
month intervention exclusively assessing changes in relation to codon 27 genotype, 62 
apparently healthy, obese (BMI > 30 kg/m2), postmenopausal (average age ~39 years 
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old) women were prescribed a very low calorie diet for three months, with no specific 
instruction regarding macronutrient intake, for three months followed by a nine month 
weight maintenance period.24 The very low calorie diet consisted of approximately 750 
kcals/d, delivered primarily through meal replacement products, for the first three 
months, and participants attended weekly group sessions with an RD.24 The following 
nine months consisted of monthly group nutrition classes covering different nutrition 
topics to assist with weight maintenance and healthy eating habits. As for the exercise 
component, participants were instructed to keep a daily physical activity log including 
activity type, duration, and perceived intensity. At baseline, three months, and 12 
months, BW, WC, and body composition via DXA were measured. Additionally, 
baseline genotyping was determined from whole blood samples. As a whole, all 
participants lost weight and experienced favorable changes in body composition. A 
significant reduction in gynoid body fat percentage favoring the wild-type allele pattern 
versus homozygous mutant-type allele pattern was demonstrated (p < 0.03).24  
 Additionally, Saliba and colleagues95 conducted a seven week dietary 
intervention assessing outcomes related to baseline genotype of mutations at codon 27 
and codon 16. In this trial, 109 apparently healthy, obese (average BMI 30-34.9 kg/m2), 
premenopausal (average age 30-39 years old) women were prescribed individualized 
diets consisting of a 600 kcal deficit based on estimated energy requirements, with no 
specific prescription regarding macronutrient intake. The dietary intervention consisted 
of three individual counseling sessions and two group sessions. As for the exercise 
component, participants attended one group session that provided information regarding 
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increasing physical activity from baseline. BW was measured at baseline and seven 
weeks and baseline genotyping was determined from whole blood samples. Overall, no 
significant differences were exhibited between health outcomes and polymorphisms of 
ADRB2 at codon 16 or 27.95  
 Furthermore, a three month dietary intervention in 78 apparently healthy, obese 
(34 ± 2.8 kg/m2), premenopausal (average age 36.7 ± 7 years old) women, provided 
individualized diets for participants based on a 600 kcal deficit from the individual’s 
estimated energy requirements multiplied by an activity factor of 1.3 (low physical 
activity).25 Participants also attended weekly dietary counseling sessions with an RD. 
Unfortunately no exercise component was included in this study. The following 
measures were collected at baseline and completion of the study: three day weighed food 
records, BW, body composition via DXA, WC, and resting metabolic rate. Additionally, 
baseline genotyping was determined via a buffy coat. By the end of the intervention, no 
significant changes in outcomes were demonstrated among allele patterns at codon 16; 
however, a trend in change in BW and FM was exhibited favoring individuals with the 
wild-type allele pattern. At codon 27, individuals with the mutant-type allele patterns 
demonstrated significantly greater reductions in BW (p=0.002) and LM (p=0.001) in 
comparison to wild-type allele pattern.25  
 In contrast, in a five month diet only intervention exclusively assessing the 
mutation at codon 16, no significant differences were exhibited between allele patterns 
and health outcomes.96 In this investigation, 150 apparently healthy, overweight and 
obese (BMI 27-38 kg/m2) men and women (39 males, 111 females), aged 20-50 years 
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old were prescribed a very low calorie diet for two months, followed by instruction to 
maintain the newly achieved body weight for the last three months. The diet consisted of 
a formula containing 50 g CHO/d, 7 g fat/d, 52 g protein/d (~500 kcal/d), along with 
unlimited non-starchy vegetable intake. No exercise component was included in this 
study.  At baseline, two months, and five months, BW and body composition via the 
BOD POD were measured. Genotyping was determined at baseline via a buffy coat. . 
While all participants experienced significant reductions in BW, BMI, FM, percent FM, 
WC, and hip circumference (p < 0.001) from baseline to five months, no significant 
differences were found between genotypes.96  
 Collectively, the relationship between allelic variants of ADRB2 at codon 16 and 
codon 27 in relation to health outcomes and success in a weight loss intervention are 
inconclusive. Of the three investigations that assessed polymorphisms at codon 16, only 
one investigation demonstrated a trend in BW and FM loss favoring the wild-type allele 
pattern,25 with the other trials demonstrating no significant differences in outcomes 
between genotype.95,96 These differences may be attributed to varying lengths of study 
and dietary protocols. Additionally, only one of the investigations addressed physical 
activity.95  
Regarding the five trials that assessed polymorphisms at codon 27, only one 
investigation demonstrated a greater reduction in BW with the mutant-type allele 
pattern.25 Further, inconsistent findings regarding changes in lean mass with regards to 
the mutant-type allele pattern exist, with one trial demonstrating a reduction in lean 
mass25 and another exhibiting an increase.83 These findings may be attributed to 
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variances in methodologies, such that the latter trial consisted only of an exercise 
intervention, while the former solely implemented dietary intervention. Interestingly, in 
an investigation including diet and exercise, gynoid body fat percentage was reduced in 
individuals with the wild-type allele pattern.24 In contrast to the increased prevalence of 
obesity demonstrated in individuals with the mutant-type allele pattern, it appears as 
though individuals with the wild-type allele pattern experience greater weight loss when 
following a hypocaloric diet. Moreover, individuals with the mutant-type allele pattern 
have exhibited greater improvements in body composition when exercise has been 
included in the intervention. 
ADRB2 rs1042713 and rs1042714 and Genetic Profiling 
As mentioned previously, on account of the high frequency of mutation at codons 
16 and 27, role in lipid metabolism, and subsequent influence on energy expenditure, 
baseline allelic patterns in these sequences of ADRB2 may serve importance in relation 
to weight status.87 The wild-type allele pattern at codon 16 has been associated with 
overweight/obesity status and related adverse health effects.87,89-92 Equitably, there is 
evidence to suggest implementation of a hypocaloric diet to promote improved measures 
of body composition in individuals with the wild-type allele pattern at codon 16.25 In 
contrast, the mutant-type allele patterns at codon 27 have more frequently been 
associated with overweight/obese weight status.85,86,88,89,92,93 Current evidence suggests 
implementation of a hypocaloric diet along with an exercise prescription to promote 
improved measures of body composition in individuals with the mutant-type allele 
pattern.24,25,83  
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Summary: Genetic Profiling and Weight Loss Interventions 
Determining baseline variation in candidate genes provides insight regarding 
clinical intervention, diet, and exercise.8 Among the few investigations that have used 
genetic profiling in correspondence with weight loss interventions, the candidate genes 
assessed have been relatively inconsistent.7-9 However, the genetic profile used by 
Dopler-Nelson and colleagues (FABP2, rs1799883; PPARG2, rs1801282; ADRB3, 
rs4994C3; ADRB2, rs1042713 and rs1042714) demonstrated clear, significant effects.9 
Furthermore, research supports a strong association between each polymorphism in this 
profile and obesity/obesity-related adverse health outcomes. 57-59,65-68,74-78,85-89,91-93 
Collectively, within a weight loss intervention, evidence suggests implementation of a 
hypocaloric diet with variations in fat and CHO content pending allelic pattern of the 
gene, and inclusion of an exercise component.13-16,18-21,17,22-25,83 Thus, more weight loss 
interventions genotyping for FABP2 (rs1799883), PPARG2 (rs1801282), ADRB3 
(rs4994C3), and ADRB2 (rs1042713 and rs1042714) together to dictate dietary 
intervention, while including an exercise component, may be useful in improving health 
outcomes from participation in a weight loss intervention. 
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CHAPTER III 
METHODS 
 
Participants 
Fifty-one, apparently healthy, sedentary, overweight and obese (41.8 ± 12.1 yrs, 
35.3 ± 8.0 kg/m2, 45.1 ± 4.8% body fat)	women were recruited from College 
Station/Bryan Texas (see Appendix C for recruitment flyer). This investigation was 
approved by the Texas A&M University Institutional Review Board, #2013-0737F. 
Participants were randomly assigned to a dietary intervention that either aligned with 
their genotype (true match) or did not align with their genotype (false match). Inclusion 
criteria consisted of the following: individuals with a BMI greater than 22 kg/m2, 
individuals who were not currently participating in a planned exercise program; 
individuals who had not been exercising for more than 30 minutes per day, three days 
per week; individuals that did not experience a weight increase or decrease of seven 
pounds within three months; individuals who were not taking ergogenic levels of 
nutritional supplements that may have affected muscle mass, anabolic/catabolic hormone 
levels, or weight loss; and individuals who were not pregnant, nursing, or planning to 
become pregnant during the next 12 months.  Additionally, individuals were not 
included if they had an uncontrolled metabolic disorder.  
Study Site 
 The familiarization session, testing sessions, and circuit workouts were 
conducted at the Exercise and Sport Nutrition Laboratory (ESNL) at Texas A&M 
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University. The Exercise and Sport Nutrition Laboratory is part of the Department of 
Health and Kinesiology within the College of Education and Human Development. 
Experimental Design 
 Individuals who met the eligibility criteria and were interested in participating 
followed the study protocol outlined in Table 1. Buccal cheek swabs collected at the 
familiarization session were shipped to Interleukin Genetics (Waltham, MA) for 
genotyping. Once genotyping results were received (~6-10 weeks post familiarization 
session), individuals still interested in participating were randomly assigned to a dietary 
intervention that either aligned with their genotype (true matches to diet) or did not align 
with their genotype (false matches to diet). Participants completed seven testing sessions 
overall including a baseline testing session, with each session approximately four weeks 
apart. The exercise protocol was conducted at baseline, mid-point (end of three months), 
and completion (end of six months) of the study.  
Sample Size Calculation 
 A power analysis was conducted to determine goal sample size for this 
investigation and was built from previous research conducted in our laboratory utilizing 
similar diet and exercise intervention and Dopler-Nelson and colleague investigation. 
The analysis was set at >0.80 and was based on change in fat mass between diet groups 
from previous research in our lab, and body weight change between genotype in Dopler-
Nelson and colleagues investigation. Overall, the goal sample size for the present 
investigation was 80 participants.  
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Independent and Dependent Variables 
 Independent variables in this investigation included baseline genotype and 
exercise intervention. Exercise compliance was determined by attendance rate at the 
Curves Exercise Circuit along with measurement of peak and average heart rate during 
each workout. Assignment to dietary intervention was dependent on baseline genotype, 
and dietary compliance was determined from four-day food records submitted at each 
monthly testing session. Other dependent variables included body weight, height, resting 
energy expenditure, body composition, waist and hip circumference, resting heart rate 
and blood pressure, peak oxygen consumption, upper and lower body muscular strength 
and endurance, biochemical data (insulin, glucose, triglycerides, total cholesterol, HDL, 
LDL), and psychosocial parameters. The monthly psychosocial evaluation conducted 
included the following questionnaires: Rosenberg Self-Esteem Scale, Social Physique 
Anxiety Scale (SPAS), Eating Satisfaction Survey, and Multidimensional Body-Self 
Relations Questionnaire- Appearance Scales. 
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Table 1: Study protocol 
 
 
Familiarization Session 
 Individuals that expressed interest in participating in the study attended a 
familiarization session at the ESNL. At the start of the session, individuals were 
screened for eligibility (Appendix D). All eligible participants received the following 
information verbally from the study coordinator: purpose and rational of the study, 
review of study requirements, review of study protocol for each testing session followed 
by a guided tour of the lab. Next individuals were instructed to read the informed 
Familiarization  
 
Baseline 
(T1) 
4 Weeks 
(T2) 
8 Weeks 
(T3) 
12 Weeks 
(T4) 
16 Weeks 
(T5) 
20 Weeks 
(T6) 
24 Weeks 
(T7) 
 
Familiarization 
Session 
 
Complete 
Paperwork 
 
Review Medical 
History 
 
Physical Exam 
 
Genetic 
Screening 
 
Determination 
of 
Qualifications to 
Participate 
 
 
Randomized 
Diet 
Assignment: 
MC (30%C, 
25%F, 45% P) 
LC (20%C, 
35%F, 45% P) 
 
Phase I – 1,400 
kcals/d for 1 
week  
Phase II – 1,500 
kcals/d for 23 
weeks 
 
Diet Record  
Review 
 
IPAQa 
 
Body Weight 
 
Hip & Waist 
Measure 
 
Resting Energy 
Expenditure 
 
Resting BPb and 
HRc 
 
Body 
Composition 
 
Fasting Blood  
 
Maximal 
Cardiopulmonary 
Exercise Test 
 
1 rep and 80% 1 
rep Bench Press 
and Leg Press 
 
Survey 
Completiond 
 
 
Diet Record  
Review 
 
IPAQa 
 
Body 
Weight 
 
Hip & Waist 
Measure 
 
Resting 
Energy 
Expenditure 
 
Resting BPa 
and HRb 
 
Body 
Composition 
 
Fasting 
Blood  
 
Survey 
Completiond 
 
 
Diet Record  
Review 
 
IPAQa 
 
Body 
Weight 
 
Hip & Waist 
Measure 
 
Resting 
Energy 
Expenditure 
 
Resting BPa 
and HRb 
 
Body 
Composition 
 
Fasting 
Blood  
 
Survey 
Completiond 
 
 
Diet Record  
Review 
 
IPAQa 
 
Body Weight 
 
Hip & Waist 
Measure 
 
Resting Energy 
Expenditure 
 
Resting BPa and 
HRb 
 
Body 
Composition 
 
Fasting Blood  
 
Maximal 
Cardiopulmonary 
Exercise Test 
 
1 rep and 80% 1 
rep Bench Press 
and Leg Press 
 
Survey 
Completiond 
 
 
Diet Record  
Review 
 
IPAQa 
 
Body 
Weight 
 
Hip & Waist 
Measure 
 
Resting 
Energy 
Expenditure 
 
Resting BPa 
and HRb 
 
Body 
Composition 
 
Fasting 
Blood  
 
Survey 
Completiond 
 
 
Diet Record  
Review 
 
IPAQa 
 
Body Weight 
 
Hip & Waist 
Measure 
 
Resting 
Energy 
Expenditure 
 
Resting BPa 
and HRb 
 
Body 
Composition 
 
Fasting Blood  
 
Survey 
Completiond 
 
 
Diet Record  
Review 
 
IPAQa 
 
Body Weight 
 
Hip & Waist 
Measure 
 
Resting Energy 
Expenditure 
 
Resting BPa and 
HRb 
 
Body 
Composition 
 
Fasting Blood  
 
Maximal 
Cardiopulmonary 
Exercise Test 
 
1 rep and 80% 1 
rep Bench Press 
and Leg Press 
 
 
Survey 
Completiond 
 
aInternational Physical Activity Questionnaire; bBlood Pressure; cHeart Rate; dSocial Physical Anxiety Scale, Rosenberg Self-Esteem Scale, Body Image 
(Multidimensional Body-Self Relations Questionnaire- Appearance Scales), and Eating Satisfaction Survey, MC - Moderate Carbohydrate diet, LC – 
Low Carbohydrate diet   
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consent form (Appendix E). Interested individuals signed the informed consent, and 
completed a general health history questionnaire (Appendix F). Upon completion of 
paperwork, height, weight, resting heart rate and blood pressure were measured. Buccal 
cheek swabs for genotyping were also collected at this time.  
 Upon completion of the familiarization session, the research nurse reviewed all 
general health history questionnaires and measures collected at the session (i.e. resting 
heart rate, blood pressure, and calculated BMI). Pending history and current 
measurements, some participants were required to submit a physician clearance 
(Appendix G) per nurse’s evaluation prior to participating in the study.  
Genotyping 
 Buccal cheek swabs were collected at the familiarization session after individuals 
signed the informed consent. Once at least 40 samples were collected, samples were 
shipped to Interleukin Genetics Inc. (Waltham, MA) for genotyping within their CLIA 
(Clinical Laboratory Improvements Amendments) certified molecular genetics 
laboratory. Here DNA was extracted from buccal cheek swabs (Puritan, Gilford, ME) 
using standard procedures for the five polymorphisms of interest (rs1801282, rs1799883, 
rs1042714, rs4994, and rs1042713). Of note, the following polymorphisms genotyped 
are functional SNPs with clinical significance (ADRB3 rs4994, ADRB2 rs1042713 and 
rs1042714). Before polymerase chain reactions (PCR), DNA was diluted to adjust 
concentrations within a range compatible with multiplex PCR conditions. Single 
Nucleotide Polymorphism (SNP) genotyping was done by the single-base extension 
(SBE) method using the SNP stream instrument and chemistry (Beckman Coulter, Brea, 
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CA) with SNPs multiplexed as needed to avoid interference. The multiplex PCR were 
treated with exonuclease I and shrimp alkaline phosphatase (USB).  The SBE reaction 
was performed per manufacturer’s protocol, and “tagged” products were hybridized to a 
microarray plate. The SNPstream instrument was used to read the plates and the 
SNPstream software was used to determine initial allele calls, which were confirmed by 
a technician. 
 Approximately six to ten weeks after sending samples to Interluekin Genetics 
Inc. (Waltham, MA) for genotyping, results were provided to the ESNL lab coordinator 
and study coordinator via email. Genotyping results included the following information: 
allelic variant within each polymorphism as notated with the Human Genome Variation 
Society (HGVS) nomenclature, mutation patterns for each individual, suggested diet 
based on genotype (low fat, low CHO, or balanced diet), suggested exercise intensity 
(high or moderate metabolic equivalents). 
Dietary Protocol 
Moderate CHO/Adequate Fat/Moderate Protein Diet (MC) 
 Participants assigned to this dietary intervention followed the Curves Complete® 
diet program. The diet consisted of a1400 kcal/d prescription for the first week of the 
program and 1500 kcal/d for the remaining 23 weeks of the program. The macronutrient 
distribution range consisted of the following: 30% kcal CHO, 25% kcal fat, 45% kcal 
protein. In order to follow the diet, participants received a Curves Complete® online diet 
program account. Within the diet program, personalized menus were generated based on 
the individual’s response to a food preference questionnaire prompted at start up of the 
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account. Participants were able to change their food preferences at any time, which 
would in turn alter menus. Additionally participants were able to change meal and snack 
options within the menus through the online program. All participants received 
instruction on how to use the online program from the study coordinator, who was a 
Registered Dietitian. Furthermore, a free application for the online diet program was 
available for Android and iPhone users to assist with dietary compliance. Table 2 
outlines the dietary protocols prescribed. 
Low CHO/Adequate Fat/Moderate Protein Diet (LC) 
 The caloric prescription within this dietary intervention was consistent with the 
prescription in the moderate CHO diet (1400 kcal/d for one week, 1500 kcal/d for 23 
weeks). The macronutrient distribution range consisted of the following: 20% kcal CHO, 
35% kcal fat, 45% kcal protein (Table 2). In order to follow the diet, participants were 
provided a menu booklet for each caloric phase of the diet. Serving sizes were quantified 
based on the Diabetic Exchange System. The study coordinator provided all participants 
instruction on how to use the exchange system to substitute food items within the menus 
per individual taste preference.  
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Table 2: Dietary protocol 
 
Time Total kcal/d Macronutrients %/d g/d kcal/d g/kg/d (90 kg) 
Moderate Carbohydrate, Adequate Fat, Moderate Protein (MC) 
1 week 1400 CHO 
Fat 
Protein 
30 
25 
45 
105 
39 
158 
420 
250 
630 
1.17 
0.43 
1.75 
23 weeks 1500 CHO 
Fat 
Protein 
30 
25 
45 
113 
42 
169 
450 
375 
675 
1.25 
0.47 
1.88 
Low Carbohydrate, Adequate Fat, Moderate Protein (LC) 
1 week 1400 CHO 
Fat 
Protein 
20 
35 
45 
60 
54 
158 
280 
490 
630 
0.78 
0.6 
1.75 
23 weeks 1500 CHO 
Fat 
Protein 
20 
35 
45 
75 
58 
169 
300 
525 
675 
0.83 
0.65 
1.88 
 
 
 
Protocol Nomenclature 
 The nomenclature for each diet is based on accepted macronutrient distribution 
cut-offs within the literature.10-12 A low carbohydrate diet is defined as less than 30% 
kcals from CHO, therefore one of the diets is considered a low CHO diet, 20% kcal 
CHO, while the other is considered moderate CHO, 30% kcal CHO.10,11 The fat content 
of both diets is considered adequate as the percent kcals falls within the recommended 
macronutrient distribution range according to the dietary guidelines (20-35% kcals fat). 
Finally, a high protein diet is defined as greater than 55% kcals from protein, thus the 
current dietary prescription is considered moderate.11,12 
Genotype Matching to Diets 
 Based on genotyping results, suggested diets consisted of low CHO, low fat, or 
balanced diet. Individuals with suggested diet of balanced diet were offered participation 
in a different weight loss study conducted in the lab at that time. Regarding the 
suggested diet of low CHO, the true match for this suggest was the low CHO, adequate 
fat, moderate protein diet (20% kcal CHO, 35% kcal fat, 45% kcal protein). The true 
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match for the suggested low fat diet was the moderate CHO, adequate fat, moderate 
protein diet (30% kcal CHO, 25% kcal fat, 45% kcal protein). Relative to LC, MC 
contained less fat deeming this as the appropriate diet assignment to use within this 
intervention.  
Dietary Supplements 
 All participants received a monthly supply of dietary supplements upon 
completion of each testing session, including baseline testing. The daily supplement 
package consisted of a  calcium and vitamin D supplement, a standard women’s 
multivitamin and mineral supplement, and an omega-3 fatty acid supplement. 
Participants were instructed to take these supplements daily with food (Tables 3-5).  
 
Table 3: Calcium and vitamin D supplement 
Nutrient Daily Dose % Daily Value 
Vitamin D (cholecalciferol) 400 IU 100% 
Calcium (calcium citrate tetrahydrate & 
calcium citrate malate) 
800 mg 80% 
Magnesium Oxide 300 mg 75% 
Zinc Gluconate 7.5 mg 50% 
Copper 2 mg 100% 
Manganese 2 mg 100% 
 
Table 4: Omega-3 fatty acid supplement 
Nutrient Daily Dose % Daily Value 
Calories 20 N/A 
Calories from Fat 20 N/A 
Total Fat 2 g 2% 
Cholesterol 0 mg 0% 
Eicosapentaenoic Acid 320 mg N/A 
Docosahexaenoic Acid 200 mg N/A 
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Table 5: Multivitamin and mineral supplement 
 
Nutrient Daily Dose % Daily Value 
Vitamin A (50% beta-carotene; 50% retinyl 
acetate) 
5000 IU 100% 
Vitamin C 200 mg 333% 
Vitamin D (cholecalciferol) 1600 IU 400% 
Vitamin E 30 IU 100% 
Vitamin K 80 mcg 100% 
Thiamin 50 mg 3333% 
Riboflavin 50 mg 2941% 
Niacin 50 mg 250% 
Vitamin B-6 50 mg 2500% 
Folic Acid 400 mcg 100% 
Vitamin B-12 50 mcg 833% 
Biotin 300 mcg 100% 
Pantothenic Acid 50 mg 500% 
Calcium Carbonate 500 mg 50% 
Magnesium Oxide 100 mg 25% 
Zinc Oxide 15 mg 100% 
Selenium 200 mcg 286% 
Copper 2 mg 100% 
Manganese 2 mg 100% 
Chromium 120 mcg 100% 
Molybdenum 75 mcg 100% 
Blend: alpha-lipoic acid; green tea leaf 
extract; bilberry, elderberry, black currant, 
and blueberry fruit powders; resveratrol 
70 mg N/A 
Hyaluronic acid & Collagen 50 mg N/A 
Phosphatidylserine & Choline 20 mg N/A 
Cranberry Concentrate 20 mg N/A 
Inositol 10 mg N/A 
Silicon Dioxide 4 mg N/A 
Boron 2 mg N/A 
Lutein 950 mcg N/A 
Lycopene 950 mcg N/A 
Zeaxanthin 190 mcg N/A 
Astaxanthin 50 mcg N/A 
Vanadium 10 mcg N/A 
 
Exercise Protocol 
 All participants followed the Curves International® (Waco, TX) exercise 
program which consisted of circuit-style training with hydraulic resistance machines, 
interspersed with calisthenic exercise three times per week and Zumba dance one time 
per week. Each workout was 30 minutes in length. The Curves circuit was comprised of 
13 hydraulic resistance machines along with a personalized kiosk system, 
CurvesSmart®, that increased resistance provided by each machine based on baseline 
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resistance settings, performance from previous workouts, and frequency of workouts 
(i.e.- every day versus every other day). All 13 machines together provided a full-body 
resistance workout. 
Prior to beginning the exercise protocol and after baseline testing, participants 
met with study personnel to set up their personal account in the CurvesSmart® Kiosk at 
the Curves exercise circuit in the ESNL. At this time, participants reviewed the circuit 
exercise protocol, learned proper form and technique for each machine, and calibrated 
each machine based on current strength. The exercise protocol for the circuit on 
calisthenic exercise days included two laps around the circuit, with 30 seconds of 
repetitions per machine followed by 30 seconds of calisthenic exercise led by a Jillian 
Michaels® video. The exercise protocol for the circuit on Zumba exercise days included 
one lap around the circuit, with one minute of repetitions per machine followed by one 
minute of Zumba dance led by a certified Zumba instructor. During each workout on the 
Curves circuit, participants wore a Polar FT4 Heart Rate Monitor (Lake Success, NY) to 
keep track of exercise intensity and circuit attendance for compliance. In addition to 
following the Curves Exercise Program, participants were provided with a standard 
pedometer and instructed to reach a goal of 10,000 steps per day on the days they were 
not exercising on the circuit. 
Testing Session Procedures 
Pre-Testing Guidelines 
 Participants received reminder emails from the study coordinator both one-week 
and 24 hours prior to each testing session. The one-week reminder email included the 
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following instruction: fast for 10-12 hours, inhibit alcohol consumption and use of non-
steroidal anti-inflammatory drugs for 24 hours, refrain from exercise for 48 hours, wear 
articles of clothing and accessories without metal secondary to the DXA scan, and bring 
in completed four-day food records (blank documents attached to email). The one-week 
reminder emails for the exercise sessions also included direction to wear comfortable 
clothing and sneakers for participation in exercise testing. The email sent 24-hours prior 
to the session included a reminder of the session time and direction to bring in completed 
four-day food records and one-week activity log (blank documents attached to the 
email). Upon arrival to the ESNL for testing sessions, study personnel confirmed 
adherence to pre-testing guidelines and collected the four-day food logs for review. 
Anthropometrics 
 At the familiarization session, height was measured to the nearest hundredth of 
an inch using the Health-O-Meter Professional 500KL scale (Alsip, IL). Weight was 
measured to the nearest tenth of pound using the aforementioned scale at the 
familiarization session, baseline-testing session, and all monthly testing sessions with 
use of the same scale. At baseline and all monthly testing sessions waist and hip 
circumference was measured to the nearest tenth of an inch with standard measuring tape 
using methods described in the American College of Sports Medicine’s Guidelines for 
Exercise Testing and Prescription.97 
Resting Energy Expenditure 
 After measuring body weight, resting energy expenditure (REE) was measured 
using an open-circuit method of indirect calorimetry with the ParvoMedics TrueMax 
  
 
65 
2400 Metabolic Measurement System (Parvomedics Inc, Sandy, UT). At the start of 
each testing session day, quality control (QC) calibration procedures were performed for 
gas calibration and flowmeter calibration. The gas analyzer was calibrated against 
known concentrations. The flowmeter calibration was conducted with the Hans Rudolph 
series 5530 three-liter syringe (Hans Rudolph Inc., Kansas City, MO) following standard 
procedures. Per manufacturer, the coefficient of variation for the device is ±2% in 
apparently healthy individuals. In order to measure REE, participants rested comfortably 
in a bed with their legs resting on a padded box while under a metabolic hood to measure 
pulmonary exchange. Expiration passively diffused from the metabolic hood through 
tubing to the metabolic cart where gas exchange was measured. The test lasted 
approximately 20 minutes in length. The five time points with a rate of oxygen 
consumption and carbon dioxide expiration varying no more than five percent after the 
first ten minutes of the test were averaged for principle variables of interest (i.e.- oxygen 
consumption in L/min, resting energy expenditure in kcal/d, respiratory quotient).98,99  
Dual Energy X-Ray Absorptiometry 
Upon completion of the REE, the next measure commonly performed was the 
dual energy X-ray absorptiometry (DXA) scan via the Hologic Discovery W QDR series 
DXA system (Waltham, MA). At the start of each testing session day, QC calibration 
procedures were performed on the DXA via scan of a phantom spine (Discovery W-
Caliber Model DPA/QDR-1 anthropometric spine phantom). In order to determine 
change in bone mineral density, body composition, visceral adipose tissue, android and 
gynoid fat deposition from baseline, DXA scans were performed monthly on all 
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participants. The DXA scan provided low-dose radiation via an x-ray scan of the entire 
body excluding the head, thus participants were required to complete a radiation consent 
form at each testing session prior to the scan (Appendix H). Each DXA scan exposed 
participants to 1.5 mRs. By the end of the study, participants were exposed to a total of 
10.5 mRs of radiation. This amount of radiation exposure is less than the amount of 
radiation one is exposed to after living in College Station, TX for one year. The 
maximum x-ray radiation dose permitted per year for non-occupational reasons is 500 
mRs. 
For the test participants were instructed to remove all articles of clothing 
containing metal prior to the scan. Participants were supine on the scan table and lined 
up within the scanning field, with their feet taped inwards in order to capture accurate 
image of the hip girdle. Participants were instructed to close their eyes when the arm of 
the machine passed overhead. The test lasted approximately six minutes in length. The 
mean coefficient of variation for all scans throughout the study were between 0.31-
0.33% with a mean intra-class correlation of 0.935. 
Resting Heart Rate and Blood Pressure 
 Resting heart rate was typically measured after the DXA scan, while the 
participant was still in the supine position, as determined by palpating the radial or ulnar 
artery. Resting blood pressure was measured thereafter with a mercurial 
sphygmomanometer (American Diagnostic Corporation, model #AD-720, Hauppuage, 
NY) following standard procedures.  
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Blood Collection 
 Fasting blood samples were collected at baseline and each monthly testing 
session. Participants were fasted for 8-12 hours prior to each blood draw and blood was 
drawn following standard phlebotomy procedures. Upon collecting blood samples, one 
tube was spun in the Heraeus Megafuge 40R centrifuge (ThermoFisher Scientific, Inc) 
immediately at 3500 rpm for 10 minutes in order to obtain a peripheral leukoctye 
sample. The remaining three tubes sat out at room temperature for 15 minutes. After 15 
minutes, two tubes were spun in the aforementioned centrifuge following the same 
procedures to obtain serum samples, and one tube was kept as whole blood. Serum, 
peripheral leukocytes, and whole blood samples were pipetted from the collection tube 
to micro-centrifuge tubes and stored in a freezer at -80° C for later analyses.  
In order to measure glucose, triglycerides, total cholesterol, LDL, and HDL 
levels from serum samples, the Cobas C 111 (Roche Diagnostics, USA) was used 
following manufacturer instructions. The tested intra-assay coefficient of variation for 
these variables was approximately less than 3% along with a inter-assay coefficient of 
variation of less than 2%.100 In addition, serum samples were used to measure fasting 
insulin levels from a commercially available enzyme linked immunoabsorbent assay 
(ELISA) kit (ALPCO Diagnostics, Salem, NH). Within the procedures for the ELISA 
kit, a BioTek ELX-808 Ultramicoplate reader (BioTek Instruments Inc, Winooski, VT) 
was used with an optical density of 450 nm against known standard curve while 
following standard procedures from the BioTek Gen5 Analysis software. The intra-assay 
coefficient of variation has been shown to range from 5.1-10.3%, and the inter-assay 
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coefficient of variation ranges from 6.7-16.6%. Glucose to Insulin ratio was calculated 
by dividing glucose (mg/dL) by insulin (µIU/L). Taking the product glucose (mmol/L) 
and insulin (µIU/L) and dividing it by 22.5 calculated Homeostatic Model of Assessment 
for Insulin Resistance (HOMA-IR).101   
Peak Aerobic Capacity 
At baseline, end of three months, and end of six months, participants completed a 
graded exercise test on a treadmill following the Bruce protocol in order to measure 
fitness via peak aerobic capacity.97 At the start of each testing session day, QC 
calibration procedures were performed for gas calibration and flowmeter calibration. The 
gas analyzer was calibrated against known concentrations. The flowmeter was calibrated 
with the Hans Rudolph series 5530 three-liter syringe (Hans Rudolph Inc., Kansas City, 
MO) following standard procedures. The coefficient of variation for calibration 
procedures was ±2% for gas and flowmeter. The ParvoMedics TrueMax 2400 Metabolic 
Measurement System (Parvomedics Inc, Sandy, UT) was used to measure oxygen 
consumption. Additionally, a 10-lead echocardiogram (ECG) was included to monitor 
tracing for safety purposes (Nasiff Cardio Card Electrocardiograph, Nasiff Associates 
Inc, Central Square NY).  
While the participant was standing, BioProtech t716 electrodes (BioProtech Inc, 
Tuston, CA) were placed at 10 sites surrounding the heart. The 10 sites included the 
following: right and left subclavicular fossa (RA, LA), fourth intercostal space at the 
right and left sternal border (V1, V2), fifth intercostal space at the mid-clavicular line 
(V4), half-way between the fourth intercostal space at the left sternal border and fifth 
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intercostal space at the mid-clavicular line (V3), fifth intercostal space at the anterior 
axillary line and midaxillary line (V5, V6), and right and left abdominal line (RL, LL). 
Prior to electrode placement, the given area was wiped down with an alcohol swab and 
Trace Prep 2236 (3M Red Dot) to improve trace quality.  
Once electrodes were placed on the participant, she was instructed to lie down on 
an exam bed for lead placement. Upon placement of the leads while the participant was 
still in the supine position, rating of perceived exertion (RPE) based on the Borg Scale 
was recorded.97 Additionally resting heart rate and blood pressure was measured and 
recorded, and an ECG was printed and reviewed by lab personnel to ensure safe 
conditions for the test. Next the participant was instructed to stand up and walk towards 
the TrackMaster tmx425c treadmill (Full Vision Inc., Newton, KS). Once the participant 
was standing comfortably on the treadmill, the Bruce protocol was reviewed, along with 
obtainment of a second RPE, heart rate and blood pressure measurement, and printed 
ECG for review. Thereafter the participant was outfitted with nose clips and a sterile 
mouthpiece equipped with a headpiece for support and tubing to connect to the 
metabolic cart for expired gas analysis. 
Prior to initiation of the Bruce protocol, a two-minute warm-up at two miles per 
hour and zero percent incline was completed. During the graded exercise test, variables 
of interest (i.e.- ventilation, carbon dioxide production, respiratory quotient, and oxygen 
consumption) were measured constantly from expiration with the electronic flowmeter, 
and oxygen and carbon dioxide analyzers. Expiration was collected from the Hans 
Rudolph 2700 series two-way non-breathing valve that was attached to the mouthpiece. 
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Furthermore, RPE, heart rate, blood pressure, and ECG were collected at the end of 
every stage. The participant continued the test until she felt as if she was unable to 
continue, which was considered her peak aerobic capacity. At this time, RPE, ECG, 
heart rate and blood pressure was obtained prior to removal of nose clips and headgear. 
After this point, the participant began the recovery stage, which consisted of a three-
minute walking cool down on the treadmill and three-minute seated recovery. At the end 
of each recovery point, RPE, ECG, heart rate and blood pressure were collected.   
Upper and Lower Body Muscular Strength and Endurance 
 Participants completed leg press and bench press exercises at baseline, end of 
three months, and end of six months to determine upper and lower body strength and 
endurance. Muscular strength was measured by determining the participants one 
repetition maximum (1 RM). Muscular endurance was determined by the number of 
repetitions the participant could complete at 80% of her 1RM.  A standard hip sled leg 
press (Nebular Fitness, Versailles, OH) and bench press (Nebula Fitness, Versailles, OH) 
was used. For the leg press, the same sled and foot position was individualized and 
consistent among all exercise testing sessions. 
 Protocol for muscular strength was consistent for upper and lower body tests. 
The participant completed two sets of 10 repetitions with no weight on the sled or bench 
press bar, with two-minute rest in between. Thereafter, weight was added to the sled or 
bar and the participant completed one repetition. After a two-minute rest more weight 
was added and the protocol continued until failure to lift the last weight added to the sled 
or bench press bar. Once 1RM was identified, the participant was provided a four-minute 
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rest, and then completed as many repetitions as possible, while still maintaining correct 
form, at 80% of her 1RM.  
Food Log and Activity Log 
 Participants were instructed to complete and bring in four days of food records, 
including three weekdays and one weekend day, for every testing session (Appendix I). 
At the familiarization session participants were provided with detailed instruction on 
how to complete a food record. The following was included as instruction for 
completing food records: record all foods and beverages containing calories; record the 
food item, quantity consumed, and how it was prepared; for combination foods prepared 
at home (i.e. a sandwich) provide quantities and preparation method for each component 
of the food (i.e.- two slices whole wheat bread, 3 oz grilled chicken, 1 tbsp light 
mayonnaise); if the food item is from a fast food restaurant, simply record the name of 
the item and size/quantity consumed (i.e. Chic-Fil-A, 8 piece grilled nuggets). Food 
records were entered and analyzed with Food Processor Nutrition Analysis Software 
Version 10.12.0 (ESHA Nutrition Research, Salem OR).  
Participants also completed a one-week activity log, which included type of 
lifestyle and physical activity, perceived intensity of each activity, duration of each 
activity, and total step count for each day of the week. The one-week activity log was 
submitted at every testing session. Detailed instructions on how to complete this log 
were included on the document.  
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Psychosocial Evaluation 
Participants completed a battery of psychosocial questionnaires at each testing 
session throughout the study. Instructions on how to complete each questionnaire were 
provided on the document.  
Rosenberg Self-Esteem Scale 
The Rosenberg Self-Esteem Scale is a global method to assess self-esteem.102 
The survey consists of 10 statements that require a response on a scale of one to four, 
with one designating strong agreement with the statement and four designating strong 
disagreement. The survey is scored on a scale of 10-40, with lower scores indicating 
lower self-esteem and vice-versa. The correlation for reliability is 0.88.103 (Appendix K) 
Social Physique Anxiety Scale 
The Social Physique Anxiety Scale (SPAS) assesses an individual’s anxiety 
related to his or her physique via a 12 question survey.104 Individuals are instructed to 
rank how they feel towards each statement related to physique and appearance on a scale 
of one to five, with one indicating “not at all true” and five indicating “extremely true.” 
Increased anxiety related to physique is associated with an increased score. The SPAS 
has demonstrated a strong correlation for reliability, r = 0.82, with women.104 (Appendix 
L) 
Eating Satisfaction Survey 
The Eating Satisfaction Survey measures the severity of six symptoms related to 
quality of dietary intervention via a 10-point likert scale, with 0 indicating no symptoms 
and 10 indicating severe symptoms. The six symptoms included in this survey are 
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appetite, hunger, satisfaction from food, feeling of fullness, amount of energy, and 
overall quality of diet. As mentioned previously the Eating Satisfaction Survey has not 
been validated; however, the survey was developed by Curves International® thus the 
survey was used to maintain consistency among other Curves studies conducted within 
the ESNL.105 (Appendix J) 
Body Image  
 The Multidimensional Body-Self Relations Questionnaire- Appearance Scales 
(MBSRQ-AS) is a validated assessment for one’s perception of body image.106 The 
survey consists of 34 statements in which the individual is instructed to rank each 
statement on a scale of one to five, with one indicating definite disagreement and five 
indicating definite agreement. The instrument covers the following domains with 
reliability correlation in parentheses: appearance evaluation (0.88), appearance 
orientation (0.88), overweight preoccupation (0.73), self-classified weight (0.70), and 
body area satisfaction (0.77).106,107 (Appendix M) 
International Physical Activity Questionnaire 
 The International Physical Activity Questionnaire (IPAQ) is a globally validated 
survey instrument used to assess lifestyle and physical activity of adults aged 15-69 
years old over a seven day period.108,109 This instrument consists of 27 questions among 
five domains. The domains included are as follows: occupational activity, transportation-
related activity, housework and maintenance activity, leisure time activity, and total time 
spent sitting. Response to each question within each domain is evaluated based on a 
metabolic equivalent (METs) of the associated activity in order to determine one’s 
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average weekly activity. The reliability correlation is approximately 0.8.110 (Appendix 
N) 
Statistical Analyses 
All data was analyzed with SPSS statistical software package, version 22 
(Chicago, IL).  One-way ANOVA or MANOVA with repeated measures and a 
confidence level set at alpha 0.05 was used to assess the data. The repeated measures 
MANOVA was 2 x 2 x 7, with diet (MC or LC) and genotype (true or false match) as 
the between subjects factors and time (baseline, 4, 8, 12, 16, 20, 24 weeks) as the within 
subjects factor. Tukey’s least significant difference analyses were utilized for 
interactions to identify where statistically significant differences or trends were obtained. 
Furthermore, Cohen’s d effect sizes were calculated from partial eta squared values for 
observed statistical trends following the methods outlined in Jacob Cohen’s text book.111  
A total of 1,305 variables were analyzed with 66,555 data points total. Of the 
66,555 data points collected among all participants who completed the study, only 203 
data points were missing, representing 0.3% of the data points. Thus missing data points 
were replaced via linear interpolation method for variables pertaining to body 
composition, resting energy expenditure, fitness, and dietary intake. Last observed value 
carried forward (LOCF) method was used to present missing data points pertaining to 
fasting glucose and blood lipid profile. Additionally, LOCF was used for the 
psychosocial questionnaires of one participant at one time point where a testing session 
was missed. 
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Multivariate analyses are expressed with the Wilks’ Lambda distribution and 
probability levels from univariate tests are based on the Greenhouse-Geisser test to 
control for sphericity. Data pertaining to means at each time point and time effects are 
presented as mean ± standard deviation and group means are presented as mean ± 
standard error. Data in figures include delta change from baseline and are presented as 
mean ± standard deviation. 
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CHAPTER IV 
STUDY OUTCOMES 
Baseline Characteristics 
Fifty-one women completed the 24-week intervention. Twenty-nine women were 
randomly assigned to a diet that aligned with their genotype (true match) and 22 women 
were randomly assigned to a diet that did not align with their genotype (false match). 
Within the true matches (T), 16 women followed the moderate CHO, adequate fat, 
moderate protein diet (MC) and 13 women followed the low CHO, adequate fat, 
moderate protein diet (LC). Within the false matches (F), 7 women followed the MC diet 
and 15 women followed the LC diet. Analyses from one-way ANOVA revealed no 
significant differences between groups at baseline for age (41.8±12.1 yrs), height 
(162.3±6.8 cm), weight (94.1±21.8 kg), BMI (35.3±8.0), fat mass (40.0±13.3 kg), fat 
free mass (47.2±8.4 kg), body fat percentage (45.1±4.8), waist circumference (96.7±13.4 
cm), and hip circumference (123±16.2 cm). This investigation was performed in 
accordance with the Declaration of Helsinki and approved by the Texas A&M 
University Institutional Review Board (#2013-0737F). Figure 1 represents the consort 
diagram of the study. Table 6 represents baseline characteristics for participants within 
each group. 
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Figure 1: Consort diagram 
CIQ = Carbohydrate Intolerance Questionnaire
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Table 6: Baseline characteristics 
 
Variable Mean T-MC T-LC F-MC F-LC P-value 
Age (yrs) 41.8 ± 12.1 39.9 ± 13.2 41.5 ± 11.3 37.1 ± 12.2 46.3 ± 11.1 0.33 
Height (cm) 162.3 ± 6.8 160.0 ± 4.5 161.0 ± 7.8 166.3 ± 7.9 164.1 ± 6.8 0.12 
Weight (kg) 94.1 ± 21.8 88.0 ± 15.6 91.4 ± 24.6 101.2 ± 15.4 99.5 ± 26.7 0.38 
BMI (kg/m2) 35.3 ± 8.0 33.6 ± 8.0 34.9 ± 7.9 36.9 ± 7.0 36.7 ± 8.8 0.68 
Fat Mass (kg) 40.0 ± 13.3 36.8 ± 9.6 38.1 ± 14.7 43.2 ± 9.1 44.1 ± 16.7  0.36 
Fat Free Mass (kg) 47.2 ± 8.4 45.1 ± 6.5 46.4 ± 9.8 51.1 ± 6.6 48.4 ± 9.5 0.40 
Body Fat (%) 45.1 ± 4.8 44.2 ± 4.6 44.1 ± 5.5 45.5 ± 3.7 46.6 ± 4.7 0.43 
Waist (cm) 96.7 ± 13.4 95.9 ± 12.3 93.6 ± 12.8 98.7 ± 13.2 98.9 ± 15.7 0.74 
Hip (cm) 123 ± 16.2 119 ± 12.4 119 ± 15.6 126 ± 11.9 128 ± 20.8 0.31 
Data presented as Mean ± SD. Significance level p < 0.05. T = true match. F = false match. MC = moderate CHO. LC = low CHO. 
Mean (n = 51), T-MC (n = 16), T-LC (n = 13), F-MC (n = 7), F-LC (n = 15).  BMI = Body Mass Index. 
 
 
 
Dietary Intake 
Absolute Energy and Macronutrient Intake 
 Repeated measures MANOVA analyses revealed a Wilks’ Lambda effect of time 
(p=0.00) with no significant interactions for time x genotype (p=0.59), time x diet 
(p=0.75), and time x genotype x diet (p=0.76). Univariate analyses revealed a significant 
effect of time for total energy, CHO, fat, and protein intake. In reference to total energy, 
CHO, and fat intake, a significant linear relationship was observed such that all 
participants significantly decreased consumption of energy, daily grams of CHOs and fat 
from baseline to completion (Energy -520±498 kcal/d, p=0.00; CHO -81.1±73.3 g/d, 
p=0.00; fat -28.0±27.3 g/d, p=0.00). In addition, a significant linear relationship was 
observed for protein intake where intake increased from baseline to completion 
(+21.3±33.7 g/d, p=0.00) for all participants. Further, no significant interactions were 
observed for time x genotype, time x diet, and time x genotype x diet.  
A trend in genotype effect for CHO intake was observed, where false matches 
consumed less grams of CHOs per day at each time point in comparison to true matches 
(p=0.08, η2p=0.063, d=0.84). The large effect size suggests a strong relationship between 
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genotype and CHO intake. A trend in genotype x diet interaction with a large effect for 
energy was observed in T-LC (p=0.06, η2p=0.071, d=0.92). At 16 weeks T-LC energy 
intake was significantly less from baseline, with a trend in difference from their 
genotype counterpart, F-MC. From baseline to completion T-LC exhibited the greatest 
reduction in energy intake (-580±521 kcal/d) followed by T-MC (-560±566 kcal/d), F-
LC (-557±464 kcal/d), and F-MC (-244±343 kcal/d). A trend in genotype x diet 
interaction with a large effect was also observed for fat intake, where a greater reduction 
in fat intake from baseline to completion was exhibited in F-LC (-34.2±31.2 g/d), 
followed by T-MC (-30.0±24.5 g/d), T-LC (-24.2±27.6 g/d), and F-MC (-17.4±13.2 g/d) 
(p=0.06, η2p=0.072, d=0.93).  
Relative Energy and Macronutrient intake 
 Multivariate analyses revealed an overall Wilks’ Lambda effect of time (p=0.00) 
with no significant time x genotype (p=0.59), time x diet (p=0.67), or time x genotype x 
diet interaction (p=0.84). Univariate analyses revealed a significant effect of time for 
relative intake of kcals (p=0.00), grams of CHO (p=0.00), protein (p=0.00), and fat 
(p=0.00). From baseline to completion all participants exhibited a linear reduction in 
relative intake of kcals (-4.7±5.7 kcal/kg/d, p=0.00), CHO (-0.8±0.8 g/kg/d, p=0.00), and 
fat (-0.3±0.3 g/kg/d, p=0.00), along with a linear increase in intake of protein (+0.3±0.4 
g/kg/d, p=0.00). There were no significant interactions for time x genotype, time x diet, 
or time x genotype x diet. Furthermore, there was a significant genotype effect for 
relative intake of CHOs such that individuals in the true match group consumed less 
g/kg of CHOs per day at each time point, and exhibited a greater reduction in CHOs 
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from baseline to completion in comparison to false matches (T -0.9±0.9, F -0.7±0.7 
g/kg/d, p=0.02). There were no other significant effects for genotype, diet, or genotype x 
diet interaction.  
Macronutrient Intake as Percent of Total Intake 
 An overall Wilks’ Lambda effect of time (p=0.00) was observed with a trend in 
time x genotype x diet interaction consisting of a moderate relationship (p=0.09, 
η2p=0.031, d=0.60). No significant interactions for time x genotype (p=0.35) and time x 
diet (p=0.50) were observed. Univariate analyses revealed a significant effect of time for 
percent calories consumed from CHO (p=0.00), protein (p=0.00), and fat (p=0.004). 
From baseline to completion of the study percent of total energy consumed from CHO 
decreased linearly (-10.6±12.3 %kcal CHO, p=0.00) for all participants, whereas percent 
of total energy consumed from protein increased linearly (+15±8.5 % kcal protein, 
p=0.00). Fat intake demonstrated a significant quadratic relationship over time, where 
intake decreased from baseline to 3-months, then increased slightly from 3-6 months, but 
remained less at 6-months in comparison to baseline (baseline-3-months: -5.1±8.3 % 
kcal fat, 3-6 months: +1.1±8.6 % kcal fat, baseline-6-months: -4.1±8.8 % kcal fat,; 
p=0.004, pq=0.01). There were no significant interactions for time x genotype, time x 
diet, and time x genotype x diet. However, there was a trend in genotype effect, along 
with a strong relationship, for percent total calories consumed from CHOs such that true 
matches demonstrated a slightly greater reduction in percent of total calories consumed 
from CHOs at each time point and from baseline to completion (T -10.8±12.1, F -
10.4±12.8 % kcal CHO; p=0.07, η2p=0.069, d=0.88). Additionally, there were no 
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significant effect of diet or interaction for genotype x diet observed between subjects. 
Tables 7-9 represent absolute energy and macronutrient intake, relative energy and 
macronutrient intake, and macronutrient intake as percent of total intake respectively in 
each group throughout the study. 
Exercise and Activity Log 
 One-way ANOVA analyses demonstrate no significant differences between 
groups for the total number of workouts completed (T-MC 82±13, T-LC 80±13, F-MC 
73±13, F-LC 83±11, p=0.30) or percentage of workouts completed (T-MC 85±13, T-LC 
83±13, F-MC 76±13, F-LC 86±11 %, p=0.30). Among workouts completed, there was 
no significant difference for average heart rate (T-MC 136±13, T-LC 136± 2, F-MC 
143±18, F-LC 134±15 bpm, p=0.50) or peak heart rate between groups (T-MC 163±14, 
T-LC 162±12, F-MC 173±15, F-LC 160±17 bpm, p=0.30). Compliance with inclusion 
of step data on the weekly activity log was poor; therefore we were unable to analyze 
this data. 
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36
.8
 
10
1.
6±
5.
0 
M
C
 
81
.0
±2
3.
4 
97
.7
±2
9.
1 
99
.2
±1
7.
4 
10
0.
1±
26
.1
 
10
5.
0±
33
.1
 
95
.4
±2
3.
9 
10
3.
9±
26
.5
 
99
.8
±4
.9
 
LC
 
77
.1
±2
0.
6 
10
8.
6±
34
.4
 
10
2.
0±
30
.8
 
10
5.
9±
37
.1
 
97
.0
±3
6.
8 
10
0.
2±
35
.2
 
97
.1
±3
1.
3 
98
.3
±4
.1
 
 
Ti
m
e 
78
.8
±2
1.
8 
10
3.
7±
32
.3
*  
10
0.
7±
25
.4
*  
10
3.
3±
32
.4
*  
10
0.
6±
35
.1
*  
98
.1
±3
0.
4*
 
10
0.
2±
29
.1
*  
 
 
Fa
t I
nt
ak
e 
(g
/d
) 
T-
M
C
 
73
.7
±2
6.
2 
45
.5
±1
7.
3 
51
.9
±1
7.
0 
47
.1
±1
7.
6 
46
.0
±1
1.
7 
43
.6
±1
2.
3 
43
.7
±1
1.
2 
50
.2
±3
.0
 
T=
0.
00
 
G
=0
.7
3 
D
=0
.7
1 
G
×D
=0
.0
6 
T×
G
=0
.5
4 
T×
D
=0
.4
7 
T×
G
×D
=0
.3
9 
T-
LC
 
78
.6
±3
2.
7 
58
.4
±2
4.
0 
48
.4
±2
0.
3 
49
.5
±1
4.
9 
48
.2
±1
2.
9 
52
.0
±1
9.
6 
54
.4
±1
5.
1 
55
.6
±3
.3
 
F-
M
C
 
75
.1
±1
5.
4 
48
.3
±1
5.
6 
54
.0
±1
4.
8 
51
.3
±1
8.
7 
58
.2
±1
6.
1 
62
.3
±2
5.
0 
57
.7
±1
7.
3 
58
.1
±4
.5
 
F-
LC
 
71
.0
±2
8.
7 
50
.4
±1
5.
2 
47
.3
±1
7.
4 
49
.3
±2
1.
0 
45
.8
±1
9.
3 
50
.4
±2
4.
4 
36
.7
±1
9.
1b
cd
 
50
.1
±3
.1
δ  
T 
75
.9
±2
8.
8 
51
.3
±2
1.
2 
20
.3
±1
8.
3 
48
.2
±1
6.
2 
47
.0
±1
2.
1 
47
.4
±1
6.
2 
48
.5
±1
4.
0 
52
.9
±2
.2
 
F 
72
.3
±2
5.
0 
49
.8
±1
5.
0 
49
.4
±1
6.
6 
50
.0
±1
9.
9 
49
.7
±1
8.
9 
54
.2
±2
4.
6 
43
.3
±2
0.
7 
54
.2
±2
.7
 
M
C
 
74
.1
±2
3.
1 
46
.4
±1
6.
5 
52
.5
±1
6.
1 
48
.4
±1
7.
6 
49
.7
±1
4.
1 
49
.3
±1
8.
7 
47
.9
±1
4.
5 
54
.2
±2
.7
 
LC
 
74
.5
±3
0.
3 
54
.1
±1
9.
8 
47
.8
±1
8.
5 
49
.4
±1
8.
1 
46
.9
±1
6.
4 
51
.1
±2
1.
9 
44
.9
±1
9.
3 
52
.9
±2
.3
 
 
Ti
m
e 
74
.3
±2
7.
0 
50
.6
±1
8.
6*
 
49
.9
±1
7.
4*
 
49
.0
±1
7.
7*
 
48
.2
±1
5.
3*
 
50
.3
±2
0.
3*
 
46
.3
±1
7.
2*
 
 
 
D
at
a 
pr
es
en
te
d 
as
 M
ea
n±
SD
. S
ig
ni
fic
an
ce
 le
ve
l p
 <
 0
.0
5.
 M
ea
n 
(n
 =
 5
1)
, T
 =
 tr
ue
 m
at
ch
 (n
 =
 2
9)
, F
 =
 fa
ls
e 
m
at
ch
 (n
 =
 2
2)
, M
C
 =
 m
od
er
at
e 
C
H
O
 (n
 =
 2
3)
, L
C
 =
 lo
w
 C
H
O
 (n
 =
 2
8)
, T
-M
C
 (n
 =
 1
6)
, T
-L
C
 
(n
 =
 1
3)
, F
-M
C
 (n
 =
 7
), 
F-
LC
 (n
 =
 1
5)
. T
 =
 ti
m
e 
ef
fe
ct
, G
 =
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t e
ff
ec
t, 
D
 =
 d
ie
t e
ff
ec
t, 
G
×D
 =
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t x
 d
ie
t e
ff
ec
t, 
T×
G
 =
 ti
m
e 
x 
ge
no
ty
pe
 m
at
ch
 to
 d
ie
t e
ff
ec
t, 
T×
D
 =
 
tim
e 
x 
di
et
 e
ff
ec
t, 
T×
G
×D
 =
 ti
m
e 
x 
di
et
 x
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t e
ff
ec
t. 
*s
ig
ni
fic
an
t t
im
e 
ef
fe
ct
 fr
om
 b
as
el
in
e 
p 
< 
0.
05
 (u
ni
va
ria
te
), 
γ 
tre
nd
 in
 g
en
ot
yp
e 
ef
fe
ct
 p
 >
 0
.0
5 
an
d 
p 
< 
0.
1,
 δ
 tr
en
d 
in
 g
en
ot
yp
e 
x 
di
et
 in
te
ra
ct
io
n 
p 
> 
0.
05
 a
nd
 p
 <
 0
.1
 (T
uk
ey
 L
SD
), 
^ 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 c
om
pa
re
d 
to
 b
as
el
in
e 
(T
uk
ey
 L
SD
). 
Le
tte
r s
up
er
sc
rip
ts
 in
di
ca
te
 si
gn
ifi
ca
nc
e 
(p
 <
 0
.0
5)
 fr
om
 T
uk
ey
 L
SD
 p
os
t h
oc
 a
na
ly
se
s:
 
b s
ig
ni
fic
an
t d
iff
er
en
ce
 fr
om
 T
-M
C
, c
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 fr
om
 T
-L
C
, d
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 fr
om
 F
-M
C
, e
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 fr
om
 F
-L
C
. 
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T
ab
le
 8
: R
el
at
iv
e 
m
ac
ro
nu
tri
en
t i
nt
ak
e 
ob
se
rv
ed
 b
et
w
ee
n 
gr
ou
ps
  
 
V
ar
ia
bl
e 
G
ro
up
 
B
as
el
in
e 
4 
W
ee
ks
 
8 
W
ee
ks
 
12
 
W
ee
ks
 
16
 
W
ee
ks
 
20
 
W
ee
ks
 
24
 
W
ee
ks
 
G
ro
up
 (S
EM
) 
P-
va
lu
e 
En
er
gy
 In
ta
ke
 
(k
ca
l/k
g/
d)
 
 
T-
M
C
 
20
.5
±6
.5
 
14
.9
±3
.3
 
16
.3
±4
.5
 
16
.0
±4
.4
 
15
.9
±3
.9
 
15
.2
±4
.4
 
15
.0
±3
.5
 
16
.2
±1
.0
 
T=
0.
00
 
G
=0
.1
3 
D
=0
.8
9 
G
×D
=0
.4
7 
T×
G
=0
.3
8 
T×
D
=0
.2
5 
T×
G
×D
=0
.8
5 
 
T-
LC
 
21
.7
±7
.1
 
17
.7
±6
.9
 
15
.8
±4
.1
 
17
.0
±4
.3
 
14
.9
±6
.3
 
15
.8
±5
.8
 
15
.7
±3
.2
 
17
.0
±1
.1
 
F-
M
C
 
17
.8
±3
.7
 
13
.2
±3
.6
 
14
.2
±4
.4
 
14
.9
±3
.1
 
16
.0
±5
.2
 
14
.8
±5
.1
 
15
.8
±3
.4
 
15
.3
±1
.6
 
F-
LC
 
17
.3
±6
.8
 
14
.0
±5
.2
 
13
.5
±5
.6
 
14
.5
±6
.1
 
13
.6
±5
.0
 
13
.9
±5
.8
 
12
.5
±6
.4
 
14
.2
±1
.1
 
T 
21
.0
±6
.7
 
16
.2
±5
.3
 
16
.0
±4
.3
 
16
.4
±4
.3
 
15
.4
±5
.0
 
15
.5
±5
.0
 
15
.3
±3
.3
 
16
.6
±0
.8
 
F 
17
.4
±5
.9
 
13
.8
±4
.7
 
13
.8
±5
.1
 
14
.6
±5
.3
 
14
.4
±5
.1
 
14
.2
±5
.5
 
13
.6
±5
.8
 
14
.7
±0
.8
 
M
C
 
19
.7
±5
.8
 
14
.4
±3
.4
 
15
.6
±4
.5
 
15
.7
±4
.0
 
15
.9
±4
.2
 
15
.1
±4
.5
 
15
.3
±3
.4
 
15
.8
±0
.9
 
LC
 
19
.3
±7
.2
 
15
.8
±6
.3
 
14
.6
±5
.0
 
15
.6
±5
.4
 
14
.2
±5
.6
 
14
.8
±5
.8
 
14
.0
±5
.3
 
15
.6
±0
.8
 
Ti
m
e 
19
.5
±6
.5
 
15
.1
±5
.2
*  
15
.0
±4
.8
*  
15
.7
±4
.8
*  
15
.0
±5
.0
*  
14
.9
±5
.2
*  
14
.6
±4
.6
*  
 
C
H
O
 In
ta
ke
 
(g
/k
g/
d)
 
 
T-
M
C
 
2.
1±
0.
8 
1.
4±
0.
7 
1.
4±
0.
6 
1.
5±
0.
6 
1.
3±
0.
5 
1.
3±
0.
6 
1.
3±
0.
5 
1.
5±
0.
1 
T=
0.
00
 
G
=0
.0
2 
D
=0
.2
4 
G
×D
=0
.5
3 
T×
G
=0
.3
0 
T×
D
=0
.4
5 
T×
G
×D
=0
.5
7 
T-
LC
 
2.
2±
0.
9 
1.
2±
0.
6 
1.
3±
0.
7 
1.
5±
0.
9 
1.
1±
0.
6 
1.
1±
0.
5 
1.
2±
0.
6 
1.
4±
0.
1 
F-
M
C
 
1.
6±
0.
7 
0.
9±
0.
3 
1.
1±
0.
6 
1.
2±
0.
6 
1.
3±
0.
7 
1.
3±
0.
6 
1.
2±
0.
6 
1.
2±
0.
2 
F-
LC
 
1.
7±
0.
7 
0.
9±
0.
5 
0.
9±
0.
4 
0.
8±
0.
3 
0.
8±
0.
4 
1.
1±
0.
5 
0.
8±
0.
4 
1.
0±
0.
1 
T 
2.
2±
0.
8 
1.
3±
0.
7 
1.
4±
0.
6 
1.
5±
0.
7 
1.
2±
0.
5 
1.
2±
0.
6 
1.
2±
0.
6 
1.
4±
0.
1 
F 
1.
6±
0.
7 
0.
9±
0.
5 
0.
9±
0.
5 
0.
9±
0.
5 
1.
0±
0.
6 
1.
0±
0.
5 
0.
9±
0.
5 
1.
1±
0.
1Γ
 
M
C
 
2.
0±
0.
8 
1.
3±
0.
6 
1.
3±
0.
6 
1.
4±
0.
6 
1.
3±
0.
6 
1.
1±
0.
5 
1.
2±
0.
5 
1.
3±
0.
1 
LC
 
1.
9±
0.
9 
1.
0±
0.
6 
1.
1±
0.
6 
1.
1±
0.
7 
1.
0±
0.
5 
0.
9±
0.
6 
1.
0±
0.
6 
1.
2±
0.
9 
 
Ti
m
e 
1.
9±
0.
8 
1.
2±
0.
6*
 
1.
2±
0.
6*
 
1.
2±
0.
7*
 
1.
1±
0.
5*
 
1.
1±
0.
6*
 
1.
1±
0.
6*
 
 
 
Pr
ot
ei
n 
In
ta
ke
  
(g
/k
g/
d)
 
  
T-
M
C
 
0.
9±
0.
3 
1.
1±
0.
3 
1.
2±
0.
3 
1.
1±
0.
3 
1.
3±
0.
4 
1.
2±
0.
3 
1.
2±
0.
3 
1.
1±
0.
1 
T=
0.
00
 
G
=0
.5
5 
D
=0
.6
1 
G
×D
=0
.7
0 
T×
G
=0
.5
0 
T×
D
=0
.3
5 
T×
G
×D
=0
.6
9 
 
T-
LC
 
1.
0±
0.
3 
1.
4±
0.
7 
1.
2±
0.
6 
1.
3±
0.
6 
1.
2±
0.
7 
1.
4±
0.
8 
1.
2±
0.
5 
1.
2±
0.
1 
F-
M
C
 
0.
9±
0.
2 
1.
1±
0.
4 
1.
1±
0.
3 
1.
2±
0.
3 
1.
1±
0.
4 
1.
1±
0.
4 
1.
3±
0.
4 
1.
1±
0.
2 
F-
LC
 
0.
8±
0.
3 
1.
2±
0.
5 
1.
2±
0.
6 
1.
3±
0.
7 
1.
1±
0.
6 
1.
1±
0.
5 
1.
1±
0.
7 
1.
1±
0.
1 
T 
0.
9±
0.
3 
1.
3±
0.
6 
1.
2±
0.
4 
1.
2±
0.
5 
1.
2±
0.
5 
1.
2±
0.
6 
1.
2±
0.
4 
1.
2±
0.
1 
F 
0.
8±
0.
3 
1.
1±
0.
5 
1.
2±
0.
5 
1.
3±
0.
6 
1.
1±
0.
5 
1.
1±
0.
5 
1.
2±
0.
6 
1.
1±
0.
1 
M
C
 
0.
9±
0.
3 
1.
1±
0.
3 
1.
1±
0.
3 
1.
2±
0.
3 
1.
2±
0.
4 
1.
1±
0.
3 
1.
2±
0.
3 
1.
1±
0.
1 
LC
 
0.
9±
0.
3 
1.
3±
0.
6 
1.
2±
0.
6 
1.
3±
0.
6 
1.
2±
0.
7 
1.
2±
0.
7 
1.
2±
0.
6 
1.
2±
0.
1 
 
Ti
m
e 
0.
9±
0.
3 
1.
2±
0.
5*
 
1.
2±
0.
5*
 
1.
2±
0.
5*
 
1.
2±
0.
5*
 
1.
2±
0.
5*
 
1.
2±
0.
5*
 
 
 
Fa
t I
nt
ak
e 
(g
/k
g/
d)
 
 
T-
M
C
 
0.
8±
0.
3 
0.
5±
0.
2 
0.
6±
0.
3 
0.
6±
0.
2 
0.
6±
0.
2 
0.
5±
0.
2 
0.
5±
0.
2 
0.
6±
0.
04
 
T=
0.
00
 
G
=0
.3
9 
D
=0
.9
2 
G
×D
=0
.4
0 
T×
G
=0
.4
8 
T×
D
=0
.4
2 
T×
G
×D
=0
.4
1 
 
T-
LC
 
0.
9±
0.
4 
0.
7±
0.
4 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
7±
0.
05
 
F-
M
C
 
0.
7±
0.
1 
0.
5±
0.
2 
0.
6±
0.
2 
0.
5±
0.
1 
0.
6±
0.
2 
0.
7±
0.
3 
0.
6±
0.
2 
0.
6±
0.
07
 
F-
LC
 
0.
8±
0.
4 
0.
6±
0.
2 
0.
5±
0.
3 
0.
6±
0.
3 
0.
5±
0.
2 
0.
6±
0.
3 
0.
4±
0.
3 
0.
6±
0.
05
 
T 
0.
9±
0.
3 
0.
6±
0.
3 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
03
 
F 
0.
8±
0.
3 
0.
5±
0.
2 
0.
5±
0.
2 
0.
6±
0.
3 
0.
5±
0.
2 
0.
6±
0.
3 
0.
5±
0.
3 
0.
6±
0.
04
 
M
C
 
0.
8±
0.
3 
0.
5±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
2 
0.
6±
0.
04
 
LC
 
0.
8±
0.
4 
0.
6±
0.
3 
0.
5±
0.
2 
0.
6±
0.
2 
0.
5±
0.
2 
0.
6±
0.
3 
0.
5±
0.
3 
0.
6±
0.
03
 
 
Ti
m
e 
0.
8±
0.
3 
0.
6±
0.
3*
 
0.
6±
0.
2*
 
0.
6±
0.
2*
 
0.
6±
0.
2*
 
0.
6±
0.
2*
 
0.
5±
0.
2*
 
 
 
D
at
a 
pr
es
en
te
d 
as
 M
ea
n±
SD
. S
ig
ni
fic
an
ce
 le
ve
l p
 <
 0
.0
5.
 M
ea
n 
(n
 =
 5
1)
, T
 =
 tr
ue
 m
at
ch
 (n
 =
 2
9)
, F
 =
 fa
ls
e 
m
at
ch
 (n
 =
 2
2)
, M
C
 =
 m
od
er
at
e 
C
H
O
 (n
 =
 2
3)
, L
C
 =
 lo
w
 C
H
O
 (n
 =
 2
8)
, T
-M
C
 (n
 =
 1
6)
, T
-L
C
 
(n
 =
 1
3)
, F
-M
C
 (n
 =
 7
), 
F-
LC
 (n
 =
 1
5)
. T
 =
 ti
m
e 
ef
fe
ct
, G
 =
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t e
ff
ec
t, 
D
 =
 d
ie
t e
ff
ec
t, 
G
×D
 =
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t x
 d
ie
t e
ff
ec
t, 
T×
G
 =
 ti
m
e 
x 
ge
no
ty
pe
 m
at
ch
 to
 d
ie
t e
ff
ec
t, 
T×
D
 =
 
tim
e 
x 
di
et
 e
ff
ec
t, 
T×
G
×D
 =
 ti
m
e 
x 
di
et
 x
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t e
ff
ec
t. 
*s
ig
ni
fic
an
t t
im
e 
ef
fe
ct
 fr
om
 b
as
el
in
e 
p 
< 
0.
05
 (u
ni
va
ria
te
), 
Γ 
si
gn
ifi
ca
nt
 g
en
ot
yp
e 
ef
fe
ct
 p
 <
 0
.0
5 
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T
ab
le
 9
: P
er
ce
nt
 to
ta
l k
ca
ls
 fr
om
 m
ac
ro
nu
tri
en
ts
 o
bs
er
ve
d 
be
tw
ee
n 
gr
ou
ps
 
 
V
ar
ia
bl
e 
G
ro
up
 
B
as
el
in
e 
4 
W
ee
ks
 
8 
W
ee
ks
 
12
 
W
ee
ks
 
16
 
W
ee
ks
 
20
 
W
ee
ks
 
24
 
W
ee
ks
 
G
ro
up
 (S
EM
) 
P-
va
lu
e 
C
H
O
 In
ta
ke
 
(%
 to
ta
l k
ca
l) 
 
T-
M
C
 
42
.3
±9
.5
 
37
.3
±1
2.
8 
33
.7
±7
.7
 
37
.2
±8
.3
 
32
.8
±8
.3
 
35
.3
±7
.3
 
33
.1
±9
.7
 
36
.0
±2
.0
 
T=
0.
00
 
G
=0
.0
7 
D
=0
.2
8 
G
×D
=0
.8
4 
T×
G
=0
.8
6 
T×
D
=0
.2
5 
T×
G
×D
=0
.5
0 
 
T-
LC
 
42
.2
±7
.7
 
29
.7
±1
2.
3 
33
.5
±1
3.
3 
35
.0
±1
4.
7 
30
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Lifestyle Activity 
  Lifestyle activity was measured monthly via IPAQ. An overall Wilks’ Lambda 
effect of time (p=0.002) was observed, with no significant interaction for time x 
genotype (p=0.95), time x diet (p=0.37), or time x genotype x diet (p=0.82). Univariate 
analyses revealed a significant time effect for vigorous intensity MET minutes that was 
quadratic in nature. Overall participants increased time participating in vigorous 
intensity activity from baseline to 6-months (+618±1198 min/wk; p=0.00, pq=0.01). 
Additionally, a significant time x diet interaction was observed for walking MET 
minutes (p=0.05). MC exhibited significant reduction in walking MET minutes at each 
time point from baseline, whereas LC exhibited significant increase in walking MET 
minutes at each time point from baseline. There were no other significant time effects, 
time interactions, genotype effects, diet effects, or genotype x diet interactions observed. 
Table 10 represents intensity of weekly lifestyle activity in each group throughout the 
study. 
Regarding occupational activity, transportation activity, house and garden 
activity, and leisure-time activity, an overall Wilks’ Lambda time effect was observed 
(p=0.04) with no significant time x genotype (p=0.53), time x diet (p=0.72), or time x 
genotype x diet (p=0.34) interaction. Univariate analyses revealed significant time effect 
for leisure-time activity such that all participants increased activity during leisure-time 
from baseline to completion (+854±1399 min/wk; p=0.002). No other significant effects 
or interactions were demonstrated within subjects among variables. Further, no 
significant between subjects effects or interactions were exhibited among variables. 
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Table 11 represents occupational, active transportation, house and garden and leisure 
time activity in each group throughout the study.   
Finally, regarding total time sitting, overall, there was no significant effect of 
time (Wilks’ Lambda p=0.52) or interaction for time x genotype (p=0.46), time x diet 
(p=0.24), or time x genotype x diet (p=0.86). Univariate analyses revealed no significant 
time effect or interactions. A significant effect of diet was observed where MC exhibited 
less time sitting at each time point in comparison to LC and exhibited the greatest 
reduction in time spent sitting from baseline to completion of the study (MC -179±169, 
LC -103±624 min/wk, p=0.03). Table 12 represents total time sitting observed between 
groups throughout the study.  
Anthropometrics and Body Composition 	
Body Weight, Fat Mass, Fat Free Mass, Body Fat Percentage 
 An overall Wilks’ Lambda effect of time (p=0.00) with no significant interaction 
for time x genotype (p=0.77), time x diet (p=0.54), or time x genotype x diet (p=0.76) 
was observed. Univariate analyses revealed a significant time effect for body weight, fat 
mass, and body fat percentage, such that all participants exhibited a reduction within 
these variables from baseline to completion (body weight -5.3±5.0 kg, p=0.00; fat mass -
4.4±3.7 kg, p=0.00; body fat percentage -2.8±2.7%, p=0.00). For fat free mass, a trend in 
time with a moderate effect was observed revealing a significant quadratic relationship, 
where fat free mass decreased from baseline to 3-months, and then increased from 3-6 
months returning close to baseline levels (baseline-3-months: -0.9±1.8 kg, 3-6-months: 
+0.2±1.7 kg, baseline-6 months -0.6±2.3 kg; pq=0.01, p=0.08, η2p=0.044, d=0.64).  
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G
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G
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84
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69
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5±
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24
1±
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8±
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40
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6±
4,
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3,
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4,
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2,
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7±
2,
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3,
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9±
2,
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3,
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2,
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4,
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1±
3,
16
4 
4,
30
1±
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40
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F-
LC
 
2,
27
9±
1,
95
1 
4,
11
6±
1,
83
5 
5,
12
5±
4,
76
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5,
01
0±
3,
00
1 
3,
78
4±
2,
14
6 
5,
44
3±
4,
84
3 
4,
61
7±
3,
22
8 
4,
33
9±
95
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3,
82
5±
5,
28
0 
4,
71
5±
4,
91
2 
5,
15
9±
6,
25
9 
4,
09
5±
4,
66
5 
4,
25
6±
3,
93
3 
5,
06
3±
6,
56
3 
3,
92
5±
4,
49
5 
4,
29
1±
69
3 
F 
3,
01
6±
2,
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0 
4,
54
6±
2,
59
7 
5,
01
3±
4,
14
8 
4,
83
1±
2,
78
1 
3,
56
9±
2,
22
6 
4,
83
9±
4,
30
3 
4,
47
5±
3,
13
9 
4,
32
0±
84
9 
M
C
 
4,
56
4±
6,
02
0 
5,
36
4±
5,
57
3 
5,
53
6±
6,
35
4 
4,
93
6±
4,
99
9 
4,
07
5±
4,
06
8 
5,
50
8±
7,
13
3 
4,
38
4±
4,
83
4 
4,
73
8±
84
1 
LC
 
2,
55
0±
1,
89
1 
3,
92
2±
1,
88
2 
4,
70
7±
4,
40
0 
4,
01
0±
2,
69
5 
3,
81
1±
2,
46
7 
4,
42
0±
3,
96
9 
3,
92
1±
3,
00
0 
3,
87
2±
70
3 
Ti
m
e 
3,
45
8±
4,
34
8 
4,
57
2±
4,
01
3 
5,
08
1±
5,
32
8 
4,
42
8±
3,
89
0 
3,
93
0±
3,
25
3 
4,
91
1±
5,
58
5 
4,
12
9±
3,
89
8 
 
D
at
a 
pr
es
en
te
d 
as
 M
ea
n±
SD
. S
ig
ni
fic
an
ce
 le
ve
l p
 <
 0
.0
5.
 M
ea
n 
(n
 =
 5
1)
, T
 =
 tr
ue
 m
at
ch
 (n
 =
 2
9)
, F
 =
 fa
ls
e 
m
at
ch
 (n
 =
 2
2)
, M
C
 =
 m
od
er
at
e 
C
H
O
 (n
 =
 2
3)
, L
C
 =
 lo
w
 C
H
O
 (n
 =
 2
8)
, T
-M
C
 (n
 =
 1
6)
, T
-L
C
 
(n
 =
 1
3)
, F
-M
C
 (n
 =
 7
), 
F-
LC
 (n
 =
 1
5)
. T
 =
 ti
m
e 
ef
fe
ct
, G
 =
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t e
ff
ec
t, 
D
 =
 d
ie
t e
ff
ec
t, 
G
×D
 =
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t x
 d
ie
t e
ff
ec
t, 
T×
G
 =
 ti
m
e 
x 
ge
no
ty
pe
 m
at
ch
 to
 d
ie
t e
ff
ec
t, 
T×
D
 =
 
tim
e 
x 
di
et
 e
ff
ec
t, 
T×
G
×D
 =
 ti
m
e 
x 
di
et
 x
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t e
ff
ec
t. 
*s
ig
ni
fic
an
t t
im
e 
ef
fe
ct
 fr
om
 b
as
el
in
e 
p 
< 
0.
05
, ^
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
 c
om
pa
re
d 
to
 b
as
el
in
e 
(T
uk
ey
 L
SD
), 
a s
ig
ni
fic
an
t d
iff
er
en
ce
 
fr
om
 M
C
 p
 <
 0
.0
5 
(T
uk
ey
 L
SD
 p
os
t h
oc
). 
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T
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up
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tiv
e 
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nd
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de
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 le
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ur
e 
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e 
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tiv
iti
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 o
bs
er
ve
d 
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tw
ee
n 
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ou
ps
 	
 
V
ar
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bl
e 
G
ro
up
 
B
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el
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e 
4 
W
ee
ks
 
8 
W
ee
ks
 
12
 
W
ee
ks
 
16
 
W
ee
ks
 
20
 
W
ee
ks
 
24
 
W
ee
ks
 
G
ro
up
 
(S
EM
) 
P-
va
lu
e 
O
cc
up
at
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M
ET
 
M
in
ut
es
 
T-
M
C
 
1,
94
8±
4,
17
4 
99
0±
2,
10
3 
1,
29
3±
3,
08
5 
1,
16
5±
1,
74
0 
73
7±
1,
85
1 
1,
57
9±
2,
49
1 
1,
16
4±
1,
86
9 
1,
26
8±
39
9 
T=
0.
35
 
G
=0
.6
8 
D
=0
.1
6 
G
×D
=0
.8
7 
T×
G
=0
.6
0 
T×
D
=0
.8
3 
T×
G
×D
=0
.3
2 
 
T-
LC
 
51
9±
70
8 
89
3±
13
49
 
61
3±
71
5 
36
9±
76
1 
30
9±
38
0 
59
7±
72
4 
35
3±
55
7 
52
2±
44
2 
F-
M
C
 
1,
32
7±
2,
73
1 
2,
30
4±
4,
36
5 
1,
67
0±
2,
67
4 
1,
10
3±
2,
42
8 
1,
22
1±
2,
77
5 
1,
01
4±
2,
11
0 
1,
08
4±
2,
65
6 
1,
38
9±
60
3 
F-
LC
 
72
2±
1,
54
3 
56
2±
91
8 
1,
47
8±
3,
03
4 
1,
07
3±
1,
82
1 
44
4±
60
9 
76
1±
99
7 
51
9±
1,
21
9 
79
4±
41
2 
T 
1,
26
9±
3,
22
4 
97
4±
1,
80
2 
96
4±
2,
37
0 
73
8±
1,
40
0 
56
5±
1,
41
6 
1,
12
3±
1,
98
2 
77
3±
1,
49
4 
89
5±
29
8 
F 
91
5±
1,
95
0 
1,
11
16
±2
,5
87
 
1,
53
9±
2,
86
1 
1,
08
3±
1,
97
4 
69
1±
1,
60
8 
84
2±
1,
39
6 
69
9±
1,
75
5 
1,
09
2±
36
5 
M
C
 
1,
75
9±
3,
74
1 
1,
39
0±
2,
93
2 
1,
40
8±
2,
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0 
1,
14
6±
1,
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7 
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4±
2,
11
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1,
40
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2,
34
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1,
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2,
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5 
1,
32
8±
36
1 
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8±
1,
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2 
71
5±
1,
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9 
1,
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7±
2,
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9 
74
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1,
45
1 
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1 
68
5±
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2±
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2 
 
Ti
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1,
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2,
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1,
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6±
2,
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1 
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1,
67
1 
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8±
1,
47
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1,
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1,
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7±
1,
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84
2±
1,
26
0 
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G
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D
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G
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.4
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LC
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74
3 
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0 
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1,
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2 
66
1±
26
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M
C
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0±
1,
27
3 
42
4±
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8 
76
8±
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8±
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0 
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34
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5±
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4 
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2 
54
5±
36
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F-
LC
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4±
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86
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87
0±
1,
23
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6 
90
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49
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9 
T=
0.
86
 
G
=0
.9
2 
D
=0
.6
8 
G
×D
=0
.2
2 
T×
G
=0
.2
3 
T×
D
=0
.9
8 
T×
G
×D
=0
.2
9 
 
T-
LC
 
1,
55
1±
1,
71
2 
1,
10
6±
85
9 
1,
19
6±
1,
65
5 
82
6±
75
1 
1,
32
1±
1,
01
6 
90
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1,
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9±
1,
24
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1,
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1,
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1,
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79
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1,
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15
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1,
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1,
09
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1,
61
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1,
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2,
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1,
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1,
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7±
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2,
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1,
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9±
1,
53
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2,
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1,
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1,
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1,
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1,
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1,
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1,
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8±
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1,
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1,
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3±
1,
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7 
1,
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8±
1,
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3 
1,
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1,
38
9 
1,
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9±
1,
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1,
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0±
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1,
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2±
26
3 
M
C
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4±
1,
51
5 
1,
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2±
2,
44
0 
1,
44
0±
1,
53
8 
1,
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7±
2,
87
9 
1,
04
8±
1,
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7 
1,
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1±
1,
75
0 
1,
26
9±
1,
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1,
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1 
LC
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7 
1,
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5±
91
8 
1,
57
8±
1,
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0 
1,
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3±
1,
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5 
1,
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0±
1,
36
6 
1,
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7±
1,
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4 
1,
37
2±
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8 
1,
27
7±
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8 
Ti
m
e 
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2±
1,
06
2 
1,
51
0±
1,
77
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1,
51
6±
1,
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1,
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3±
2,
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1,
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6±
1,
43
5*
 
1,
59
2±
1,
60
8*
 
1,
32
6±
1,
12
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D
at
a 
pr
es
en
te
d 
as
 M
ea
n±
SD
. S
ig
ni
fic
an
ce
 le
ve
l p
 <
 0
.0
5.
 M
ea
n 
(n
 =
 5
1)
, T
 =
 tr
ue
 m
at
ch
 (n
 =
 2
9)
, F
 =
 fa
ls
e 
m
at
ch
 (n
 =
 2
2)
, M
C
 =
 m
od
er
at
e 
C
H
O
 (n
 =
 2
3)
, L
C
 =
 lo
w
 C
H
O
 (n
 =
 2
8)
, T
-M
C
 (n
 =
 1
6)
, T
-L
C
 
(n
 =
 1
3)
, F
-M
C
 (n
 =
 7
), 
F-
LC
 (n
 =
 1
5)
. T
 =
 ti
m
e 
ef
fe
ct
, G
 =
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t e
ff
ec
t, 
D
 =
 d
ie
t e
ff
ec
t, 
G
×D
 =
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t x
 d
ie
t e
ff
ec
t, 
T×
G
 =
 ti
m
e 
x 
ge
no
ty
pe
 m
at
ch
 to
 d
ie
t e
ff
ec
t, 
T×
D
 =
 
tim
e 
x 
di
et
 e
ff
ec
t, 
T×
G
×D
 =
 ti
m
e 
x 
di
et
 x
 g
en
ot
yp
e 
m
at
ch
 to
 d
ie
t e
ff
ec
t. 
*s
ig
ni
fic
an
t t
im
e 
ef
fe
ct
 fr
om
 b
as
el
in
e 
p 
< 
0.
05
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ab
le
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m
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W
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W
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38
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9 
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1,
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7±
76
 
T=
0.
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G
=0
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0 
D
=0
.0
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Thus, while all participants lost body weight, fat mass, and body fat percentage, fat free 
mass was maintained relatively well throughout the study. Aside from time effects, there 
were no time x diet, time x genotype, or time x genotype x diet interactions.  
A trend in genotype with moderate effect was revealed for body weight where 
false matches presented with greater body weight at each time point in comparison to 
true matches and demonstrated a greater reduction in body weight from baseline to 6-
months (F -5.6±5.0, T -5.0±5.0 kg, p=0.10, η2p=0.056, d=0.78). Post-hoc power analyses 
revealed a required sample size of 690 with a difference of 2.2 kg body weight to detect 
statistical significance between groups. Additionally a trend in genotype with strong 
effect for fat free mass was observed where false matches presented with more fat free 
mass at each time point and experienced better retention in fat free mass from baseline to 
6-months (F -0.4±2.3, T -0.8±2.3 kg, p=0.09, η2p=0.062, d=0.83). Post-hoc power 
analyses revealed a sample size of 3,181 with a difference of 2.7 kg fat free mass to 
detect statistical significance between groups. No other significant genotype or diet 
effects were observed along with no significant interaction for genotype x diet. Table 13 
represents body weight, fat mass, fat free mass, and body fat percentage in each group 
throughout the study. Figures 2-9 represent changes in body weight, fat mass, fat free 
mass, and body fat percentage between diet and genotype throughout the study. Since we 
did not observe statistically significant interactions favoring true matches among body 
composition variables, we reject H1. 	
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Figure 2: Delta change in body weight observed between genotype. Values presented as mean ± SD,  
n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05), γ trend in genotype effect p > 0.05 and p < 0.1 
 
 
 
 
Figure 3: Delta change in body weight observed between diet groups Values presented as mean ± SD,  
n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
 	
 
93 
 
Figure 4: Delta change in fat mass observed between genotype. Values presented as mean ± SD, n = 51, 
T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
Figure 5: Delta change in fat mass observed between diet groups. Values presented as mean ± SD, n = 51, 
MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
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Figure 6: Delta change in fat free mass observed between genotype. Values presented as mean ± SD,  
n = 51, T: n= 29, F: n = 22. γ trend in genotype effect p > 0.05 and p < 0.1 
 
 
 
 
Figure 7: Delta change in fat free mass observed between diet groups. Values presented as mean ± SD,  
n = 51, MC: n = 23, LC: n = 28 
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Figure 8: Delta change in body fat percentage observed between genotype. Values presented as  
mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
Figure 9: Delta change in body fat percentage observed between diet groups. Values presented as  
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
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Visceral Adipose Tissue 
 Overall, a Wilks’ Lambda effect of time (p<0.001) with no significant time x 
genotype (p=0.14), time x diet (p=0.26), or time x genotype x diet (p=0.51) interaction 
was observed for visceral adipose tissue mass, area, and volume. Univariate analyses 
revealed significant time effects for visceral adipose tissue mass, area, and volume, 
where all measures decreased linearly from baseline to completion for all participants 
(mass: -155.9±240.9 grams, p<0.001; area: -32.3±49.9 cm2, p<0.001; volume: -
168.5±260.4 cm3, p<0.001). There were no significant time interactions, genotype or diet 
effects, or genotype x diet interactions. Table 14 represents visceral adipose tissue mass, 
area, and volume observed for each group throughout the study. Since we did not 
observed statistical significant interactions favoring true matches for visceral adipose 
tissue, we reject H2. 
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Fat Deposition 
Regarding android fat deposition, an overall Wilks’ Lambda effect of time was 
exhibited (p=0.00) with no significant interactions for time x genotype (p=0.38), time x 
diet (p=0.93), or time x genotype x diet (p=0.37). Univariate analyses revealed 
significant effect of time for android total mass, fat mass, fat free mass, and fat 
percentage. A significant linear relationship was observed for total mass, fat mass, and 
fat percentage, such that all participants exhibited a reduction in these variables from 
baseline to completion (total mass: -747±863grams, p=0.00; fat mass: -532±528 grams, 
p=0.00; body fat percentage: -2.9±3.2 %, p=0.00). A significant cubic relationship was 
observed for fat free mass where fat free mass decreased from baseline to three months, 
then increased slightly from 3-5 months and decreased from 5-6 months (baseline-3-
months: -205±385 grams, 3-5-months: +45±268 grams, 5-6-months: -56±336 grams 
p=0.003, pc=0.02). From baseline to completion, participants experienced a reduction in 
android fat free mass (-215±452 grams).  
No significant time interactions were observed; however a trend in time x 
genotype x diet interaction with moderate effect for total mass was observed. From 
baseline to completion F-LC experienced the greatest reduction in android total mass (-
1004±872 grams), followed by T-MC (-732±919 gram), T-LC (-593±801 grams) and F-
MC (-517±875 grams) (p=0.09, η2p=0.045, d=0.73). Post-hoc power analyses revealed a 
required sample size of 411 with a difference of 509 grams android total mass to detect 
statistical significance between groups. Additionally, a trend in time x genotype x diet 
with moderate effect for android fat free mass was observed such that upon completion, 
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F-MC exhibited greatest retention in fat free mass (-68±435 grams), followed by T-LC (-
182±460 grams), T-MC (-234±459 grams), and F-LC (-294±473 grams) (p=0.08, 
η2p=0.043, d=0.71). Post-hoc power analyses revealed a required sample size of 797 with 
a difference of 45.9 grams android fat free mass to detect statistical significance between 
groups. 
Moreover, a significant genotype effect was revealed for android total mass such 
that false matches presented with larger total mass at each time point and experienced a 
greater reduction in total mass upon completion of the study (F -849.1±882.8, T -
669.7±855.4 grams, p=0.05). A significant genotype effect was also exhibited for fat free 
mass. While false matches contained greater fat free mass at each time point, true 
matches exhibited better retention of android fat free mass from baseline to completion 
(T -210.5±451.7, F -222.0±463.8 grams, p=0.04). Along with this, a trend in genotype 
with a strong effect was observed for fat mass where false matches once more presented 
with larger fat mass at each time point and exhibited a greater reduction in fat mass upon 
completion (F -627±583, T -459±480 grams, p=0.07, η2p=0.071, d=0.89). Post-hoc 
power analyses revealed a required sample size of 753 with a difference of 646 grams 
android fat mass to detect statistical significance between groups. Table 15 represents 
android total mass, fat mass, fat free mass, and fat percentage in each group throughout 
the study. Figures 10-17 represent changes in android total mass, fat mass, fat free mass, 
and fat percentage between genotype and diet groups at each time point throughout the 
study.  
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Figure 10: Delta change in android total mass observed between genotype. Values presented as  
mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05), Γ genotype effect (p < 0.05) 
 
 
 
 
Figure 11: Delta change in android total mass observed between diet groups. Values presented as  
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
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Figure 12: Delta change in android fat mass observed between genotype. Values presented as mean ± SD, 
n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
Figure 13: Delta change in android fat mass observed between diet. Values presented as mean ± SD,  
n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05). 
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Figure 14: Delta change in android fat free mass observed between genotype. Values presented as  
mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05), Γ genotype effect (p < 0.05) 
 
 
 
 
 
Figure 15: Delta change in android fat free mass observed between diet groups. Values presented as  
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
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Figure 16: Delta change in android fat percentage observed between genotype. Values presented as  
mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
 
Figure 17: Delta change in android fat percentage observed between diet groups. Values presented as 
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05 
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In addition to android fat deposition, gynoid fat deposition was also measured.. 
An overall Wilks’ Lambda effect of time was exhibited (p=0.00) with no significant 
interaction for time x genotype (p=0.31), time x diet (p=0.31), or time x genotype x diet 
(p=0.24). Univariate analyses revealed significant effect of time for gynoid total mass, 
fat mass, and fat percentage, where all participants demonstrated a reduction in these 
variables from baseline to completion (total mass: -865±1010 grams, p=0.00; fat mass: -
831±886 gram, p=0.00; fat percentage: -2.5±2.3 %, p=0.00). A significant time x 
genotype x diet interaction was revealed for gynoid total mass such that from baseline to 
completion F-LC experienced the greatest loss in gynoid total mass (-1012.1±1025.8 
grams) followed by T-MC (-899.9±1132.0 grams), T-LC (-850.7±793.7 grams), and F-
MC (-507.6±1170.5 grams) (p=0.04).  No other significant time interactions were 
observed.  
Furthermore, a trend in genotype with a strong effect was exhibited for total 
mass, where true matches presented with less gynoid total mass at each time point and 
experienced a greater reduction in total mass upon completion (T -878±978, F -
852±1073 grams, p=0.09, η2p=0.062, d=0.83). Post-hoc power analyses revealed a 
required sample size of 13,468 with a difference of 427.4 grams gynoid total mass to 
detect statistical significance between groups. Figure 18 represents change in gynoid 
total mass between genotype. A trend in genotype with strong effect was also observed 
for fat free mass, where false presented with greater gynoid fat free mass at each time 
point in comparison to true and experienced better retention in fat free mass upon 
completion (F +3.0±665, T -199±534 grams, pp=0.09, η2p=0.061, d=0.82). Post-hoc 
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power analyses revealed a required sample size of 15,681 with a difference of 3,432 
grams gynoid fat free mass to detect statistical significance between groups. No other 
trends or significant effects were revealed for genotype, diet, or genotype x diet 
interaction. Table 16 represents gynoid total mass, fat mass, fat free mass, and fat 
percentage in each group throughout the study. Figures 19-25 represent changes in 
gynoid total mass, fat mass, fat free mass, and fat percentage between genotype and diet 
groups at each time point throughout the study. Since statistically significant interactions 
in favor of true matches was not observed for fat deposition, we reject H3.  
 
 
 
Figure 18: Delta change in gynoid total mass observed between genotype. Values presented as mean ± 
SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) γ trend in genotype effect p > 0.05 and p < 0.1 
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Figure 19: Delta change in gynoid total mass observed between diet groups. Values presented as  
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
 
 
 
 
Figure 20: Delta change in gynoid fat mass observed between genotype. Values presented as mean ± SD, 
n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
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Figure 21: Delta change in gynoid fat mass observed between diet groups. Values presented as  
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
 
 
 
 
Figure 22: Delta change in gynoid fat free mass observed between genotype. Values presented as  
mean ± SD, n = 51, T: n = 29, F: n = 22. γ trend in genotype effect p > 0.05 and p < 0.1 
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Figure 23: Delta change in gynoid fat free mass observed between diet groups. Values presented as mean 
± SD, n = 51, MC: n = 23, LC: n = 28 
 
 
 
 
Figure 24: Delta change in gynoid fat percentage observed between genotype. Values presented as  
mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
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Figure 25: Delta change in gynoid fat percentage observed between diet groups. Values presented as 
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
 
 
 
Waist and Hip Circumference 
 An overall Wilks’ Lambda effect of time (p=0.00) was observed with no 
significant interaction for time x genotype (0.89), time x diet (p=0.37), and time x 
genotype x diet (p=0.53). Univariate analyses revealed a significant effect of time for 
waist circumference and hip circumference, where all participants demonstrated a 
reduction in variables upon completion of the study (waist -5.2±5.7 cm, p=0.00; hip -
5.0±4.0 cm, p=0.00). A trend in waist to hip ratio with moderate effect size (p=0.09, 
η2p=0.040, d=0.61) was also observed containing a trend in cubic relationship (pc=0.06). 
Aside from time effects, no significant time interactions were observed. Moreover, for 
hip circumference a trend in genotype with a strong effect was revealed where true 
matches presented with smaller hip circumference at each time point in comparison to 
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false and experienced a greater reduction in hip circumference from baseline to 
completion (T -5.1±5.5, F -4.9±3.7 cm, p=0.07, η2p=0.070, d=0.88). No other significant 
effects or trends in genotype, diet, or genotype x diet interaction were observed. Table 
17 represents waist circumference, hip circumference, and waist to hip ratio for each 
group throughout the study. Since we did not observe statistically significant interactions 
in favor of true matches for anthropometric variables we reject H4.  
BMI and Resting Energy Expenditure 
 An overall effect of time was observed (Wilks’ Lambda p=0.00) with no 
significant interaction for time x genotype (p=0.49), time x diet (p=0.71), and time x 
genotype x diet (p=0.81). Findings regarding changes in body weight are described 
earlier. Univariate analyses revealed a significant effect of time among all variables with 
no significant time interactions. All participants experienced a significant reduction in 
BMI and increase in absolute and relative resting energy expenditure (REE) (BMI -
1.7±2.6 kg/m2, p=0.00; absolute REE +63±247 kcal/d, p=0.02; relative REE +1.8±2.9 
kcal/kg/d, p=0.00). In addition, a significant effect of genotype for absolute REE was 
observed such that false matches presented with larger REE at each time point in 
comparison to true and exhibited a greater increase in REE upon completion (T 
+54.8±256.2, F +74.0±239 kcal/d, p=0.03). No other significant genotype, diet, or 
genotype x diet interaction was observed. Table 18 represents changes in weight, BMI, 
and absolute and relative energy expenditure in each group throughout the study. Based 
on these findings we reject H5 since we did not observed statistically significant 
interactions in favor of true matches for resting energy expenditure.  
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Fitness 
Peak Aerobic Capacity (VO2) 
Multivariate analyses revealed significant time effect (Wilks’ Lambda p=0.00) 
with no significant interaction for time x genotype (p=0.87), time x diet (p=0.76), and 
time x genotype x diet (p=0.17). Univariate analyses revealed a significant time effect 
for absolute and relative VO2, and time to exhaustion (TTE). All participants exhibited 
an increase in all variables from baseline to completion (absolute VO2 +0.2±0.2 L/min, 
p=0.00; relative VO2 +3.7±3.2 ml/kg/min, p=0.00; TTE +1.1±0.7 minutes, p=0.00). 
Further a trend in time x genotype x diet interaction with a large effect size was 
exhibited for absolute VO2 (p=0.08 η2p=0.056, d=0.82). The trend was linear in nature 
and overall favored F-MC (+5.7±5.7), followed by T-LC (+4.1±3.2), T-MC (+3.4±2.0), 
and F-LC (+2.9±2.7 L/min). The same relationship was demonstrated for relative VO2 
(p=0.07, η2p=0.058, d=0.84). No other significant time interactions, genotype or diet 
effects, and genotype x diet interaction were observed. Table 19 represents absolute and 
relative peak aerobic capacity, and time to exhaustion in each group throughout the 
study. Figures 26-31 represent absolute and relative peak aerobic capacity and time to 
exhaustion for genotype and diet groups throughout the study. All in all we accept Ho6 
since we did not observe statistically significant interactions favoring true matches for 
cardiorespiratory fitness.  	
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Table 19: Absolute and relative peak aerobic capacity and time to exhaustion observed 
between groups 
 
Variable Group Baseline 12 
Weeks 
24 
Weeks 
Group (SEM) P-value 
VO2max (L/min) T-MC 1.98±0.33 2.14±0.36^ 2.15±0.34^ 2.09±0.08 T = 0.00 
G = 0.79 
D = 0.38 
G×D = 0.81 
T×G = 0.97 
T×D = 0.39 
T×G×D = 
0.08 
 
T-LC 1.89±0.36 2.06±0.38^ 2.11±0.36^ 2.03±0.09 
F-MC 1.97±0.19 2.18±0.27^c 2.25±0.32^bc 2.14±0.12 
F-LC 1.96±0.28 2.06±0.36^d 2.06±0.33^bcd 2.03±0.08 
T 1.94±0.34 2.10±0.36 2.10±0.35 2.06±0.06 
F 1.96±0.25 2.10±0.34 2.10±0.34 2.08±0.07 
MC 1.98±0.29 2.15±0.33 2.18±0.33 2.11±0.07 
LC 1.93±0.31 2.06±0.36 2.09±0.34 2.03±0.06 
 Time 1.95±0.30 2.10±0.35* 2.13±0.34*   
VO2max 
(ml/kg/min) 
T-MC 22.9±4.2 25.9±4.6^ 26.3±4.3^ 25.0±1.2 T = 0.00 
G = 0.18 
D = 0.59 
G×D = 0.79 
T×G = 0.54 
T×D = 0.37 
T×G×D = 
0.07 
 
T-LC 21.6±0.47 24.5±5.5^ 25.6±5.4^ 23.9±1.3 
F-MC 19.8±3.2 22.9±4.2^bc 25.5±6.4^ 22.7±1.8 
F-LC 20.6±4.5 22.9±5.5^bc 23.5±6.0^bcd 22.3±1.2 
T 22.3±4.4 25.3±4.9 26.0±4.8 24.5±0.9 
F 20.4±4.0 22.9±5.0 24.1±6.0 22.5±1.1 
MC 22.0±4.1 25.0±4.6 26.0±4.9 23.8±1.1 
LC 21.1±4.5 23.7±5.4 24.5±5.7 23.1±0.9 
 Time 21.5±4.3 24.3±5.1* 25.2±5.4*   
Time to Exhaustion 
(min) 
T-MC 7.9±1.9 8.8±1.6 9.1±1.5 8.6±0.4 T = 0.00 
G = 0.30 
D = 0.90 
G×D = 0.75 
T×G = 0.96 
T×D = 0.42 
T×G×D = 
0.86 
 
T-LC 8.0±1.3 8.8±1.4 9.1±1.4 8.7±0.4 
F-MC 7.5±1.0 8.5±1.2 8.8±1.4 8.3±0.6 
F-LC 7.5±1.6 8.2±1.6 8.5±1.6 8.1±0.4 
T 8.0±1.7 8.8±1.5 9.1±1.4 8.6±0.3 
F 7.5±1.4 8.3±1.5 8.6±1.5 8.2±0.3 
MC 7.8±1.7 8.7±1.4 9.0±1.4 8.4±0.3 
LC 7.8±1.5 8.5±1.5 8.8±1.5 8.4±0.3 
 Time 7.8±1.6 8.6±1.5* 8.9±1.5*   
Data presented as Mean±SD. Significance level p < 0.05. Mean (n = 51), T = true match (n = 29), F = false match (n = 
22), MC = moderate CHO (n = 23), LC = low CHO (n = 28), T-MC (n = 16), T-LC (n = 13), F-MC (n = 7), F-LC (n = 
15). T = time effect, G = genotype match to diet effect, D = diet effect, G×D = genotype match to diet x diet effect, 
T×G = time x genotype match to diet effect, T×D = time x diet effect, T×G×D = time x diet x genotype match to diet 
effect. *significant time effect from baseline p < 0.05, ^ significant difference compared to baseline (Tukey LSD). 
Letter superscripts indicate significance (p < 0.05) from Tukey LSD post hoc analyses: bsignificant difference from T-
MC, csignificant difference from T-LC, dsignificant difference from F-MC, esignificant difference from F-LC 
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Figure 26: Delta change in absolute peak aerobic capacity observed between genotype. Values presented 
as mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
Figure 27: Delta change in absolute peak aerobic capacity observed between diet groups. Values 
presented as mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
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Figure 28: Delta change in relative peak aerobic capacity observed between genotype. Values presented 
as mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
Figure 29: Delta change in relative peak aerobic capacity observed between diet groups. Values presented 
as mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
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Figure 30: Delta change in time to exhaustion observed between genotype. Values presented as  
mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
Figure 31: Delta change in time to exhaustion observed between diet groups. Values presented as mean ± 
SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
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Upper and Lower Body Muscular Strength and Endurance 
 An overall Wilks’ Lambda time effect was observed (p=0.00) with no significant 
interaction for time x genotype (p=0.83), time x diet (p=0.35), and time x genotype x 
diet (p=0.96). Univariate analyses revealed significant time effect for lower and upper 
body muscular strength (p=0.00), with no significant time effect for lower or upper body 
muscular endurance (p=0.44 and p=0.16 respectively). From baseline to completion, all 
participants experienced an increase in lower and upper body muscular strength (lower: 
+51.1±56.7 kg, p=0.00; upper +5.7±3.9 kg, p=0.00). Further, a significant time x diet 
interaction was observed for lower body muscular strength where individuals in MC 
demonstrated greater improvements throughout the study in comparison to LC (baseline-
3 months: MC +46.4±55.7, LC +24.6±28.2, baseline-6 months: MC +72.4±68.6, LC 
+33.5±37.6 kg, p=0.4). No other significant time interactions were observed. A 
significant diet effect was exhibited for lower body muscular strength such that MC 
demonstrated greater strength at each time point along with a greater increase in strength 
upon completion (p=0.04). No other significant diet or genotype effects, or diet x 
genotype interactions were observed. Table 20 represents upper and lower body strength 
and endurance observed in each group from baseline to completion. Figures 32-35 
represents changes in lower and upper body strength for genotype and diet groups at 
each time point measured. Since we did not observe statistically significant interactions 
favoring true matches for upper or lower body muscular strength and endurance, we 
accept Ho7 and Ho8 respectively.  
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Table 20: Upper and lower body strength and endurance observed between groups  
 
Variable Group Baseline 12 
Weeks 
24 
Weeks 
Group (SEM) P-value 
Leg Press 1RM 
(kg) 
T-MC 228.7±98.9 278.7±114.3 304.5±132.8 270.6±20.6 T = 0.00 
G = 0.75 
D = 0.04 
G×D = 0.93 
T×G = 0.36 
T×D = 0.04 
T×G×D = 
0.69 
 
T-LC 191.3±51.0 219.8±54.8 238.5±62.8 216.5±22.8 
F-MC 226.3±66.3 264.6±87.4 290.9±92.7 260.6±31.1 
F-LC 196.4±57.2 217.6±72.7 218.0±76.8 210.7±21.3 
T 211.9±81.9 252.3±95.8 274.9±110.7 243.6±15.4 
F 205.9±60.3 232.5±78.8 241.2±87.1 235.6±18.8 
MC 228.0±88.7 274.4±105.0^ 300.4±120.0^ 265.6±18.7Đ 
LC 194.0±53.5 218.6 ±63.8^a 227.5 ±70.1^a 231.6±15.6 
 Time 209.3±72.8 243.8±88.5* 260.4±101.7*   
Leg Press 
Endurance (reps) 
T-MC 17±8 17±9 15±8 15±1.2 T = 0.44 
G = 0.30 
D = 0.57 
G×D = 0.19 
T×G = 0.38 
T×D = 0.88 
T×G×D = 
0.72 
 
T-LC 14±5 12±5 11±3 13±1.4 
F-MC 13±2 11±4 12±5 12±1.8 
F-LC 12±7 13±6 14±6 13±1.3 
T 15±6 14±7 13±6 14±0.9 
F 12±6 12±5 13±6 12±1.1 
MC 15±7 14±8 14±7 14±1.1 
LC 13±6 13±5 12±5 13±0.9 
 Time 14±6 13±7 13±6   
Bench Press 1RM 
(kg) 
T-MC 36.5±8.2 39.5±9.5 42.6±8.9 39.5±1.9 T = 0.00 
G = 0.51 
D = 0.12 
G×D = 0.72 
T×G = 0.44 
T×D = 0.58 
T×G×D = 
0.71 
 
T-LC 33.7±6.3 36.2±5.3 40.2±7.2 36.7±2.1 
F-MC 35.7±7.4 39.3±8.2 41.6±7.4 38.9±2.9 
F-LC 32.1±8.1 34.2±7.8 36.8±8.7 34.4±2.0 
T 35.3±7.4 38.0±7.9 41.5±8.1 38.1±1.4 
F 33.3±7.9 35.8±8.1 38.3±8.4 36.6±1.8 
MC 36.3±7.8 39.4±8.9 42.3±8.3 39.2±1.7 
LC 32.9±7.3 35.1±6.7 38.4±8.0 35.6±1.5 
 Time 34.4±7.6 37.1±8.0* 40.2±8.3*   
Bench Press 
Endurance (reps) 
 
 
 
 
 
 
 
 
T-MC 8±2 8±3 7±3 8±0.5 T = 0.16 
G = 0.74 
D = 0.76 
G×D = 0.97 
T×G = 0.79 
T×D = 0.58 
T×G×D = 
0.41 
 
T-LC 9±3 8±3 7±3 8±0.6 
F-MC 9±3 7±2 7±2 8±0.8 
F-LC 8±4 8±4 8±3 8±0.5 
T 9±3 8±3 7±3 8±0.4 
F 8±3 8±3 8±3 8±0.5 
MC 9±2 8±3 7±3 8±0.5 
LC 8±3 8±3 8±3 8±0.4 
Time 8±3 8±3 7±3  
Data presented as Mean±SD. Significance level p < 0.05. Mean (n = 51), T = true match (n = 29), F = false match (n = 22), 
MC = moderate CHO (n = 23), LC = low CHO (n = 28), T-MC (n = 16), T-LC (n = 13), F-MC (n = 7), F-LC (n = 15). T = 
time effect, G = genotype match to diet effect, D = diet effect, G×D = genotype match to diet x diet effect, T×G = time x 
genotype match to diet effect, T×D = time x diet effect, T×G×D = time x diet x genotype match to diet effect. *significant 
time effect from baseline p < 0.05, Đ signifciant diet effect p < 0.05, ^ significant difference compared to baseline (Tukey 
LSD), asignificant difference from MC p < 0.05 (Tukey LSD post hoc). 
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Figure 32: Delta change in lower body muscular strength observed between genotype. Values presented 
as mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
Figure 33: Delta change in lower body muscular strength observed between diet. Values presented as 
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05), Đ diet effect (p < 0.05), asignificant 
difference from MC p < 0.05 (Tukey LSD post hoc). 
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Figure 34: Delta change in upper body muscular strength observed between genotype. Values presented 
as mean ± SD, n = 51, T: n = 29, F: n = 22, * time effect (p < 0.05) 
 
 
 
 
Figure 35: Delta change in upper body muscular strength observed between diet. Values presented as 
mean ± SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05) 
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Biochemical Markers 
Blood Lipid Profile 
 A significant effect of time was observed (Wilks’ Lambda p=0.00) along with a 
significant time x diet interaction (p=0.001) and no significant time x genotype (p=0.39) 
or time x genotype x diet interaction (p=0.36). Univariate analyses revealed significant 
time effect with a quadratic relationship for total cholesterol (p=0.00, pq=0.00), HDL 
cholesterol (p=0.00, pq=0.00), LDL cholesterol (p=0.00, pq=0.00), and triglycerides 
(p=0.00, pq=0.02). However all participants experienced favorable changes for blood 
lipids by 6-months (total cholesterol -7.2±36.0 mg/dL, HDL +4.6±13.3 mg/dL, LDL -
2.5±29.3 mg/dL, Triglycerides -20.9±57.9 mg/dL). A significant time x diet interaction 
was observed for total cholesterol, HDL, LDL, and triglycerides such that MC 
demonstrated significant reductions from baseline to completion and greater reductions 
in comparison to LC for total cholesterol (MC: -25.2±31.3, LC: +7.7±33.1 mg/dL, 
p=0.001), LDL (MC: -13.6±28.6, LC: +6.7±26.9 mg/dL, p=0.01), and triglycerides 
(MC: -37.1±65.7, LC: -7.6 ± 47.7 mg/dL, p=0.00). LC demonstrated a greater increase 
in HDL upon completion in comparison to MC (MC: -0.6±12.2, LC: +8.9±12.8 mg/dL, 
p=0.01). Further a significant time x genotype interaction was observed for triglycerides, 
such that from baseline to completion false matches experienced a significant reduction 
in triglycerides and greater reduction in comparison to true matches (T -9.9±62.3, F -
35.5±49.1 mg/dL, p=0.05). There were no other time interactions among variables.  
In addition, significant diet effect was experienced in total cholesterol (p=0.00), 
LDL (p=0.00), and triglycerides (p=0.00), where MC presented with larger blood lipids 
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at each time point in comparison to LC. A trend in genotype x diet interaction with a 
large effect was observed for total cholesterol such that by week 12 T-MC and F-MC 
presented with cholesterol that was significant different from T-LC and F-LC (p=0.06,  
η2p=0.074, d=0.94). Further, T-MC and F-MC demonstrated greater reductions in total 
cholesterol upon completion (T-MC -26.0±32.1, F-MC -23.5±32.0, F-LC +7.0±31.8, T-
LC +8.5±35.8 mg/dL). Similarly, a significant genotype x diet interaction was observed 
for LDL cholesterol. By week 12 T-MC and F-MC presented with LDL that was 
significantly different from T-LC and F-LC. From baseline to completion, T-MC 
exhibited the greatest reduction in LDL (-15.8±26.7 mg/dL) followed by F-MC (-
8.6±34.2), F-LC (+3.7±28.1 mg/dL), and T-LC (+10.1±26.3 mg/dL) (p=0.02). No other 
significant genotype x diet interactions, or genotype or diet effects was observed among 
variables. Table 21 represents fasting blood lipids in each group at each time point 
measured. Figures 36-39 represent changes in total cholesterol, LDL, HDL, and 
triglycerides by diet group for each time point measured throughout the study. Figure 40 
represents changes in triglycerides for genotype. Since statistically significant 
interactions favoring true matches were not observed for any measured blood lipids, we 
reject H9. 
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Table 21: Fasting blood lipids observed between groups 
 
Variable Group Baseline 12 
Weeks 
24 
Weeks 
Group (SEM) P-value 
Total Cholesterol 
(mg/dL) 
T-MC 253.5±54.3 282.1±55.5ce 227.5±42.4 254.4±9.8δ T = 0.00 
G = 0.91 
D = 0.00 
G×D = 0.06 
T×G = 0.95 
T×D=0.001 
T×G×D = 0.79 
 
T-LC 176.9±31.1 194.5±42.6 185.4±40.4 185.6±10.8 
F-MC 225.6±46.3 264.6±67.6c 202.1±37.5 230.8±14.8δ 
F-LC 200.0±40.7 213.0±39.7 206.9±46.3 206.7±10.1 
T 219.1±59.1 242.8±66.3 208.6±46.0 220.0±7.3 
F 208.2±43.2 229.4±54.4 205.4±42.9 218.7±9.0 
MC 245.0±52.6 276.8±58.4^ 219.8±41.9^ 242.6±8.9Đ 
LC 189.3±37.8 204.4 ±41.4^a 197.0±44.2a 196.1±7.4 
 Time 214.4±52.6 237.1±61.2* 207.2±44.3τ   
HDL (mg/dL) T-MC 56.7±17.4 68.7±18.2 56.8±15.3 60.7±4.2 T = 0.00 
G = 0.40 
D = 0.27 
G×D = 0.94 
T×G = 0.88 
T×D = 0.01 
T×G×D = 0.42 
 
T-LC 50.3±18.0 57.8±14.6 56.4±13.7 54.8±4.6 
F-MC 62.2±22.7 71.0±24.0 60.2±22.7 64.5±6.3 
F-LC 51.4±14.7 64.0±19.7 62.8±20.6 59.4±4.3 
T 53.8±17.6 63.8±17.3 56.6±14.4 57.8±3.1 
F 54.8±17.8 66.2±20.8 61.9±20.8 61.9±3.8 
MC 58.4±18.8 69.4±19.6^ 57.8±17.4^ 62.6±3.8 
LC 50.9±16.0 61.1 ±17.5^a 59.8±17.7^ 57.1±3.2 
 Time 54.3±17.6 64.8±18.7* 58.9±17.5*   
LDL (mg/dL) T-MC 162.2±42.7 184.1±46.4c 146.5±38.0 164.2±7.9ϒ T = 0.00 
G = 0.73 
D = 0.00 
G×D = 0.02 
T×G = 0.98 
T×D = 0.01 
T×G×D = 0.72 
 
T-LC 99.5±24.4 113.0±25.2 109.6±31.1 107.4±8.7 
F-MC 133.2±31.5 155.7±49.2c 124.6±44.6 137.9±11.9ϒ 
F-LC 122.6±30.1 133.2±31.5 126.4±33.0 127.4±8.1 
T 134.1±47.3 152.2±52.2 129.9±39.2 135.8±5.9 
F 126.0±30.2 140.4±38.3 125.8±36.0 132.6±7.2 
MC 153.4±41.2 175.4±48.0^ 139.8±40.4^ 151.1±7.1Đ 
LC 111.9±29.5 123.8 ±30.1^a 118.6±32.7a 117.4±6.0 
 Time 130.6±40.7 147.1±46.6* 128.2±37.5   
Triglycerides 
(mg/dL) 
 
 
 
 
 
 
 
 
T-MC 179.2±86.9 188.6±81.5 147.6±54.4 171.8±13.3 T = 0.001 
G = 0.69 
D = 0.00 
G×D = 0.94 
T×G = 0.05 
T×D = 0.00 
T×G×D = 0.31 
 
T-LC 102.6±32.1 97.9±35.5 119.3±60.0 106.6±14.7 
F-MC 183.2±80.9 221.0±115.3 133.4±60.5 179.3±20.1 
F-LC 129.5±45.4 104.6±36.6 100.9±33.0 111.7±13.7 
T 144.9±77.4 147.9±78.8 134.9±57.7 139.2±9.9 
F 146.6±62.4 141.7±88.2 111.2±44.8^f 145.4±12.1 
MC 180.4±83.3 198.4±91.6^ 143.3±55.3^ 175.5 ±12.0Đ 
LC 117.0±41.4 101.5 ±35.6^a 109.4±47.4 a 109.1±10.1 
Time 145.6±70.6 145.2±82.2 124.7±53.4*  
Data presented as Mean±SD. Significance level p < 0.05. Mean (n = 51), T = true match (n = 29), F = false match (n = 22), 
MC = moderate CHO (n = 23), LC = low CHO (n = 28), T-MC (n = 16), T-LC (n = 13), F-MC (n = 7), F-LC (n = 15). T = 
time effect, G = genotype match to diet effect, D = diet effect, G×D = genotype match to diet x diet effect, T×G = time x 
genotype match to diet effect, T×D = time x diet effect, T×G×D = time x diet x genotype match to diet effect. *significant 
time effect from baseline p < 0.05, τ trend in time effect from baseline p > 0.05 and p < 0.1 (univariate), Đ signifciant diet 
effect p < 0.05, ϒ significant genotype x diet interaction p < 0.05 (Tukey LSD), δ trend in genotype x diet interaction p > 0.05 
and p < 0.1 (Tukey LSD), ^ significant difference compared to baseline (Tukey LSD). Letter superscripts indicate 
significance (p < 0.05) from Tukey LSD post hoc analyses: asignificant difference from MC, bsignificant difference from T-
MC, csignificant difference from T-LC, dsignificant difference from F-MC, esignificant difference from F-LC, fsignificant 
difference from T. 
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Figure 36: Delta change in total cholesterol observed between diet groups. Values presented as mean ± 
SD, n = 51, MC: n = 23, LC: n = 28, * time effect (p < 0.05), Đ diet effect (p < 0.05), asignificant 
difference from MC (p < 0.05, Tukey LSD post hoc). 
 
 
 
 
Figure 37: Delta change in HDL observed between diet groups. Values presented as mean ± SD, n = 51, 
MC: n = 23, LC: n = 28, * time effect (p < 0.05), asignificant difference from MC (p < 0.05, Tukey LSD 
post hoc). 
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Figure 38: Delta change in LDL observed between diet groups. Values presented as mean ± SD, n = 51, 
MC: n = 23, LC: n = 28* time effect (p < 0.05), Đ diet effect (p < 0.05), asignificant difference from MC 
(Tukey LSD post hoc). 
 
 
 
 
Figure 39: Delta change in triglycerides observed between diet groups. Values presented as mean ± SD, n 
= 51, MC: n = 23, LC: n = 28* time effect (p < 0.05), Đ diet effect (p < 0.05), asignificant difference from 
MC (p < 0.05, Tukey LSD post hoc). 
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Figure 40: Delta change in triglycerides observed between genotype. Values presented as mean ± SD, n = 
51, T: n = 29, LC: n = 22, * time effect (p < 0.05), fsignificant difference from T (p < 0.05, Tukey LSD 
post hoc). 
 
 
 
Markers Related to Insulin Resistance 
 
 Multivariate analyses did not reveal any significant effects for time (p=0.31), 
time x genotype (p=0.26), time x diet (p=0.60), time x genotype x diet (p=0.18). 
Univariate analyses revealed a trend in time with a moderate effect between time and 
fasting insulin, such that all participants experienced a clinically insignificant increase in 
fasting insulin levels from baseline to completion (+1.1±5.2 µIU/mL, p=0.08, η2p=0.062, 
d=0.77). No other time effects or interactions were observed among variables.  
 A significant genotype effect was observed for insulin such that false matches 
presented with larger fasting insulin values at all time points in relation to true matches 
(p=0.04). However, true matches experienced a slight, yet clinically insignificant, 
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increase in change of fasting insulin from baseline to completion (T +1.9±5.3, F 
+0.2±5.1 µIU/mL). Additionally, a significant genotype effect was observed for 
glucose/insulin ratio, where false matches experienced an increase in glucose/insulin 
ratio from baseline to completion while true matches experienced the opposite 
(F+0.4±4.1, T-1.5±3.8, p=0.03). Similarly, a trend in genotype with a large effect was 
observed for HOMA-IR where false matches experienced a reduction in HOMA-IR and 
true matches experienced an increase (F-0.06±1.3, T0.5±1.2, p=0.06, η2p=0.075, 
d=0.92). Finally a diet effect was observed, such that LC presented with greater fasting 
blood glucose at baseline and completion in comparison to MC (p=0.001). There were 
no other genotype effects, diet effects, or genotype x diet interactions observed. Table 22 
represents glucose, insulin, glucose/insulin ratio, and HOMA-IR in each group from 
baseline to completion. Since statistically significant interactions favoring true matches 
were not observed for markers related to insulin resistance, we accept Ho10.  
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Table 22: Markers related to insulin resistance observed between groups  
 
Variable Group Baseline 24 
Weeks 
Group (SEM) P-value 
Glucose (mg/dL) T-MC 85.0±7.3 90.0±9.3 87.0±1.6 T = 0.57 
G = 0.54 
D = 0.001 
G×D = 0.93 
T×G = 0.48 
T×D = 0.54 
T×G×D = 0.31 
 
 T-LC 95.6±8.2 95.0±9.8 92.2±1.8 
 F-MC 86.4±6.6 85.5±8.6 87.0±2.5 
 F-LC 93.9±10.6 94.3±11.3 91.9±1.7 
 T 89.7±9.3 92.2±9.7 91.3±1.4 
 F 91.5±10.0 91.5±11.1 90.0±1.7 
 MC 85.4±7.0 88.6±9.1 87.0±1.5 
 LC 94.7±9.4 94.6±10.4 92.1±1.2Đ 
 Time 90.5±9.6 91.9±10.2  
Insulin (µIU/mL) T-MC 11.2±7.5 12.2±5.7 11.7±1.6 T = 0.08 
G = 0.04 
D = 0.80 
G×D = 0.25 
T×G = 0.40 
T×D = 0.75 
T×G×D = 0.11 
 
T-LC 12.0±5.0 15.0 ±7.2 13.5±1.8 
F-MC 17.0±8.5 19.2 ±5.5 18.1±2.5 
F-LC 15.8±8.1 15.0 ±7.6 15.4±1.7 
T 11.6±6.4 13.5±6.4 12.6±1.2 
F 16.2±8.0 16.3±7.2 16.7±1.5Γ 
MC 13.0±8.1 14.3±6.4 14.9±1.5 
LC 14.0±7.0 15.0±7.3 14.4±1.2 
 Time 13.5±7.4 14.7±6.8τ   
Glucose/Insulin Ratio T-MC 10.5±5.2 9.2±4.9 9.9±0.9 T = 0.15 
G = 0.03 
D = 0.78 
G×D = 0.13 
T×G = 0.24 
T×D = 0.30 
T×G×D = 0.12 
T-LC 9.4±3.9 7.5±3.0 8.5±1.0 
F-MC 6.5±3.8 4.9±1.9 5.7±1.4 
F-LC 7.1±2.6 8.4±5.3 7.7±1.0 
T 10.0±4.6 8.5±4.2 9.2±0.7 
F 6.9±2.9 7.3±4.7 6.7±0.9Γ 
MC 9.3±5.1 7.9±4.7 7.8±0.8 
LC 7.5±3.0 8.0±4.3 8.1±0.7 
Time 8.5±4.2 8.0±4.4  
HOMA-IR T-MC 2.3±1.5 2.7±1.2 2.5±0.4 T = 0.12 
G = 0.06 
D = 0.55 
G×D = 0.32 
T×G = 0.22 
T×D = 0.72 
T×G×D = 0.16 
T-LC 2.8±1.2 3.6±1.9 3.2±0.4 
F-MC 3.6±1.7 4.0±1.0 3.8±0.6 
F-LC 3.8±2.1 3.5±1.7 3.6±0.4 
T 2.6±1.4 3.1±1.6 2.9±0.3 
F 3.7±2.0 3.6±1.5 3.7±0.3γ 
MC 2.7±1.6 3.1±1.3 3.1±0.3 
LC 3.3±1.8 3.5±1.8 3.4±0.3 
Time 3.1±1.6 3.3±1.6  
Data presented as Mean±SD. Significance level p < 0.05. Mean (n = 51), T = true match (n = 29), F = false match (n = 
22), MC = moderate CHO (n = 23), LC = low CHO (n = 28), T-MC (n = 16), T-LC (n = 13), F-MC (n = 7), F-LC (n = 
15). T = time effect, G = genotype match to diet effect, D = diet effect, G×D = genotype match to diet x diet effect, 
T×G = time x genotype match to diet effect, T×D = time x diet effect, T×G×D = time x diet x genotype match to diet 
effect. Γ significant genotype effect p < 0.05, τ trend in time from baseline p > 0.05 and p < 0.1, γ trend in genotype 
effect p > 0.05 and p < 0.1 
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Psychosocial Evaluation 
Self-Esteem and Social Physical Anxiety 
 Regarding self-esteem as measured by the Rosenberg self-esteem scale, 
multivariate analyses revealed a significant time effect for self esteem scores (p=0.001) 
with no significant interaction for time x genotype (p=0.82), time x diet (p=0.91), or 
time x genotype x diet (p=0.19). Univariate analyses revealed a significant time effect 
such that all participants reported increased self-esteem from baseline to completion 
(+1.8±3.0; p=0.00). No significant time interactions were observed. Moreover a trend in 
diet with moderate effect was observed such that individuals in LC reported higher self-
esteem scores at all time points. A change in reported self-esteem score increased greater 
in LC versus MC from baseline to completion (MC: +1.6±3.5, LC: +2.0±2.6; p=0.10, 
η2p=0.056, d=0.79). No significant genotype effect or genotype x diet interaction was 
observed. 
Furthermore, for anxiety as measured by the social physical anxiety scale, 
multivariate analyses revealed a significant time effect for social physical anxiety scores 
(p=0.00) along with a significant time x genotype x diet interaction (p=0.03), and no 
significant interaction for time x genotype (p=0.66), and time x diet (p=0.89). Univariate 
analyses also revealed a significant time effect, such that from baseline to completion all 
participants exhibited reduced ratings of social anxiety regarding physique (-3.1±5.6; 
p=0.00). A significant time x genotype x diet interaction was observed with a significant 
cubic relationship (p=0.03, pc=0.00) such that anxiety scores fluctuated between diets 
and genotypes throughout the duration of the study; however overall F-MC experienced 
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the greatest reduction in social anxiety (-4.3±5.8), followed by T-LC (-3.6±5.5), T-MC (-
2.7±6.0), F-LC (-2.4±5.6). There were no other time effects, time interactions, genotype 
or diet effect, or genotype x diet interaction observed. Table 23 represents self-esteem 
and social physical anxiety score in each group throughout the study. 
Eating Satisfaction Survey 
 Among the six domains within the eating satisfaction survey, appetite, hunger, 
satisfaction from food, feeling of fullness, amount of energy, and overall quality of diet, 
multivariate analyses revealed significant Wilks’ Lambda time effect (p=0.00) and time 
x diet interaction (p=0.05), with no significant time x genotype (p=0.23) or time x 
genotype x diet interaction (p=0.77). Univariate analyses revealed significant time 
effects for appetite, hunger, amount of energy, and overall diet quality. The time effect 
for appetite demonstrated a significant quadratic relationship revealing a significant 
decline in appetite for all participants from baseline to 3-months followed by a steady 
increase from 3-6- months, but still an overall decline in appetite upon completion 
(baseline-3-months: -0.5±1.4, baseline-6-months: -0.1±1.3; p=0.01, pq=0.00). The time 
effect for hunger exhibited a significant cubic relationship (p=0.03, pc=0.01) such that 
hunger rating fluctuated throughout the course of the study, with a trend towards 
significance from baseline after one month of intervention and a significant difference 
from baseline after two months for all participants. Further, energy demonstrated a 
significant linear relationship such that all participants reported increased energy levels 
throughout the duration of the study (baseline to 6-months: +1.6±1.8; p=0.00). Finally,  
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overall diet quality exhibited a significant linear relationship such that all participants 
reported an increase in diet quality from baseline to six months (+1.7±2.1; p=0.00). 
Along with observed time effects, a trend for time x genotype with a moderate 
effect was observed for feeling of fullness and demonstrated a significant quadratic 
relationship. False matches experienced a greater decline in feeling of fullness from 
baseline to 3-months (T -0.03±1.7, F -0.6±0.6), and smaller increase in ratings from 3-6 
months (T +0.10±1.4, F +0.09±1.4). Overall false matches experienced a decline in 
feeling of fullness from baseline to completion while ratings for true matches was 
relatively unchanged upon completion in comparison to baseline levels (T +0.07±1.8, F -
0.5±1.9; pq=0.04, p=0.09, η2p=0.039, d=0.67). Additionally a trend in time x diet with 
moderate effect for feeling of fullness was observed that exhibited a significant cubic 
relationship indicating fluctuation over time in fullness ratings within diet groups; 
however, overall from baseline to completion, MC exhibited an increase in fullness (MC 
+0.61±1.8, LC -0.86±1.6; pc=0.02, p=0.08, η2p=0.041, d=0.68). 
Further, a significant time x diet interaction was also observed for overall quality 
of diet with a significant quadratic relationship. MC demonstrated a greater increase in 
diet quality from baseline to 3-month (MC +2.7±1.8, LC +0.9±2.2) with a slight decline 
in quality ratings from 3-6 months, while LC quality ratings increased from 3-6 months 
(MC -0.30±1.3, LC +0.25±1.7; p=0.03, pq=0.01). Along with this, no diet or genotype 
effects were observed, nor was a significant genotype x diet interaction evident. Table 24 
represents eating satisfaction ratings among the six domains in each group throughout 
the study. 
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Table 24: Eating satisfaction observed between groups 
 
Variable Group Baseline 4 
Weeks 
8 
Weeks 
12 
Weeks 
16 
Weeks 
20 
Weeks 
24 
Weeks 
Group 
(SEM) 
P-value 
Appetite T-MC 6.5±1.2 5.4±1.1 5.4±1.3 5.5±1.1 6.1±1.1 6.1±1.7 6.3±1.5 5.9±0.2 T=0.01 
G=0.12 
D=0.28 
G×D=0.38 
T×G=0.28 
T×D=0.39 
T×G×D=0.86 
 
T-LC 6.3±1.2 5.5±1.5 5.1±1.3 6.1±1.9 5.5±2.0 6.1±2.1 6.4±1.4 5.8±0.3 
F-MC 5.9±1.2 6.1±0.9 5.6±1.5 5.3±1.0 6.0±1.3 5.6±1.4 5.6±1.5 5.7±0.4 
F-LC 5.5±1.1 5.1±1.3 4.5±1.4 5.2±0.9 5.3±1.4 5.1±1.4 5.4±1.2 5.2±0.2 
T 6.4±1.2 5.5±1.3 5.2±1.2 5.8±1.5 5.8±1.6 6.1±1.8 6.3±1.4 5.9±0.2 
F 5.6±1.1 5.4±1.3 4.9±1.5 5.2±0.9 5.6±1.4 5.3±1.4 5.5±1.3 5.4±0.2 
MC 6.3±1.2 5.7±1.1 5.4±1.3 5.4±1.0 6.1±1.1 5.9±1.6 6.1±1.5 5.8±0.2 
LC 5.9±1.2 5.3±1.4 4.8±1.3 5.6±1.5 5.4±1.7 5.6±1.8 5.9±1.4 5.5±0.2 
 Time 6.1±1.2 5.5±1.3* 5.1±1.4* 5.5±1.3* 5.7±1.5 5.7±1.7 6.0±1.4   
Hunger 
 
T-MC 5.7±1.6 5.1±1.7 5.3±1.6 5.1±1.8 5.9±1.3 6.0±1.8 6.1±1.9 5.6±0.3 T=0.03 
G=0.49 
D=0.16 
G×D=0.97 
T×G=0.59 
T×D=0.40 
T×G×D=0.51 
 
T-LC 5.1±1.8 4.8±1.7 4.2±1.6 5.5±2.0 5.1±2.1 5.5±1.9 5.4±1.6 5.1±0.3 
F-MC 5.4±1.1 5.1±1.1 5.4±1.7 5.4±1.5 5.4±1.3 5.3±1.0 5.1±1.9 5.3±0.4 
F-LC 5.3±1.0 4.9±1.0 4.1±1.6 4.6±1.3 4.9±1.3 5.1±1.5 5.0±1.1 4.8±0.3 
T 5.4±1.7 4.9±1.6 4.8±1.7 5.2±1.8 5.5±1.7 5.8±1.8 5.8±1.8 5.3±0.2 
F 5.3±1.0 5.0±1.0 4.6±1.7 5.5±1.7 5.1±1.3 5.1±1.4 5.1±1.3 5.1±0.3 
MC 5.6±1.4 5.1±1.5 5.4±1.6 5.2±1.7 5.7±1.3 5.8±1.6 5.8±1.9 5.5±0.3 
LC 5.2±1.4 4.8±1.3 4.2±1.6 5.0±1.7 5.0±1.7 5.3±1.7 5.2±1.3 5.0±0.2 
 Time 5.4±1.4 4.9±1.4τ 4.7±1.7* 5.1±1.7 5.3±1.5 5.5±1.6 5.5±1.6   
Satisfaction 
from Food 
T-MC 5.6±1.9 6.4±1.1 6.6±1.0 5.9±1.5 6.4±1.3 6.5±0.8 6.4±1.3 6.3±0.3 T=0.17 
G=0.60 
D=0.73 
G×D=0.37 
T×G=0.16 
T×D=0.20 
T×G×D=0.23 
 
T-LC 6.1±1.4 7.0±1.2 6.8±1.1 6.5±1.8 6.5±1.9 6.1±2.2 6.2±2.2 6.4±0.3 
F-MC 5.7±1.0 7.0±1.6 6.3±1.0 6.4±1.5 6.1±1.7 6.1±1.2 7.0±0.6 6.4±0.4 
F-LC 6.5±1.0 5.8±1.5 5.6±1.1 6.1±1.2 5.8±1.2 6.0±1.2 6.3±1.1 6.0±0.3 
T 5.8±1.6 6.7±1.2 6.7±1.0 6.1±1.7 6.4±1.6 6.3±1.6 6.3±1.7 6.4±0.2 
F 6.3±1.0 6.2±1.6 5.8±1.1 6.2±1.3 5.9±1.3 6.1±1.2 6.5±1.0 6.2±0.2 
MC 5.7±1.6 6.6±1.3 6.5±1.0 6.1±1.5 6.3±1.4 6.4±0.9 6.6±1.1 6.3±0.2 
LC 6.3±1.2 6.4±1.5 6.1±1.2 6.3±1.5 6.1±1.6 6.0±1.7 6.3±1.6 6.2±0.2 
 Time 6.0±1.4 6.5±1.4 6.3±1.1 6.2±1.5 6.2±1.5 6.2±1.4 6.4±1.4   
Feeling of 
fullness 
T-MC 5.9±1.8 6.3±1.2 6.4±1.2 6.3±1.5 6.3±1.1 6.2±1.6 6.6±1.5 6.3±0.2 T=0.50 
G=0.58 
D=0.60 
G×D=0.50 
T×G=0.09 
T×D=0.08 
T×G×D=0.27 
 
T-LC 6.9±1.3 7.1±1.0 6.6±0.9 6.4±1.3 7.0±1.4 6.2±2.0 6.2±1.6 6.6±0.3 
F-MC 6.7±1.4 7.3±1.4 6.1±1.1 6.4±1.3 6.0±1.8 6.9±1.6 7.0±1.5 6.6±0.4 
F-LC 7.5±1.5 6.2±1.3 6.5±1.2 6.7±1.3 6.2±1.2 6.6±1.4 6.5±1.4 6.6±0.3 
T 6.3±1.7 6.6±1.2^ 6.5±1.1 6.3±1.4^ 6.6±1.2^ 6.2±1.7 6.4±1.5 6.5±0.2 
F 7.2±1.4 6.6±1.4^ 6.4±1.1^ 6.6±1.3^f 6.1±1.4^f 6.7±1.4^f 6.7±1.4^f 6.6±0.2 
MC 6.1±1.7 6.6±1.3^ 6.4±1.2^ 6.3±1.4 6.2±1.3 6.4±1.6^ 6.7±1.5 6.5±0.2 
LC 7.2±1.4 6.6±1.2^ 6.5±1.0^ 6.5±1.3^ 6.6±1.3^f 6.4±1.6^ 6.4±1.5 6.6±0.2 
Time 6.7±1.6 6.6±1.3 6.5±1.1 6.4±1.3 6.4±1.3 6.4±1.6 6.5±1.5  
Amount of 
Energy 
T-MC 4.9±1.6 6.6±1.5 6.6±1.7 6.3±1.8 6.5±1.4 6.4±1.8 6.8±1.6 6.3±0.3 T=0.00 
G=0.89 
D=0.94 
G×D=0.78 
T×G=0.70 
T×D=0.47 
T×G×D=0.58 
 
T-LC 5.0±1.9 6.9±1.1 6.5±1.2 6.6±1.3 7.2±0.8 5.9±1.5 6.6±2.0 6.4±0.3 
F-MC 5.4±1.1 6.9±1.7 6.6±1.6 6.1±1.8 6.6±1.8 6.3±0.8 7.3±1.8 6.4±0.4 
F-LC 5.3±1.2 6.7±1.3 6.9±1.3 6.6±0.9 6.3±1.0 6.3±1.3 6.4±1.0 6.3±0.3 
T 5.0±1.7  6.8±1.3 6.6±1.5 6.5±1.5 6.8±1.2 6.2±1.6 6.7±1.7 6.3±0.2 
F 5.3±1.2 6.7±1.4 6.8±1.4 6.5±1.2 6.4±1.3 6.3±1.1 6.7±1.3 6.4±0.2 
MC 5.1±1.5 6.7±1.5 6.6±1.6 6.3±1.7 6.5±1.5 6.4±1.5 7.0±1.7 6.4±0.2 
LC 5.1±1.5 6.8±1.2 6.7±1.2 6.6±1.1 6.7±1.0 6.1±1.4 6.5±1.5 6.4±0.2 
Time 5.1±1.5 6.8±1.3* 6.7±1.4* 6.5±1.4* 6.6±1.2* 6.2±1.4* 6.7±1.6*  
Overall 
Quality of 
Diet 
T-MC 4.0±1.9 6.3±1.5 6.2±1.5 6.6±0.8 6.8±1.2 6.2±1.2 6.5±1.2 6.1±0.2 T=0.00 
G=0.87 
D=0.25 
G×D=0.87 
T×G=0.42 
T×D=0.03 
T×G×D=0.64 
 
T-LC 4.7±1.9 6.7±1.3 5.4±2.0 5.2±1.6 6.5±1.2 5.9±1.9 5.9±1.6 5.8±0.2 
F-MC 3.9±1.1 7.0±1.2 6.6±1.0 6.7±1.0 6.3±1.4 6.3±0.8 5.9±1.6 6.1±0.3 
F-LC 4.8±1.1 6.3±1.2 5.9±1.4 6.1±1.5 6.1±1.0 5.9±1.6 5.9±1.5 5.8±0.2 
T 4.3±1.9 6.5±1.4 5.8±1.8 5.9±1.4 6.7±1.2 6.1±1.6 6.2±1.4 5.9±0.2 
F 4.5±1.1 6.5±1.2 6.1±1.3 6.3±1.4 6.2±1.1 6.0±1.3 5.9±1.5 6.0±0.2 
MC 4.0±1.7 6.5±1.4^ 6.3±1.3^ 6.6±0.8^ 6.7±1.3^ 6.2±1.1^ 6.3±1.3^ 6.1±0.2 
LC 4.8±1.5 6.5±1.2^ 5.6±1.7^a 5.6±1.6^a 6.3±1.1^a 5.9±1.7^ 5.9±1.5^a 5.8±0.2 
Time 4.4±1.6 6.5±1.3* 5.9±1.6* 6.1±1.4* 6.5±1.2* 6.0±1.5* 6.1±1.4*  
Data presented as Mean±SD. Significance level p < 0.05. Mean (n = 51), T = true match (n = 29), F = false match (n = 22), MC = moderate 
CHO (n = 23), LC = low CHO (n = 28), T-MC (n = 16), T-LC (n = 13), F-MC (n = 7), F-LC (n = 15). T = time effect, G = genotype match to 
diet effect, D = diet effect, G×D = genotype match to diet x diet effect, T×G = time x genotype match to diet effect, T×D = time x diet effect, 
T×G×D = time x diet x genotype match to diet effect. *significant time effect from baseline p < 0.05, τ trend in time effect from baseline p > 
0.05 and p < 0.1 (univariate), ^ significant difference compared to baseline (Tukey LSD). Letter superscripts indicate significance (p < 0.05) 
from Tukey LSD post hoc analyses: asignificant difference from MC, fsignificant difference from T. 
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Body Image 
 The five domains within the body image questionnaire include appearance 
evaluation, appearance orientation, body area satisfaction, overweight preoccupation, 
and self-classification of weight. Multivariate analyses revealed significant Wilks’ 
Lambda effect of time (p=0.00) with no significant interaction for time x genotype 
(p=0.32), time x diet (p=0.59), or time x genotype x diet (p=0.58). Univariate analyses 
revealed a significant time effect for appearance evaluation and body area satisfaction 
such that all participants reported an increase in rating of appearance and satisfaction 
with most areas of the body from baseline to completion of the study (appearance: 
+0.5±0.6;  p=0.01; body area satisfaction: +0.36±0.45; p=0.00). In addition a significant 
time effect was observed for overweight preoccupation suggesting that from baseline to 
completion, all participants exhibited an increase in rating for fat anxiety, weight 
vigilance, dieting, and eating restraint (+0.4±0.7; p=0.00). Further a significant time 
effect and time x genotype interaction was observed for self-classification of weight. The 
time effect demonstrated a reduction in rating of overweight perception from baseline to 
completion for all participants (-0.4±0.7; p=0.00). The time x genotype interaction 
demonstrated a greater reduction in rating of overweight perception from baseline to 
completion in favor of the false matches (F -0.5±0.7, T -0.2±0.7; p=0.04). There were no 
other time effects, time interactions, genotype effect, diet effects, or genotype x diet 
interactions observed. Table 25 represents body image ratings among the five domains 
within the questionnaires. Overall, since no statistically significant interactions favoring 
true matches were observed for the psychosocial evaluation, we accept Ho11. 
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Table 25: Body image observed between groups  
Variable Group Baseline 4 
Weeks 
8 
Weeks 
12 
Weeks 
16 
Weeks 
20 
Weeks 
24 
Weeks 
Group 
(SEM) 
P-value 
Appearance 
Evaluation 
T-MC 2.3±0.7 2.7±0.5 2.7±0.7 2.7±0.7 2.9 ±0.8 2.9±0.7 2.9±0.7 2.7±0.2 T=0.00 
G=0.68 
D=0.86 
G×D=0.98 
T×G=0.97 
T×D=0.28 
T×G×D=0.59 
 
T-LC 2.5±0.6 2.6±0.6 2.7±0.6 2.6±0.6 2.8±0.9 2.7±0.9 2.8±0.8 2.7±0.2 
F-MC 2.4±0.5 2.8±0.8 2.8±0.9 2.8±1.0 2.8±0.9 2.9±0.7 3.1±0.5 2.8±0.3 
F-LC 2.5±0.9 2.6±0.8 2.7±0.8 2.8±0.8 2.9±0.7 2.9±0.8 2.8±0.7 2.8±0.2 
T 2.4 ±0.7 2.6 ±0.5 2.6±0.7 2.7±0.7 2.8±0.8 2.8±0.8 2.9±0.7 2.7±0.1 
F 2.5 ±0.8 2.7 ±0.8 2.7±0.8 2.8±0.8 2.9±0.8 2.9±0.7 2.9±0.6 2.8±0.2 
MC 2.3±0.7 2.7±0.6 2.7±0.8 2.7±0.8 2.9±0.8 2.9±0.7 3.0±0.6 2.8±0.2 
LC 2.5±0.7 2.6±0.7 2.7±0.7 2.7±0.7 2.8±0.8 2.8±0.8 2.8±0.7 2.7±0.1 
 Time 2.4±0.7 2.7±0.6* 2.7±0.7* 2.7±0.7* 2.8±0.8* 2.9±0.8* 2.9±0.7*   
Appearance 
Orientation 
 
T-MC 3.4±0.6 3.4±0.4 3.5±0.5 3.4±0.5 3.4±0.5 3.4±0.5 3.4±0.4 3.4±0.1 T=0.62 
G=0.98 
D=0.92 
G×D=0.34 
T×G=0.78 
T×D=0.67 
T×G×D=0.56 
 
T-LC 3.4±0.5 3.2±0.7 3.2±0.7 3.2±0.6 3.3±0.8 3.2±0.7 3.3±0.6 3.3±0.1 
F-MC 3.3±0.4 3.3±0.4 3.3±0.5 3.3±0.6 3.2±0.5 3.3±0.3 3.1±0.3 3.2±0.2 
F-LC 3.4±0.7 3.4±0.5 3.4±0.6 3.4±0.6 3.4±0.6 3.4±0.6 3.3±0.7 3.4±0.1 
T 3.4±0.5 3.3±0.5 3.3±0.6 3.3±0.5 3.3±0.6 3.3±0.6 3.3±0.5 3.3±0.1 
F 3.4±0.6 3.3±0.4 3.4±0.6 3.4±0.6 3.3±0.6 3.4±0.5 3.3±0.6 3.3±0.1 
MC 3.3±0.5 3.3±0.4 3.4±0.5 3.3±0.5 3.3±0.5 3.4±0.5 3.3±0.4 3.3±0.1 
LC 3.4±0.6 3.3±0.6 3.3±0.6 3.3±0.6 3.4±0.7 3.3±0.6 3.3±0.7 3.3±0.1 
 Time 3.4±0.6 3.3±0.5 3.3±0.6 3.3±0.5 3.3±0.6 3.3±0.5 3.3±0.6   
Body Area 
Satisfaction 
T-MC 2.6±0.5 2.9±0.4 2.8±0.5 3.0±0.5 3.0±0.6 3.0±0.5 3.0±0.6 2.9±0.1 T=0.00 
G=0.56 
D=0.41 
G×D=0.73 
T×G=0.30 
T×D=0.81 
T×G×D=0.60 
 
T-LC 2.5±0.5 2.6±0.6 2.7±0.5 2.8±0.5 2.8±0.7 2.8±0.7 2.8±0.8 2.7±0.1 
F-MC 2.7±0.5 3.0±0.4 2.9±0.4 2.9±0.5 2.9±0.5 3.0±0.5 3.1±0.3 2.9±0.2 
F-LC 2.6±0.5 2.8±0.6 2.9±0.6 2.8±0.6 2.9±0.6 3.1±0.6 3.0±0.6 2.9±0.1 
T 2.6±0.5 2.8±0.5 2.8±0.5 2.9±0.5 2.9±0.6 2.9±0.6 2.9±0.7 2.8±0.1 
F 2.6±0.5 2.9±0.6 2.9±0.5 2.9±0.6 2.9±0.6 3.1±0.6 3.0±0.5 2.9±0.1 
MC 2.6±0.5 2.9±0.4 2.9±0.5 3.0±0.5 3.0±0.6 3.0±0.5 3.0±0.5 2.9±0.1 
LC 2.6±0.5 2.8±0.6 2.8±0.5 2.8±0.6 2.9±0.7 2.9±0.7 2.9±0.7 2.8±0.1 
 Time 2.6±0.5 2.8±0.5* 2.8±0.5* 2.9±0.5* 2.9±0.6* 3.0±0.6* 3.0±0.6*   
Overweight 
Preoccupation 
T-MC 2.8±0.6 3.3±0.5 3.4±0.5 3.4±0.4 3.4±0.5 3.3±0.6 3.3±0.5 3.3±0.1 T=0.00 
G=0.21 
D=0.37 
G×D=0.75 
T×G=0.49 
T×D=0.37 
T×G×D=0.51 
 
T-LC 3.0±1.0 3.7±0.7 3.6±0.7 3.3±0.8 3.3±0.8 3.4±0.8 3.3±0.8 3.4±0.2 
F-MC 2.7±0.4 3.0±0.6 3.0±0.4 3.2±0.4 3.1±0.4 3.0±0.4 3.1±0.4 3.0±0.2 
F-LC 2.8±0.8 3.3±0.6 3.3±0.6 3.4±0.6 3.3±0.6 3.2±0.7 3.2±0.8 3.2±0.1 
T 2.9±0.8 3.5±0.6 3.4±0.6 3.4±0.6 3.3±0.6 3.3±0.7 3.3±0.6 3.3±0.1 
F 2.8±0.7 3.2±0.6 3.2±0.6 3.3±0.5 3.2±0.6 3.1±0.6 3.1±0.7 3.1±0.1 
MC 2.8±0.6 3.2±0.5 3.3±0.5 3.3±0.4 3.3±0.5 3.2±0.5 3.2±0.5 3.1±0.1 
LC 2.9±0.9 3.5±0.7 3.4±0.7 3.3±0.7 3.3±0.7 3.3±0.7 3.2±0.8 3.3±0.1 
Time 2.8±0.7* 3.4±0.6* 3.3±0.6* 3.3±0.6* 3.3±0.6* 3.2±0.6* 3.2±0.7*  
Self 
Classification 
of Weight 
T-MC 4.25±0.9 4.0±0.9 4.1±0.7 3.9±0.9 4.0±0.7 3.9±0.9 3.9±0.7 4.0±0.2 T=0.00 
G=0.36 
D=0.59 
G×D=0.66 
T×G=0.04 
T×D=0.38 
T×G×D=0.11 
 
T-LC 4.23±1.0 4.3±0.9 4.1±1.0 4.2±0.7 4.2±0.6 4.2±0.6 4.1±0.9 4.2±0.2 
F-MC 4.6±0.6 4.6±0.6 4.4±0.6 4.5±0.7 3.8±1.2 4.3±0.7 3.8±1.2 4.3±0.2 
F-LC 4.6±0.4 4.4±0.5 4.3±0.5 4.3±0.5 4.1±0.5 4.1±0.5 4.2±0.6 4.3±0.2 
T 4.2±0.9 4.2±0.9 4.1±0.8^ 4.0±0.8^ 4.1±0.7^ 4.0±0.8^ 4.0±0.8^ 4.1±0.1 
F 4.6±0.5 4.5±0.6^f 4.4±0.5^f 4.4±0.6^f 4.0±0.8^f 4.2±0.6^f 4.1±0.8^f 4.3±0.1 
MC 4.3±0.8 4.2±0.9 4.2±0.7 4.1±0.9 4.0±0.9 4.0±0.9 3.9±0.9 4.1±0.1 
LC 4.4±0.8 4.4±0.7 4.2±0.8 4.3±0.6 4.2±0.5 4.1±0.6 4.2±0.7 4.2±0.1 
Time 4.4±0.8 4.3±0.8τ 4.2±0.7 4.2±0.7* 4.1±0.7* 4.1±0.7* 4.0±0.8*  
Data presented as Mean±SD. Significance level p < 0.05. Mean (n = 51), T = true match (n = 29), F = false match (n = 22), MC = moderate 
CHO (n = 23), LC = low CHO (n = 28), T-MC (n = 16), T-LC (n = 13), F-MC (n = 7), F-LC (n = 15). T = time effect, G = genotype match to 
diet effect, D = diet effect, G×D = genotype match to diet x diet effect, T×G = time x genotype match to diet effect, T×D = time x diet effect, 
T×G×D = time x diet x genotype match to diet effect. *significant time effect from baseline p < 0.05. τ trend in time effect from baseline p > 
0.05 and p < 0.1 (univariate), ^ significant difference compared to baseline (Tukey LSD), fsignificant difference from T p < 0.05 (Tukey LSD 
post hoc). 
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Summary of Significance and Trends 
 A multitude of significance and trends have been demonstrated within this 
investigation regarding genotype effects, diet effects, time x genotype interactions, time 
x diet interaction, and time x genotype x diet interactions. Tables 26 and 27 provide a 
comprehensive overview of relevant findings related to psychosocial health and physical 
health.  
 
Table 26: Significant findings and trends related to psychosocial health 
Variable Effect or Interaction  P-value Effect Size 
(cohens d) 
Interpretation 
Self-Esteem Diet 0.10 0.79 Moderate effect 
Favor LC 
Eating Satisfaction- 
Feeling of Fullness 
Time x Diet 
 
Time x Genotype 
0.08 
 
0.09 
0.68 
 
0.67 
Moderate effect 
Favor MC 
Moderate effect 
Favor true match 
Eating Satisfaction- 
Diet Quality 
Time x Diet 0.03* 0.78 Moderate effect 
Favor MC 
Social Physical Anxiety Time x Genotype x 
Diet 
0.03* 1.9 Large effect 
FMC, TLC,TMC, FLC# 
Body Image- 
Weight Classification 
Time x Genotype 0.04* 0.77 Moderate effect 
Favor false match 
Mean (n = 51), MC = moderate CHO (n = 23), LC = low CHO (n = 28), T = True match (n = 29), F = False match (n = 22), TMC (n 
= 16), TLC (n = 13), FMC (n = 7), FLC (n = 15), *indicates statistical significance, p < 0.05, # time x genotype x diet interaction 
interpretation includes genotype and diet combination listed from most favorable to least favorable health outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	
 
140 
Table 27: Significant findings and trends related to physical health 
 
Variable Effect or Interaction  P-value Effect Size 
(cohens d) 
Interpretation 
Body Weight Genotype 0.10 0.78 Moderate effect 
Favor false match 
Fat Free Mass Genotype 0.09 0.83 Large effect 
Favor false match 
Android- Total Mass Genotype 
 
Time x Genotype x Diet 
 
0.05* 
 
0.09 
0.94 
 
0.73 
Large effect 
Favor false match 
Moderate effect 
FLC, TMC, TLC, FMC# 
Android- Fat Free Mass Genotype 
 
Time x Genotype x Diet 
 
0.04* 
 
0.08 
0.98 
 
0.71 
Large effect 
Favor true match 
Moderate effect 
FMC, TLC, TMC, FLC# 
Android- Fat Mass Genotype 0.07 0.89 Large effect 
Favor false match 
Gynoid- Total Mass Time x Genotype x Diet 
 
Genotype 
 
0.04* 
 
0.09 
0.93 
 
0.83 
Large effect 
FLC, TMC, TLC, FMC# 
Large effect 
Favor true match 
Gynoid- Fat Free Mass Genotype 0.09 0.82 Large effect 
Favor false match 
Hip Circumference Genotype 0.07 0.88 Large effect 
Favor true match 
Absolute EE Genotype 0.03* 1.03 Large effect 
Favor false match 
Absolute VO2 Time x Genotype x Diet 
 
0.08 0.82 Large effect 
FMC, TLC, TMC, FLC# 
Relative VO2 Time x Genotype x Diet 
 
0.07 0.84 Large effect 
FMC, TLC, TMC, FLC# 
Lower Body Strength Diet 
 
Time x Diet 
0.04* 
 
0.04* 
1.01 
 
1.01 
Large effect 
Favor MC 
Large effect 
Favor MC 
Total Cholesterol Diet 
 
Time x Diet 
 
Genotype x Diet 
0.00* 
 
0.001* 
 
0.06 
1.89 
 
1.45 
 
0.94 
Large effect 
Favor MC 
Large effect 
Favor MC 
Large effect 
TMC, FMC, FLC, TLC# 
HDL Time x Diet 0.01* 1.11 Large effect 
Favor LC 
LDL Diet 
 
Time x Diet 
 
Genotype x Diet 
0.001* 
 
0.01* 
 
0.02* 
1.70 
 
1.14 
 
1.20 
Large effect 
Favor MC 
Large effect 
Favor MC 
Large effect 
TMC, FMC, FLC, TLC# 
Triglycerides Diet 
 
Time x Diet 
 
Time x Genotype 
0.00* 
 
0.00* 
 
0.05* 
1.99 
 
1.57 
 
0.84 
Large effect 
Favor MC 
Large effect 
Favor MC 
Large effect 
Favor false match 
Glucose Diet 0.01* 1.24 
 
Large effect 
Favor LC 
Insulin Genotype 0.04* 1.02 Large effect 
Favor false match 
Glucose/Insulin Ratio Genotype 0.03* 1.04 Large effect 
Favor false match 
HOMA-IR Genotype 0.06 0.92 Large effect 
Favor false match 
Mean (n = 51), MC = moderate CHO (n = 23), LC = low CHO (n = 28), T = True match (n = 29), F = False match (n = 22), TMC (n = 16), 
TLC (n = 13), FMC (n = 7), FLC (n = 15), *indicates statistical significance, p < 0.05, # time x genotype x diet interaction interpretation 
includes genotype and diet combination listed from most favorable to least favorable health outcome. 
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
Summary 
 The concept of genetic profiling within the arena of weight management is in its 
infancy. Of the few studies that have applied genetic profiling to weight loss7-9, available 
results from Dopler-Nelson and colleagues9 study demonstrated a 2-3 fold greater 
reduction in BW in true matches versus false matches (p=0.02), along with greater 
reductions in waist circumference (p=0.01) and triglycerides (p=0.007), and an increase 
in HDL (p=0.01). These clear-cut findings with the simple genetic profile used 
warranted further investigation. Since their study was retrospective, we aimed to use the 
same genetic profile in a prospective study. Therefore, the purpose of our 6-month 
weight loss intervention was to determine if prospectively matching individuals to a 
dietary intervention that aligned with their genotype (true match) would demonstrate 
greater improvements in health outcomes in comparison to individuals matched to a diet 
that did not align with their genotype (false match). 
While Dopler-Nelson and colleagues9 used commercialized diet programs, we 
used the Curves International diet and exercise program as previous research from our 
lab has demonstrated advantageous health outcomes with this program in comparison to 
other commercialized weight management programs.26,112-116 Additionally, based on our 
review of the weight loss interventions that have assessed each candidate gene within the 
tested genetic profile, evidence suggests inclusion of an exercise component within 
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weight loss interventions utilizing these candidate genes for profiling.117 Thus, we tested 
the Curves Complete diet, which was a moderate CHO, adequate fat, moderate protein 
diet (30% kcal CHO, 25% kcal fat, 45% kcal protein; MC), in comparison to a lower 
CHO, adequate fat, moderate protein diet (20% kcal CHO, 35% kcal fat, 45% kcal 
protein; LC). All participants engaged in the Curves Exercise program, a circuit-style 
resistance-training program completed four days per week, and were encouraged to 
complete 10,000 steps per day three days per week to increase lifestyle activity. We 
hypothesized that true matches would experience greater improvements in measured 
health variables upon completion of the study in comparison to false matches. Overall 
we found the opposite of our hypothesized outcomes. 
Compliance to Diet, Exercise, and Lifestyle Activity Prescription 
 Among all participants, significant time effects were observed for total energy 
intake (-520±498 kcal/d, p=0.00) supporting adherence to the caloric restriction. Total 
CHO intake was reduced in both diet groups and conformed to the classifications of a 
moderate CHO diet and low CHO diet. Fat intake was also reduced and complied with 
the classification of a diet adequate in fat. While fat intake in MC was higher than the 
prescription, intake was still lower than the prescription for LC and actual intake of fat in 
LC. Individuals in LC met their dietary prescription for fat. Protein intake increased in 
both groups and while lower than the 45% prescription, intake was still high enough for 
the diet to be considered moderate in protein. 
 Additionally, exercise compliance among all participants was acceptable, 
averaging 86±11% completion of the prescribed workouts. Reported vigorous MET 
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minutes also increased over time for all participants (+618±1198 min/wk, p=0.00). 
Lifestyle activity increased for all participants as evidenced by the time effect for 
reported leisure-time MET minutes (+854±1399 min/wk; p=0.002). Taken together, 
these findings support the notion of compliance among participants within the diet and 
exercise prescription, and encouraged increase in lifestyle activity.  
Anthropometrics, Body Composition, Resting Energy Expenditure 
Upon completion of the 6-month intervention, all participants experienced 
weight loss success, -5.3±5.0 kg BW. The amount of weight loss observed in the present 
investigation aligns with previous research conducted in our lab testing a similar diet and 
exercise regimen (-3.1±3.726, -6.1±3.2115, -5.1±4.2116 kg BW). True matches lost 5.0±5.0 
kg BW and false matches lost 5.6±5.0 kg BW. These findings contrast the reductions 
observed in Dopler-Nelson and colleagues9 investigation, where at six-months true 
matches lost approximately 6-7 kg BW and false matches lost about 2-3 kg BW. 
Additionally, while all participants in the present investigation experienced a reduction 
in waist circumference from baseline to completion (-5.2±5.7 cm), significant 
differences or trends in genotype were not observed, which contrasts Dopler-Nelson and 
colleagues9 findings of a significant difference for change in waist circumference 
favoring true matches.  
The discrepancy in results between studies may be attributed to the degree of 
CHO and fat restriction within the prescribed diets per genotype. In Dopler-Nelson and 
colleagues9 study CHO and fat prescription per genotype was restricted to a much 
greater degree than restriction in the present study. For example, true matches to low 
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CHO diet may have followed the Atkins diet (20 g CHO/d x 2-3 months then ≤ 50 g 
CHO/d) whereas true matches to low fat may have followed the Ornish diet (≤ 10% kcal 
fat/d). In the present investigation, true matches to low CHO were assigned to LC (20% 
kcal CHO/d or 60 g CHO/d x 1 week then 75 g CHO/d x 2-24 weeks) while true 
matches to low fat were assigned to MC (25% kcal fat or 39 g fat/d x 1 week then 42 g 
fat/d x 2-24 weeks).  
Additionally, the present investigation included a supervised, structured exercise 
program, whereas participation in unsupervised daily physical activity was encouraged 
in Dopler-Nelson and colleagues9 study. Further, the exercise program in the present 
investigation included circuit-style resistance training exercises, whereas the encouraged 
exercise in Dopler-Nelson and colleagues9 investigation may have been exclusively 
aerobic, resistance, or a combination of both pending on the diet group participants were 
matched to (i.e. LEARN, Ornish, Atkins, Zone). Therefore, the inclusion of a structured 
exercise program consisting of circuit-style resistance training may contribute to 
findings favoring false matches in the present investigation.  
Along with anthropometric measurements, we also assessed changes in body 
composition, fat deposition, and visceral adipose tissue (VAT). This is the first 
investigation to date to assess changes in these variables with the tested genetic profile. 
The observed significant differences and trends with moderate-large effect sizes favoring 
false matches have great implications towards disease prevention. While all participants 
experienced a significant quadratic effect for fat free mass (0-3-months: -0.9±1.8 kg, 3-
6-months: +0.2±1.7 kg, pq=0.01), upon completion of the study a trend in genotype with 
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a large effect was observed favoring false matches such that false matches retained on 
average 0.4 more kg fat free mass (F -0.4±2.3, T -0.8±2.3 kg). Additionally, a trend in 
genotype with a large effect was observed for gynoid fat free mass where false matches 
gained gynoid fat free mass upon completion (+3.0±665 grams) and true matches lost 
mass (-199±534 grams). Coordinately, although false matches lost more body weight, 
the better retention in fat free mass may likely contribute to the significant genotype 
effect for resting energy expenditure, where false matches experienced a 20 kcal/d 
increase in absolute resting energy expenditure upon completion in comparison to true 
matches (F +74.0±239, T +54.8±256.2 kcal/d). These findings are note-worthy as we 
know improvements in fat free mass are linked with reducing risk of disease and 
mortality.118,119 
Additionally, we measured android fat deposition and visceral adiposity as 
markers of abdominal obesity. It is known that abdominal obesity, particularly excessive 
accumulation of visceral adipose tissue, increases ones risk of chronic disease and all-
cause mortality.120,121 Our findings demonstrate favorable changes in android fat 
deposition and visceral fat for false matches. While all participants experienced a 
reduction in android total mass (-747±863grams), a significant genotype effect was 
observed such that false matches lost an average of about 179.4 more grams of android 
total mass upon completion (F -849.1±882.8, T -669.7±855.4 grams). Further while all 
participants reduced android fat mass (-532±528 grams), a trend in genotype with large 
effect favored false matches, as they also lost on average 168 grams more of android fat 
mass in comparison to true matches (F -627±583, T -459±480 grams). Additionally, 
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while not statistically significant, a moderate effect was observed for VAT mass, area, 
and volume for time x genotype interaction where false matches experienced greater 
reductions from baseline to completion in VAT mass (T -152.6±233.7, F -160.4±255.6 
g; p=0.20, η2p=0.032, d=0.6) area (-31.6±48.5, F -33.3±52.9 cm2; p=0.20, η2p =0.031, 
d=0.59) and volume (T -164.6±252.7, F -173.6±276 cm3; p=0.22, η2p=0.030, d=0.58). 
These findings suggest potential for use of this profile in coordination with the tested 
diet and exercise program for reducing abdominal obesity and chronic disease risk.  
While the present investigation overwhelmingly favors the false match matches 
genotype in relation to the tested diets for body composition variables, these results 
contrast recently reported 3-month preliminary findings.122 Among the preliminary 
findings, while no significant difference in BW change was observed (T -4.33±3.6, F -
3.91±3.9 kg, p=0.36), significant differences for reduction in fat mass (T -3.81±2.5, F -
1.92±3.2 kg, p=0.01) and body fat percentage (T -2.15±2.3, F 0.01±2.1 %, p=0.002), and 
better retention of fat free mass (T -0.76±1.8, F -2.16±2.3 kg, p=0.042) was observed in 
favor of true matches. Therefore, evidence from the preliminary findings and present 
investigation suggest a genetic impact on markers of body composition related to health 
and disease risk; however, it is clear that more research is needed to identify the 
combination of genes and allelic variants to best predict diet and exercise prescription 
within a weight management program for optimization of health acutely (i.e. < 3-
months) and more long-term (> 3-months).  
Furthermore, as with any weight management program, the behavioral aspect 
must be considered. In contrast to the present investigation, data from preliminary 
 	
 
147 
findings were collected during the spring and summer months. It has been demonstrated 
through previous research that time of year, specifically fall and winter months and the 
holiday season, play a significant role in reduction of physical activity, increase in 
energy intake, and alteration in body composition (i.e. increase fat mass and body fat 
percentage).123-126 Data from the present investigation was collected from April 2014-
May 2015 with rolling admission into the weight loss program.  Thus, differences 
between the present investigation and preliminary findings may be associated with 
holiday interference and differences in time of year in relation to study course among 
participants secondary to rolling admission.  
Fitness 
 While all participants experienced a significant increase in absolute and relative 
peak aerobic capacity from baseline to completion (absolute VO2 +0.2±0.2 L/min, 
p=0.00; relative VO2 +3.7±3.2 ml/kg/min), a trend in time x genotype x diet interaction 
with a large effect was observed for absolute and relative VO2 peak favoring false 
matches in MC. These findings support the notion of greater outcomes observed in false 
matches, as false match MC demonstrated the greatest improvements in 
cardiorespiratory fitness.  
 In addition a significant diet effect and time x diet interaction was observed for 
lower body strength in favor of MC. From these results we can conclude that MC is most 
beneficial in terms of improving strength. These findings are consistent with previous 
research conducted in our lab comparing the macronutrient distribution used in MC to 
other diets in relation to impact on markers of fitness.26,112,113  
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Biochemical Markers 
 All participants experienced reductions in total cholesterol (-7.2±36.0 mg/dL), 
LDL (-2.5±29.3 mg/dL), and triglycerides (-20.9±57.9 mg/dL), and an increase in HDL 
cholesterol (+4.6±13.3 mg/dL) from baseline to completion. We observed significant 
diet effects and time x diet interactions favoring MC for total cholesterol (MC -
25.2±31.3, LC +7.7±33.1 mg/dL), LDL (MC -13.6±28.6, LC +6.7±26.9 mg/dL), and 
triglycerides (MC -37.1±65.7, LC -7.6 ± 47.7 mg/dL). These findings are consistent with 
a previous investigation in our lab comparing similar macronutrient distribution to other 
diets.114 Furthermore a significant time x diet interaction was observed for HDL favoring 
LC (LC +8.9±12.8, MC -0.6±12.2 mg/dL). These findings are expected considering LC 
total cholesterol increased steadily overtime; thus we would expect the observed 
increases in HDL and LDL.  
 We did not observe any genotype effects for total cholesterol and LDL, which is 
consistent with Dopler-Nelson and colleagues9 findings; however, we did observe a 
trend in genotype x diet interaction with a large effect for total cholesterol, and a 
significant genotype x diet interaction for LDL, where true MC was favored (cholesterol: 
T-MC -26.0±32.1, F-MC -23.5±32.0, F-LC +7.0±31.8, T-LC +8.5±35.8 mg/dL; LDL: T-
MC -15.8±26.7, F-MC -8.6±34.2, F-LC +3.7±28.1, T-LC +10.1±26.3 mg/dL). 
Furthermore a significant time x genotype interaction for triglycerides favoring false 
matches upon completion was observed (F -35.5±49.1 mg/dL, T -9.9±62.3), which 
contrasts Dopler-Nelson and colleagues9 results. For HDL cholesterol, there was no 
significant genotype effect or trend observed, which contrasts Dopler-Nelson and 
 	
 
149 
colleagues9 results, as they observed a significant increase in HDL for true matches.  
Difference between studies regarding blood lipids is likely related to differences in 
dietary composition as previously discussed.  
 Regarding markers related to insulin resistance, a significant diet effect was 
observed favoring LC, such that LC experienced a reduction in fasting blood glucose 
upon completion (LC -0.02±13.0, MC +3.2±9.2 mg/dL, p=0.01). Although blood 
glucose levels increased slightly in MC upon completion, levels remained within normal 
limits. Further, this observed change might be attributed to dietary habits of participants 
prior to the testing session, such as length of fast between testing sessions (8 hours 
versus 12 hours), size and dietary components of last meal. 
 In addition, a significant genotype effect was observed for fasting insulin and 
glucose/insulin ratio, along with a trend towards significance with a large effect in 
HOMA-IR favoring false matches. While fasting insulin levels were greater in false 
matches at each time point in comparison to true matches (T: baseline 11.6±6.4, 6-
months 13.5±6.4, F: baseline 16.2±8.0, 6-months 16.3±7.2 µIU/L), levels remained 
relatively stable throughout the course of the study as opposed to increasing slightly as 
observed in true matches. These findings are congruent with blood glucose results for 
true and false matches over time (T: baseline 89.7±9.3, 6-months 92.2±9.7, F: baseline 
91.5±10.0, 6-months 91.5±11.1 mg/dL). Coordinately false matches experienced an 
increase in glucose/insulin ratio upon completion (F +0.4±4.1, T-1.5±3.8, p=0.03) and 
reduction in HOMA-IR (F-0.06±1.3, T0.5±1.2, p=0.06, η2p=0.075, d=0.92). Overall 
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these findings suggest improvements in glucose metabolism favoring false matches over 
true.  
Psychosocial Evaluation 
 We found the MC diet to promote the most favorable results with regards to 
satiation and diet quality, whereas LC exhibited improved results with self-esteem 
levels. A significant time x diet interaction was observed for diet quality favoring MC 
upon completion, with an average rating of diet quality greater than one unit in MC 
compared to LC (MC +2.3±2.0, LC +1.14±2.0). Along with this a time x diet trend with 
moderate effect was observed for reported feeling of fullness, where overall participants 
in MC reported greater satiation upon completion from baseline (MC +0.61±1.8, LC -
0.86±1.6). Interestingly, a trend in diet with a moderate effect was observed for self-
esteem score, where individuals in LC reported greater rating of self-esteem at all time 
points including overall from baseline to completion (LC +2.0±2.6, MC +1.6±3.5).  
 Regarding genotype, a significant time x genotype interaction was observed for 
self-classified weight (i.e. perception of over or underweight independent of actual 
weight status) with regards to body image such that false matches exhibited the greatest 
reduction in self-classification of overweight in comparison to true matches (F -0.5±0.7, 
T -0.2±0.7). Related to findings favoring MC and false matches, a significant time x 
genotype x diet interaction was observed for social physical anxiety such that false 
match MC exhibited the greatest reductions in social physical anxiety over time in 
comparison to other genotype x diet combinations.  
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Conclusions  
 Overall, results showed that both diet interventions in coordination with the 
structured exercise program elicited improvements in anthropometrics, body 
composition, resting energy expenditure, fitness, blood lipid profile, and some 
psychosocial variables. Additionally, false matches experienced favorable results among 
the majority of variables in comparison to true matches. Thus, findings suggest MC 
prescription for individuals with the low CHO genotype per the tested genetic profile.  
Considering the relatively small sample size of the present investigation, 
significant differences and trends containing moderate to large effect sizes in response to 
genotype, and observed health benefits facilitating disease prevention, more research is 
warranted testing this genetic profile. Moreover, since only some of the candidate genes 
in the tested profile are considered functional single nucleotide polymorphisms with 
clinical significance (ADRB3rs4994, ADRB2 rs1042713 and rs 1042714), more 
research is necessary to identify the ideal combination of genes and allelic variants to 
best predict diet and exercise prescription within a weight management program. 
Furthermore, the pre-investigation power analysis suggested a goal sample size 
of 80 participants. This analysis was based on previous research from our laboratory 
assessing changes in fat mass between diet groups, and change in body weight between 
genotype in the Dopler-Nelson investigation9. Post-hoc power analyses regarding the 
moderate and large effect sizes related to body composition and fat deposition in the 
present investigation suggest a sample size ranging from 400-800 participants in order to 
detect statistically significant differences between genotype for body composition and 
 	
 
152 
fat deposition variables. These findings further support the necessity of conducting the 
present investigation with a larger sample size. Overall, future investigations should take 
the following points into consideration: larger sample size, degree of CHO and fat 
restriction within the tested diets, incorporation of a structured exercise program, time of 
year data is collected, and uniform admission into the study. 
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APPENDIX C 
 
RECRUITMENT FLYER 
 
 
 
 
Want to get fit and lose weight?   
 
Participants Needed for a Study    
 
Researchers in the Exercise & Sport Nutrition Laboratory 
(ESNL) at Texas A&M University are recruiting 
approximately 320 women between the ages of 18 and 60 
to participate in a weight loss program.  Participants will be 
randomized into one of four intervention groups involving 
varying exercise and nutritional requirements for 24 weeks.  
Eligible participants will receive $300 for completing the 
study.  Eight visits approximately one month apart will be 
required.   
 
For more information call:   
 
Exercise & Sport Nutrition Laboratory (ESNL) 
Department of Health & Kinesiology (HLKN)   
1700 Research Parkway 
Suite # 2500  
979-458-1743/979-458-1715 
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APPENDIX D 
 
PARTICIPANT ELIGIBILITY SCREENING 
 
 
Texas A&M University: Exercise & Sport Nutrition Laboratory 
Trial:  Effects of Diet Type Selection Based on Response to a Carbohydrate 
Intolerance Questionnaire and Genetic Screening on Success to a Weight 
Loss and Exercise Program - Entrance Criteria 	
	Phone	Script:		“Hello	this	is	the	Exercise	&	Sport	Nutrition	Laboratory.		I	am	going	to	
ask	you	a	few	general	questions	to	see	if	you	qualify	for	the	study	you	expressed	
interest	in.”			
	
Gender:		 	 1.		Are	you	female?	Yes	–	Possible	FAM	 No	–	Screen	Failure	 	
	
Age:			 1.		Are	you	between	the	ages	of	18	&	60?		(they	must	be	60	when	they	sign	the	consent,	they	may	turn	61	during	the	study)	Yes	–	Possible	FAM		 No	–	Screen	Failure		
Exercise	History:		 1.		Have	you	participated	in	a	planned	exercise	program	within	the	last	three	months?		Yes	–	Screen	Failure	 No	–	Possible	FAM		
    
2.  Do you exercise more than 30 minutes per day, 3 days per week?   
Yes – Screen Failure No – Possible FAM 
 
3.  Have you experienced recent weight change of ±7 lbs. within the last 
3 months?    Yes	–	Screen	Failure	 No	–	Possible	FAM	
	
Exclusion	Criteria:		 1.	Are	you	pregnant	or	nursing,	or	plan	to	become	pregnant	during	the	next	12	months?	Have	you	recently	been	pregnant	in	the	past	12	months?	Yes	–	Screen	Failure	 No	–	Possible	FAM		2.	Do	you	have	any	uncontrolled	metabolic	disorder	including	known	electrolyte	abnormalities;	heart	disease,	arrhythmias,	diabetes,	thyroid	disease,	or	hypogonadism;	a	history	of	hypertension,	hepatorenal,	musculoskeletal,	autoimmune,	or	neurological	disease?			Yes	–	Screen	Failure	 No	–	Possible	FAM			
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3.	Are	you	currently	taking	thyroid,	hyperlipidemic,	hypoglycemic,	anti-hypertensive,	or	androgenic	medications?							Yes	–	Screen	Failure	 No	–	Possible	FAM		4.	Have	you	taken	ergogenic	levels	of	nutritional	supplements	that	may	affect	muscle	mass	(e.g.,	creatine,	HMB),	anabolic/catabolic	hormone	levels	(androstenedione,	DHEA,	etc.),	or	weight	loss	(e.g.,	ephedra,	thermogenics,	etc.)	within	the	past	three	months?				Yes	–	Screen	Failure	 No	–	Possible	FAM	 Not	Sure	–	Consult	w/ESNL	Staff	prior	to	testing		5.	Are	you	willing	to	take	part	in	a	regular	moderate	exercise	program?	Yes	–	Possible	FAM	 No	–	Screen	Failure		 			
BMI:			 	 	 Do	you	have	a	BMI	greater	than	22?							 	 	 Minimum	Body	Weight	Needed	for	a	BMI	=	22	Height(ft./in.)	 Minimum	Wt.	(lbs.)						Height(ft./in.)		Minimum	Wt.	(lbs.)		 	 	 4’10’’	 	 105	 	 	 5’9”	 	 149		 	 	 4’11”	 	 109	 	 	 5’10”	 	 153		 	 	 5’0”	 	 112	 	 	 5’11”	 	 157		 	 	 5’1”	 	 116	 	 	 6’0”	 	 162		 	 	 5’2”	 	 120	 	 	 6’1”	 	 166		 	 	 5’3”	 	 124	 	 	 6’2”	 	 171		 	 	 5’4”	 	 128	 	 	 6’3”	 	 176		 	 	 5’5”	 	 132	 	 	 6’4”	 	 180		 	 	 5’6”	 	 136	 	 	 6’5”	 	 185		 	 	 5’7”	 	 140	 	 	 6’6”	 	 190		 	 	 5’8”	 	 144		 	 	 Yes	–	Possible	FAM	 No	–	Screen	Failure		
Summary:			 If	the	potential	participant	meets	all	conditions	for	a	possible	FAM,	please	schedule	them.				
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APPENDIX E 
 
INFORMED CONSENT 
 
 
Project	Title:		Effects	of	Diet	Type	Selection	Based	on	Response	to	a	Carbohydrate	Intolerance	Questionnaire	and	Genetic	Screening	on	Success	to	a	Weight	Loss	and	Exercise	Program			
You	 are	 invited	 to	 take	 part	 in	 a	 research	 study	 being	 conducted	 by	 Dr.	
Richard	 Kreider,	 a	 researcher	 from	 Texas	 A&M	 University	 and	 funded	 by	
Curves	 International.	 	 The	 information	 in	 this	 form	 is	 provided	 to	help	 you	
decide	whether	or	not	to	take	part.	If	you	decide	to	take	part	in	the	study,	you	
will	 be	 asked	 to	 sign	 this	 consent	 form.	 If	 you	 decide	 you	 do	 not	 want	 to	
participate,	there	will	be	no	penalty	to	you,	and	you	will	not	lose	any	benefits	
you	normally	would	have.		
Why	Is	This	Study	Being	Done?	The	purpose	of	 this	 study	 is	 to	determine	 if	 stratification	of	 individuals	based	on	responses	 to	 a	 Carbohydrate	 Intolerance	 Questionnaire	 (CIQ),	 genetic	 screening,	and/or	 DNA	 methylation	 affects	 weight	 loss	 success	 and/or	 health	 outcomes	 of	women	 following	 the	 Curves	 moderate	 carbohydrate,	 high	 protein,	 low	 fat	 diet	(30%	 CHO,	 45%	 PRO,	 25%	 FAT)	 or	 the	 Curves	 carbohydrate	 restricted,	 high	protein,	moderate	fat	diet	(20%	CHO,	45%	PRO,	35%	FAT).			
	
Why	Am	I	Being	Asked	To	Be	In	This	Study?		You	are	being	asked	to	be	in	this	study	because	you	are	a	female	between	the	ages	of	 18	 and	60	years	of	 age	with	 a	Body	Mass	 Index	 (BMI)	>	22	 and/or	 a	body	 fat	percentage	>	30%.		You	will	not	be	allowed	to	participate	in	this	study	if	you	report	a	recent	weight	change	of	plus	or	minus	7	lbs.	within	the	past	3	months.		In	addition	you	will	not	be	allowed	to	participate	 in	this	study	if	you	report	any	uncontrolled	metabolic	 or	 cardiovascular	 disorder;	 including	 known	 electrolyte	 abnormalities,	heart	disease,	arrhythmias,	diabetes,	thyroid	disease,	or	a	history	of	hypertension,	hepatorenal,	 musculoskeletal,	 autoimmune,	 or	 neurological	 disease;	 if	 you	 are	taking	 any	 weight	 loss	 supplements	 and/or	 ergogenic	 levels	 of	 nutritional	supplements	 within	 the	 last	 3	 months	 that	 may	 affect	 body	 composition	 and/or	anabolic/catabolic	hormone	 levels;	 a	history	of	pregnancy	or	 lactation	within	 the	past	 12	 months	 or	 intentions	 to	 become	 pregnant	 during	 the	 next	 12	 months;	participation	 in	 a	 regular	 exercise	 program	 within	 the	 past	 3	 months;	 or,	 the	presence	 of	 any	 absolute	 or	 relative	 contraindications	 for	 exercise	 testing	 or	prescription	 as	 outlined	 by	 the	 American	 College	 of	 Sports	Medicine	 unless	 your	personal	physician	 feels	 the	 condition	 is	 controlled,	would	not	be	a	 limitation	 for	you	 to	 participate	 in	 the	 study,	 and	 clears	 you	 for	 participation.	 	 If	 you	 do	 not	
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qualify	for	this	study	we	will	keep	your	contact	information	(phone	number	and/or	e-mail)	and	contact	you	at	a	later	date	for	potential	entry	into	a	similar	study.						
How	Many	People	Will	Be	Asked	To	Be	In	This	Study?	Approximately	320	people	will	be	invited	to	participate	in	this	study	locally.			
What	Are	the	Alternatives	to	being	in	this	study?	The	alternative	to	being	in	the	study	is	not	to	participate.			
What	Will	I	Be	Asked	To	Do	In	This	Study?	You	will	be	asked	to	not	exercise	 for	48	hours	nor	eat	or	drink	calorie	containing	drinks	 for	 12	 hours	 before	 each	 testing	 session/visit.	 	 You	will	 also	 be	 asked	 to	record	 all	 food	 and	drinks	 you	 eat	 and	drink	 on	 food	 record	 forms	 for	 four	 days	(including	 one	 weekend	 day)	 prior	 to	 all	 of	 the	 testing	 sessions/visits.	 	 Your	participation	 in	 this	 study	 will	 last	 up	 to	 approximately	 six	 months	 and	 include	eight	visits	(visit	1	~	1	hour/visit2,5	and	8	~	3	hours/visit	3,4,6,	and	7	~	1.5	hours).		These	visits	are	detailed	below	and	in	Table	1.				Visit	1	(week	one)	–	Familiarization	This	 visit	 will	 last	 about	 one	 hour.	 	 During	 this	 visit	 details	 of	 the	 study	will	 be	explained,	 human	 subject	 consent	 forms	 will	 be	 signed,	 personal	 and	 medical	history	 information	 will	 be	 completed,	 a	 carbohydrate	 intolerance	 questionnaire	will	 be	 completed,	 and	 you	 will	 have	 a	 general	 physical	 that	 will	 include	measurement	of	fasting	blood	to	determine	if	you	can	participate	in	the	study.		You	will	donate	approximately	5	ml	 (1	 teaspoon)	of	 fasting	blood	 from	a	vein	 in	your	arm	according	to	standard	procedures.		Three	cheek	swabs	will	then	be	taken	from	your	 inner	 cheek	 for	 a	 genetic	 screening.	 	 We	 will	 be	 evaluating	 DNA	 to	 assess	which	diet	may	be	more	effective	from	a	metabolism	viewpoint.	 	The	samples	will	be	 destroyed	 after	 analysis.	 	 You	 will	 also	 be	 weighted	 and	 have	 your	 height	measured.				Visit	2,	5	and	8	(week	0,	12	and	24)	–	(T1,	T4	and	T7)	These	visits	will	last	about	three	hours.		During	these	visits	you	will	first	be	asked	to	 complete	 a	 physical	 activity	 questionnaire,	 a	 quality	 of	 life	 inventory,	 a	 social	physique	 anxiety	 scale,	 a	 self-esteem	 scale,	 a	 body	 image	 questionnaire	 and	 an	eating	satisfaction	inventory.		These	items	will	take	about	30	minutes	to	complete.		The	 samples	 will	 be	 destroyed	 after	 analysis.	 	 You	 will	 then	 have	 your	 resting	energy	 expenditure	 determined.	 	 This	will	 take	 about	 30	minutes.	 	 You	will	 then	donate	approximately	20	milliliters	(4	teaspoons)	of	blood	from	a	vein	in	your	arm.		Blood	 samples	 will	 be	 obtained	 by	 standard/sterile	 procedures	 using	 a	 needle	inserted	 into	a	vein	 in	your	arm.	 	This	will	 take	about	15	minutes.	 	You	will	 then	have	 your	 total	 body	 composition	 measured,	 total	 body	 water	 determined,	hip/waist	measurements	determined,	resting	blood	pressure	determined	and	heart	
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rate	measured.		Collectively	these	tests	will	take	about	30	minutes.		You	will	then	be	prepared	to	perform	a	maximal	treadmill	test.		This	test	will	take	about	30	minutes	to	 complete.	 	 You	 will	 then	 perform	 a	 one	 repetition	 maximum	 and	 80%	 of	 1	repetition	maximum	endurance	repetition	test	on	the	bench	press	and	hip/leg	sled	using	standard	procedures.		These	tests	will	take	about	30	minutes	to	complete.		In	the	 event	 of	 an	 emergency	 during	 an	 exercise	 test	 proper	 emergency	 response	protocols	 (calling	 9-911	 for	 serious	 injury	 or	 a	 medical	 emergency,	 calling	Biosafety/EHS	 for	 cleanup	 assistance	 or	 spill	 team	 response,	 calling	 UPD	 for	incidents	in	public	areas,	retrieving	AED	located	in	the	lab,	performing	CPR	or	other	First	 Aid	 techniques,	 etc.)	 will	 be	 followed	 by	 the	 Exercise	 &	 Sport	 Nutrition	Laboratory	(ESNL)	staff	depending	on	the	severity	of	the	emergency.								Visit	3,	4,	6	and	7	(week	4,8,16	and	20)	–	(T2,	T3,	T5	and	T6)	These	visits	will	last	about	one	and	a	half	hours.		The	same	tests	will	be	performed	at	 visits	 3,4,6	 and	 7	 minus	 the	 cheek	 swabs	 and	 the	 exercise	 tests	 (maximal	treadmill	test,	bench	press	test	and	hip/leg	press	test).				After	the	familiarization	and	baseline	testing	you	will	be	matched	according	to	BMI,	age	 and	 body	 fat	 percentage	 and	 randomly	 assigned	 to	 one	 of	 four	 groups	including:		1.)	CIQ-Negative	–	Genetic	Screen	high	carbohydrate	recommended;		2.)	CIQ-Negative	 –	 Genetic	 Screen	 high	 protein	 recommended;	 3.)	 	 CIQ-Positive	 –	Genetic	 Screen	 high	 carbohydrate	 recommended;	 or,	 4.)	 	 CIQ-Positive	 –	 Genetic	Screen	 high	 protein	 recommended.	 	 You	 will	 then	 be	 randomized	 to	 follow	 the	Curves	Complete	moderate	carbohydrate,	high	protein,	low	fat	diet	(30%	CHO,	45%	PRO,	 25%	 FAT)	 (CC-I)	 or	 the	 Curves	 Complete	 II	 carbohydrate	 restricted,	 high	protein,	moderate	fat	diet	(20%	CHO,	45%	PRO,	35%	FAT)	(CC-II)	and	supervised	resistance	based	 exercise	 program.	 	 This	will	 involve	 consuming	1,400	kcals/day	for	 1	 week	 and	 1,500	 kcals/day	 at	 the	 prescribed	 macronutrient	 intakes	 for	 23	weeks.		Meal	plans	on	the	Curves	Complete	diets	will	be	provided	with	limited	food	options	 for	 the	 first	 two	weeks.	 	 Thereafter,	more	 variety	 in	 food	 choices	will	 be	provided	to	meet	macronutrient	goals.		Additionally,	the	Curves	Complete	diets	will	be	 designed	 by	 a	 dietitian	 with	 a	 goal	 of	 providing	 foods	 with	 low	 amounts	 of	saturated	fat.		You	will	also	be	asked	to	take	the	Curves	Essential	2	Go-Nutra	Stock	which	 includes	 a	 Time	 Released	 Biomultiple	 multiple	 vitamin,	 a	 Bioavailable	Calcium	supplement	and	an	Omega-3	supplement.	 	 	 In	addition	 if	you	expected	to	exercise	 four	days	per	week	using	the	Curves	30	minute	circuit	 training	program.			Each	circuit	 style	workout	consists	of	14	resistance	exercises	 that	work	all	major	muscle	 groups.	 	 These	 are	 set	 up	 with	 floor-based	 calisthenics	 exercises	 (e.g.,	running/skipping	in	place,	arm	circles,	Zumba	dance,	etc.)	designed	to	maintain	an	elevated	 heart	 rate.	 	 You	 may	 also	 be	 asked	 to	 wear	 a	 heart	 rate	 monitor.	 	 All	exercise	 sessions	 will	 be	 held	 in	 the	 Exercise	 and	 Sport	 Nutrition	 Laboratory.		Research	 Assistants	 will	 monitor	 your	 exercise	 sessions	 and	 record	 your	attendance.	 	 You	will	 also	 be	 encouraged	 to	walk	 for	 30	minutes	 at	 a	 brisk	 pace	
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and/or	 accumulate	 10,000	 steps	 per	 day	 on	 non-circuit	 training	 days.	 	 The	International	 Physical	 Activity	 Questionnaire	 (IPAQ),	 daily	 physical	 activity	 logs	and	daily	steps	recorded	from	a	pedometer	will	be	used	to	assess	physical	activity	patterns.												
Table	1.			Assessment	and	Timeline	Overview		
 
 
 
 
 
 
Familiarization		
	
Baseline	
(T1)	
4	Weeks	
(T2)	
8	Weeks	
(T3)	
12	Weeks	
(T4)	
16	Weeks	
(T5)	
20	Weeks	
(T6)	
24	Weeks	
(T7)	
	
Familiarization	
Session	
	
Complete	
Paperwork	
	
Review	
Medical	history	
	
Physical	Exam	
	
Fasting	Blood		
	
Genetic	
Screening	
	
Determination	
of	
Qualifications	
to	Participate	
	
Group	
Assignment:	
1)+CIQ,GEN-HC	
2)+CIQ,GEN-HP	
3)-CIQ,GEN-HC	
4)-CIQ,GEN-HP	
	
Randomized	
Diet	
Assignment:	
CC-I	(30%C,	
45%P,	25%F)	
CC-II	(20%C,	
45%P,35%F)	
	
Phase	I	–	1,400	
kcals/d	for	1	
week	Phase	II	–	
1,500	kcals/d	
for	23	weeks	
	
Diet	Record		
Review	
	
IPAQa	
	
Body	Weight	
	
Hip	and	Waist	
Measurements	
	
Resting	Energy	
Expenditure	
	
Resting	BPb	and	
HRc	
	
	
Body	
comp/water	
	
Fasting	Blood		
Gene	Expression	
DNA	
Methylation	
	
Maximal	
Cardiopulmonar
y	Exercise	Test	
	
1	rep	and	80%	1	
rep	Bench	Press	
and	Leg	Press	
Measures		
	
Survey	
Completiond	
	
	
Diet	Record		
Review	
	
IPAQ	
	
Body	Weight	
	
Hip	and	Waist	
Measurements	
	
Resting	Energy	
Expenditure	
	
Resting	BPa	and	
HRb	
	
Body	
comp/water	
	
Fasting	Blood		
	
Survey	
Completiond	
	
	
Diet	Record		
Review	
	
IPAQ	
	
Body	Weight	
	
Hip	and	Waist	
Measurements	
	
Resting	Energy	
Expenditure	
	
Resting	BPa	
and	HRb	
	
Body	
comp/water	
	
Fasting	Blood		
	
Survey	
Completiond	
	
	
Diet	Record		
Review	
	
IPAQ	
	
Body	Weight	
	
Hip	and	Waist	
Measurements	
	
Resting	Energy	
Expenditure	
	
Resting	BPa	
and	HRb	
	
Body	
comp/water	
	
Fasting	Blood		
Gene	
Expression	
DNA	
Methylation	
	
Maximal	
Cardiopulmon
ary	Exercise	
Test	
	
1	rep	and	80%	
1	rep		Bench	
Press	and	Leg	
Press	
Measures		
	
Survey	
Completiond	
	
	
Diet	Record		
Review	
	
IPAQ	
	
Body	Weight	
	
Hip	and	Waist	
Measurements	
	
Resting	Energy	
Expenditure	
	
Resting	BPa	
and	HRb	
	
Body	
comp/water	
	
Fasting	Blood		
	
Survey	
Completiond	
	
	
Diet	Record		
Review	
	
IPAQ	
	
Body	
Weight	
	
Hip	and	
Waist	
Measurem
ents	
	
Resting	
Energy	
Expenditur
e	
	
Resting	BPa	
and	HRb	
	
Body	
comp/wate
r	
	
Fasting	
Blood		
	
Survey	
Completion
d	
	
	
Diet	Record		
Review	
	
IPAQ	
	
Body	Weight	
	
Hip	and	
Waist	
Measuremen
ts	
	
Resting	
Energy	
Expenditure	
	
Resting	BPa	
and	HRb	
	
Body	
comp/water	
	
Fasting	Blood		
Gene	
Expression	
DNA	
Methylation	
	
Maximal	
Cardiopulmo
nary	Exercise	
Test	
	
1	rep	and	
80%	1	rep	
Bench		Press	
and	Leg	Press	
Measures		
	
Survey	
Completiond	
	
aInternational	Physical	Activity	Questionnaire;	bBlood	Pressure;	cHeart	Rate;		
dStandardized	quality	of	life	(SF-36),	social	physique	anxiety,	self-esteem,	body	image,	and	eating	satisfaction	inventories		
CC-I	-	Curves	Complete	Diet	I	(Phase	I	1,400	kcals/d,	Phase	II	1,500	kcals/d	at	30%	C,	45%	P,	25%	F)	and	Exercise	Program	
CC-II	-	Curves	Complete	Diet	II	(	Phase	I	1,400	kcals/d,	Phase	II	1,500	kcals/d	20%	C,	45%	P,	35%	F)	and	Exercise	Program	
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You may be removed from the study by the investigator for these reasons: 
• You	do	not	show	up	for	your	scheduled	testing	sessions/visits	and	the	investigators	are	unable	to	contact	you	to	reschedule.		
• You	do	not	follow	your	assigned	diet	protocol.		
• You	do	not	follow	your	assigned	exercise	protocol.			
Are	There	Any	Risks	To	Me?	
The things that you will be doing are greater than risks that you would come across in 
everyday life.  Although the researchers have tried to avoid risks, you may feel that some 
questions/procedures that are asked of you will be stressful or upsetting.  You do not 
have to answer anything you do not want to.  You will be exposed to a low level of 
radiation during the body composition test, which is similar to the amount of natural 
background radiation you would receive in one month while living in College Station 
Texas.  In addition, a very low level of electrical current will be passed through your 
body during the body water test.  This analyzer is commercially available and has been 
used in the health care/fitness industry as a means to assess body composition and body 
water for over 20 years.  The use of these analyzers have been shown to be a safe 
method of measuring body composition and total body water and are approved by the 
FDA.  You will donate about 1 teaspoon (5 milliliters) of blood during the initial 
familiarization/screening visit and then about 4 teaspoons (20 milliliters) at each of the 
seven testing sessions throughout the study using standard procedures.  These 
procedures may cause a small amount of pain when the needle is inserted into the vein as 
well as some bleeding and bruising.  You may also experience some dizziness and/or 
faint if you are not used to having blood drawn.  The exercise tests that will be 
performed may cause symptoms of fatigue, shortness of breath, and/or muscular 
fatigue/discomfort.  The exercise tests may also cause short-term muscle soreness and 
moderate fatigue for several days following the tests.  You may also experience muscle 
strains/pulls during the exercise testing and/or training program.  However, exercise 
sessions will be conducted by trained staff and monitored to ensure you follow 
appropriate exercise guidelines.  You will follow a prescribed dietary regimen involving 
consuming 1,400 or 1,500 calories per day during various phases of the program.  In 
addition, one group will eat a high percentage of calories in the form of protein.  
Although the total amount of total protein is not excessive (up to 169 grams/day) it may 
be higher than you are used to eating and may exceed recommended protein intake for 
active individuals.  As a result, you may experience weight loss or gain, feelings of 
hunger or fullness, and/or changes in appetite and/or mood during various phases of the 
dietary intervention.  In addition your risk to participation in this study may be greater if 
you have medical clearance to participate with a controlled medical condition.  The 
likelihood of any of these occurring is slim.   
Are	There	Any	Benefits	To	Me?		The	direct	benefit	to	you	by	being	in	this	study	is	to	know	more	about	your	health	and	fitness	status	from	the	tests	to	be	performed.	 	However,	even	if	no	 individual	benefit	is	obtained,	you	will	be	paid	for	your	participation.					
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Will	There	Be	Any	Costs	To	Me?		Aside	from	your	time,	there	are	no	costs	for	taking	part	in	the	study.	
	
Will	I	Have	To	Pay	Anything	If	I	Get	Hurt	In	This	Study?	If	 you	 suffer	 any	 injury	 as	 a	 result	 of	 taking	 part	 in	 this	 research	 study,	 please	understand	that	nothing	has	been	arranged	to	provide	free	treatment	of	the	injury	or	any	other	type	of	payment.	However,	all	needed	facilities,	emergency	treatment	and	professional	services	will	be	available	to	you,	just	as	they	are	to	the	community	in	general.	You	should	 report	any	 injury	 to	Dr.	Richard	Kreider	at	979-845-1333.		You	will	not	give	up	any	of	your	legal	rights	by	signing	this	consent	form.		
Will	I	Be	Paid	To	Be	In	This	Study?	You	will	receive	a	total	of	$300	($20	for	the	Familiarization	and	$40	for	each	additional	testing	session	T1-T7)	in	one	check	at	the	end	of	the	study.		Payment	will	occur	after	finishing	all	eight	sessions	and	after	all	study	materials	(food	records,	etc.)	have	been	turned	in	to	the	study	staff.		You	will	be	pain	on	a	prorated	basis	if	you	are	unable	to	complete	the	entire	study.						
Will	Information	From	This	Study	Be	Kept	Private?	The	 records	 of	 this	 study	will	 be	 kept	 private.	 	 No	 identifiers	 linking	 you	 to	 this	study	 will	 be	 included	 in	 any	 sort	 of	 report	 that	 might	 be	 published.	 	 Research	records	will	be	stored	securely	and	only	ESNL	staff	will	have	access	to	the	records.				Information	about	you	will	be	stored	in	locked	file	cabinets	in	a	locked	file	room	in	an	 ID	 card	 swipe	 access	 controlled	 laboratory.	 	 Computer	 files	will	 be	 protected	with	a	password.		This	consent	form	will	be	filed	securely	in	an	official	area.				People	who	have	access	to	your	information	include	the	Principal	Investigator	and	research	study	personnel.		Representatives	of	regulatory	agencies	such	as	the	Office	of	 Human	 Research	 Protections	 (OHRP)	 and	 entities	 such	 as	 the	 Texas	 A&M	University	Human	Subjects	Protection	Program	(HSPP)	may	access	your	records	to	make	 sure	 the	 study	 is	 being	 run	 correctly	 and	 that	 information	 is	 collected	properly.				The	agency	that	 is	funding	this	study	(Curves	International)	and	the	institution(s)	where	study	procedures	are	being	performed	(Texas	A&M	University)	may	also	see	your	information.		However,	any	information	that	is	sent	to	them	will	be	coded	with	a	number	so	that	they	cannot	tell	who	you	are.		Representatives	from	these	entities	can	see	information	that	has	your	name	on	it	if	they	come	to	the	study	site	to	view	records.		If	they	are	any	reports	about	this	study,	your	name	will	not	be	in	them.				
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Information	 about	 you	 and	 related	 to	 this	 study	 will	 be	 kept	 confidential	 to	 the	extent	permitted	or	required	by	law.		
Who	may	I	Contact	for	More	Information?	You	may	contact	the	Principal	Investigator,	Richard	Kreider,	PhD,	to	tell	him	about	a	 concern	 or	 complain	 about	 this	 research	 at	 979-845-1333	 or	rkreider@hlkn.tamu.edu.	 	 You	 may	 also	 contact	 the	 Co-Investigator/Laboratory	Research	 Associate,	 Chris	 Rasmussen,	 at	 979-458-1741	 or	crasmussen@hlkn.tamu.edu.			For	questions	about	your	rights	as	a	research	participant;	or	if	you	have	questions,	complaints,	or	concerns	about	the	research,	you	may	call	the	Texas	A&M	University	Human	Subjects	Protection	Program	office	at	(979)	458-4067	or	irb@tamu.edu.		
	
What	if	I	Change	My	Mind	About	Participating?	This	 research	 is	 voluntary	 and	 you	 have	 the	 choice	whether	 or	 not	 to	 be	 in	 this	research	study.		You	may	decide	to	not	begin	or	to	stop	participating	at	any	time.		If	you	choose	not	to	be	in	this	study	or	stop	being	in	the	study,	there	will	be	no	effect	on	 your	 student	 status,	 medical	 care,	 employment,	 evaluation,	 relationship	 with	Texas	 A&M	University,	 etc.	 	 Any	 new	 information	 discovered	 about	 the	 research	will	be	provided	to	you.		This	information	could	affect	your	willingness	to	continue	your	participation.					
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STATEMENT	OF	CONSENT	
I	agree	to	be	in	this	study	and	know	that	I	am	not	giving	up	any	legal	rights	by	
signing	this	form.		The	procedures,	risks,	and	benefits	have	been	explained	to	
me,	 and	 my	 questions	 have	 been	 answered.	 	 I	 know	 that	 new	 information	
about	this	research	study	will	be	provided	to	me	as	it	becomes	available	and	
that	the	researcher	will	tell	me	if	I	must	be	removed	from	the	study.			I	can	ask	
more	questions	if	I	want.			A	copy	of	this	entire	consent	form	will	be	given	to	
me.			___________________________________	 	 ____________________________________	Participant’s	Signature	 	 	 	 Date			___________________________________	 ____________________________________	Printed	Name	 Date			
INVESTIGATOR'S	AFFIDAVIT:	Either	 I	have	or	my	agent	has	carefully	explained	 to	 the	participant	 the	nature	of	the	above	project.	I	hereby	certify	that	to	the	best	of	my	knowledge	the	person	who	signed	this	consent	form	was	informed	of	the	nature,	demands,	benefits,	and	risks	involved	in	his/her	participation.		___________________________________	 ____________________________________	Signature	of	Presenter	 Date		___________________________________	 ____________________________________	Printed	Name	 Date	
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APPENDIX F  
 
GENERAL HEALTH QUESTIONNAIRE 	
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APPENDIX G 
 
PHYSICIAN CLEARANCE FORM 
 
Dear Provider:  One of your patient’s would like to participate in a study titled “Effects of Diet 
Type Selection Based on Response to a Carbohydrate Intolerance Questionnaire and Genetic 
Screening on Success to a Weight Loss and Exercise Program” that is being conducted by the 
Exercise & Sport Nutrition Laboratory (ESNL) at Texas A&M University.  In order to do so, she 
must meet the selection criteria described below and/or have approval from her personal 
physician to participate in the study.  The study will involve having sedentary and overweight 
female participants participate in the Curves exercise and weight loss program for 24 weeks.  
The assessments to be performed are listed below.  Please check the test/tests you do not feel 
comfortable having your patient complete (if any).  In addition please staple a copy of your 
letterhead to this form to verify that it has been reviewed.       
_____Fasting blood     _____Fasting resting energy expenditure (REE)  
_____Bench press/Leg press assessments _____Bioelectrical Impedance Analysis (BIA) 
_____Diet intervention (see table attached)  _____Bone densitometry (DEXA) 
_____BodyMetrix Ultrasound assessment  
_____Maximal cardiorespiratory stress test (Bruce protocol)  
Details about these specific tests are included below and in the attached participant consent 
form.  If you feel she meets the entrance criteria and/or any existing medical condition that she 
may have is under control and would not be a limitation for her to participate in the study, 
please sign the medical clearance below.   
Selection Criteria     
Approximately 80 sedentary and overweight female participants (BMI > 22 and/or body fat 
percentage > 30%) between the ages of 18 and 60 will participate in this study.		I understand that 
in order to participate in this study, a trained individual will examine me to determine whether I 
qualify to participate. 
 
Participants will not be allowed to participate in this study if they:    
1. have recent history of weight change (+7 lb within 3 months); 
2. have any metabolic disorders including known electrolyte abnormalities; heart disease, 
arrhythmias, diabetes, thyroid disease, or hypogonadism; a history of hypertension, 
hepatorenal, musculoskeletal, autoimmune, or neurological disease; if they are taking 
thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive, or androgenic medications;  
3. have been pregnant or lactating within the past 12 months or are planning to become 
pregnant during the next 12 months;  
4. have participated in a planned exercise program or have exercised regularly (> 30 min/d 3 
days/wk) within the past three months;  
5. have taken any weight loss medications and/or dietary supplements that may affect muscle 
mass or body weight during the three month time period prior to beginning the study;   
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6. have any absolute or relative contraindications for exercise testing or prescription as outlined 
by the American College of Sports Medicine;  
 
The only exception to these selection criteria will be if the prospective participant has a medical 
condition or history that the participant’s personal physician feels is controlled and therefore 
would not be a limitation for them to participate in the study.   
 
Medical Clearance  
 
I medically clear ______________________ to participate as a participant in this study. 
  
Name   ___________________________  Date _________________ 
 
Signature  ___________________________ 
 
 
Diet Breakdown. 
 
 
Blood Samples. Participants will fast overnight for twelve (12) hours and then donate 
approximately 1 teaspoon (5 milliliters) of fasting blood once and 4 teaspoons (20 milliliters) of 
fasting blood 7 times throughout the duration of the 24 week study.  Blood samples will be 
obtained using standard phlebotomy procedures using standard sterile venipuncture of an 
antecubital vein by laboratory technician’s trained in phlebotomy in compliance with guidelines 
established by the Texas Department of Health and Human Services. The phlebotomists and lab 
technicians will wear personal protective clothing (gloves, lab coats, etc.) when handling blood 
Diet	
	
	
Kcals	
	
	
Macronutrients	
Diet	
Content	
(%)	
	
	
g/d	
	
	
Kcals/
d	
g/kg/d	
(90	kg)	
Curves	Complete	I	–Moderate	Carbohydrate	/		High	Protein	/	Low	Fat	Diet	(CC-I)	 	
	
1	Week	
	1,400	kcals/d	 	CHO	PRO	FAT	
	30	45	25	
	105	158	39	
	420	630	350	
	1.17	1.75	0.43	
	
	
23	Weeks	
	1,500	kcals/d	 	CHO	PRO	FAT	
	30	45	25	
	113	169	42	
	450	675	375	
	1.25	1.88	0.47	
Curves	Complete	II	–Carbohydrate	Restricted	/	High	Protein	/	High	Fat	Diet	(CC-II)	 	
	
1	Week	
	1,400	kcals/d	 	CHO	PRO	FAT	
	20	45	35	
	70	158	54	
	280	630	490	
	0.78	1.75	0.60	
	
	
23	Weeks	
	1,500	kcals/d	 	CHO	PRO	FAT	
	20	45	35	
	75	169	58	
	300	675	525	
	0.83	1.88	0.65	
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samples.  Participants will be seated in a phlebotomy chair.  Their arm will be cleaned with a 
sterile alcohol wipe and sterile gauze.  A standard rubber tourniquet will then be placed on the 
brachium.  An antecubital vein will be palpated and then a 23 gauge sterile needle attached to a 
plastic vacutainer holder will be inserted into the vein using standard procedures. Two serum 
separation vacutainer tubes (red tops) and one EDTA vacutainer tube (purple top) will be 
inserted into the vacutainer holder for blood collection in succession using multiple sample 
phlebotomy techniques.  Once samples are obtained, the vacutainer holder and needle will be 
removed.  The needle will be discarded as hazardous waste in a plastic sharps container.  The 
site of the blood draw will then be cleaned with a sterile alcohol wipe and gauze and a sterile 
Band-Aid will be placed on the site.  The blood collection tubes will be labeled and placed in a 
test tube rack for later analysis.    
 
Resting Energy Expenditure Assessment.  Resting energy expenditure assessments will be 
made according to standard protocols using the Parvo Medics TrueOne 2400 Metabolic 
Measurement System.  This will involve the participants lying down on an exam table, having a 
light blanket placed over them to keep warm and inserting ear plugs in their ears to reduce 
distractions.  A see through metabolic canopy will then be placed over their neck and head so 
that metabolic measurements can be obtained.  The participant will lie motionless without going 
to sleep for 15-minutes. Metabolic measurements will then be obtained to determine resting 
oxygen uptake and energy expenditure.   
 
Body Composition Assessments (BIA & DEXA).  Participants will undergo body composition 
tests in the ESNL.  Prior to each assessment, height will be measured using standard 
anthropometry and total body weight will be measured using a calibrated electronic scale with a 
precision of +/-0.02 kg.  Total body water will then be estimated using a Xitron 4200 Bioelectrical 
Impedance Analyzer (San Diego, CA) which measures bio-resistance of water and body tissues 
based on a minute low energy, high frequency current (500 micro-amps at a frequency of 50 
kHz) transmitted through the body. This analyzer is commercially available and has been used in 
the health care/fitness industry as a means to assess body composition and body water for over 
20 years.  The use of this device has been approved by the Food and Drug Administration (FDA) 
to assess total body water and the current to be used has been deemed safe. This is measured 
through four electrodes placed on the body: one electrode will be placed on the posterior surface 
of the right wrist, in between the radial and ulna styloid processes (wrist bones), another 
electrode will be placed on the posterior surface of the right hand at the distal base of the second 
metacarpal; the third electrode will be placed on the anterior surface of the right foot at the distal 
end of the first metatarsal.  Participants will lie on a table in the supine position and electrodes 
will be connected to the analyzer.  After they are connected, age, gender, weight, height, and 
activity level are entered into the unit by the technician.  After the unit has measured the 
resistance, which takes approximately 30 seconds, the unit then calculates total body water and 
body water percent.   
 
Body composition/bone density will then be determined using a calibrated Hologic Discovery W 
dual-energy x-ray absorptiometry (DEXA) by qualified personnel with limited x-ray technology 
training under the supervision of Richard B. Kreider, PhD, MX. The DEXA body composition test 
will involve having the participant lie down on their back in a standardized position in a pair of 
shorts/t-shirt or a gown.  A low dose of radiation will then scan their entire body for approximately 
six (6) minutes. The DEXA segments regions of the body (right arm, left arm, trunk, right leg, and 
left leg) into three compartments for determination of fat, soft tissue (muscle), and bone mass. 
Radiation exposure from DEXA for the whole body scan is approximately 1.5mR per scan. This 
is similar to the amount of natural background radiation a person would receive in one month 
while living in College Station, TX.  The maximal permissible x-ray dose for non-occupational 
exposure is 500 mR per year. Total radiation dose will be less than 5mR for the entire study.  
Since women of child bearing age may serve as subjects in this study, each subject will 
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complete a questionnaire related to their menstrual cycle timing, sexual activity, use of birth 
control pills, and desire to become pregnant (see attached).  DEXA tests will be performed within 
14-days of the onset of their period in menstruating women of child bearing age who do not use 
oral contraceptives according to NCRP and ARP radiology standards in order to reduce the 
possibility of exposure of an unknown fetus to radiation.   
 
Fat layer thickness and localized muscle layer thickness will then be determined using a 
BodyMetrix BX2000 utilizing ultrasound technology.  Seven sites will be used including the 
chest, axilla, tricep, scapula, waist, hip and thigh.  When used with BodyView software it can be 
used to estimate total body fat percentage.         
 
Strength Tests.  All strength/exercise tests will be supervised by certified lab assistants 
experienced in conducting strength tests using standard procedures.  Strength testing will 
involve the participants performing one repetition maximum (1 RM) on the isotonic bench press 
and the Nebula Fitness Olympic Power Station.  Participants will warm-up (2 sets of 8 – 10 
repetitions at approximately 50% of anticipated maximum) on the bench press.  Participants will 
then perform successive 1 RM lifts starting at about 70% of anticipated 1RM and increasing by 5 
– 10 lbs until they reaches their 1RM.  Participants will then rest for 10 minutes and warm-up on 
the Nebula 45° Leg press (2 sets of 8 – 10 repetitions at approximately 50% of anticipated 
maximum).  They will then perform successive 1RM lifts on the leg press starting at about 70% 
of anticipated 1RM and increasing by 10 – 25 lbs until reaching the subject’s 1RM.   
 
Cardiopulmonary Exercise Tests.  Cardiopulmonary exercise tests will be performed by 
trained exercise physiologists in accordance to standard procedures described by the American 
College of Sports Medicine’s (ACSM) Guidelines for Exercise Testing and Prescription.  This will 
involve preparing the participant’s skin s for placement of 10 ECG electrodes.  Electrode sites 
will be cleansed with a sterile alcohol gauze using a circular motion.  The site will be allowed to 
air dry or will be dried with a gauze pad.  Electrodes will then be placed on the right subclavicular 
fossa (RA), left subclavicular fossa (LA), right abdomen (RL), left abdomen (LL), 4th intercostals 
space at the right sternal border (V1), 4th intercostals space at the left sternal border (V2), 
equidistant between V2 and V4 (V3), 5th intercostal space at the midclavicular line (V4), 5th 
intercostal space at the anterior axillary line (V5), and 5th intercostals space at the axillarly line 
(V6) of the chest.  The participant will then be attached to an ECG.  Resting blood pressure, 
heart rate, and a 12-lead ECG will be obtained.  The exercise specialist will then review the 12-
lead ECG to ensure that no contraindications for exercise testing are apparent based on the 
ACSM guidelines.  Participants will then be seated on a treadmill.  A sterile mouthpiece attached 
to a head harness will be secured on them.   The participant will then have a nose clip placed on 
their nose.  Resting expired gases will be collected using the Parvo Medics 2400 TrueOne 
Metabolic Measurement System.  Once the participant is ready to begin the test protocol, they 
will be instructed to straddle the treadmill with both legs while the treadmill is turned on at a 
speed of 1.7 mph and at a 0% grade.  The participant will then use one foot to repeatedly swipe 
the belt in order to gauge the speed of the motion.  Once they are familiar with this speed, they 
will step onto the belt while still gripping the handrail with both hands.  Once the participant 
becomes comfortable walking on the treadmill, he/she will let go of the handrail and begin 
walking freely.  The participant will then perform a standard symptom-limited Bruce treadmill 
maximal exercise test using the following speeds and grades: 
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_____________________________________________________________________________ 
 Stage             Speed           Grade(%) 
 Duration(min.) 
_____________________________________________________________________________
  
 1     1.7    10  
 3 
 2     2.5    12  
 3 
 3     3.3    14  
 3 
 4     4.2    16  
 3 
 5     5.0    18  
 3 
 6     5.5    20  
 3 
 7     6.0    22  
 3 
_____________________________________________________________________________ 
 
The participant will be encouraged to exercise to their maximum unless they experiences clinical 
signs to terminate the exercise test as stated by the ACSM’s Guidelines for Exercise Testing and 
Prescription (i.e., angina, dyspnea, dizziness, a decline in systolic blood pressure, dangerous 
dysrhythmias (increasing or multi-form premature ventricular contractions, ventricular 
tachycardia, supraventricular tachycardia, new atrial fibrillation, or A-V block), lightheadedness, 
confusion, ataxia, cyanosis, nausea, excessive rise in systolic blood pressure over 250 mmHg or 
diastolic over 120 mmHg, chronotropic impairment, failure of the monitoring system, or other 
signs or symptoms for terminating the test).  The test may also be terminated at the request of 
the participant.  Once the exercise test is complete, the participant will observe a 3-6 minute 
active recovery period followed by a 3-6 minute seated recovery period.  The normal exercise 
time to maximum of the Bruce treadmill protocol for untrained women is typically about 9 minutes 
(near the completion of stage III or just entering stage IV).  Heart rate (HR), ECG tracings, and 
expired gases will be monitored continuously throughout the exercise test.   Blood pressure (BP) 
and ratings of perceived exertion (RPE) will be obtained toward the end of each stage.  
Participants will be asked to report any unusual signs or symptoms to the exercise specialists 
during the exercise test.  These tests will determine maximal aerobic capacity and anaerobic 
threshold to determine the effects of the exercise training on fitness and exercise capacity. 	
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APPENDIX H 
 
RADIATION CONSENT 
 
 
Texas A&M University: Exercise & Sport Nutrition Laboratory 
Trial:  Effects of Diet Type Selection Based on Response to a Carbohydrate 
Intolerance Questionnaire and Genetic Screening on Success to a Weight 
Loss and Exercise Program        
 
Radiation Exposure Questionnaire for Women of Child Bearing Age 
 
Radiation exposure may affect fetal development.  Although the DEXA test 
will only expose you to a small amount of radiation (1.5mR per scan), you 
should be aware that there is a possibility that if you become pregnant 
during the course of the study that the x-ray exposure may be harmful to 
the fetus. Therefore, it is important to conduct x-ray tests within 10-14 days 
of the start of a female’s menstrual cycle if the she is of child bearing age, 
sexually active, and/or is not taking birth control pills.  The following 
questionnaire must be completed so that we know when it is an appropriate 
time to conduct the DEXA body composition tests.  Please be assured that 
this information will be kept confidential within the limits permitted by law. 
 
Current Age?        _______            
Age of first period?       _______           
Date of last period?       _______             
Normal length of menstrual cycle?    _______ 
Do you use birth control pills?     _______ 
Are you pregnant or have a desire for pregnancy?  _______ 
 
Note:  If you happen to get pregnant during the course of this study, you 
must notify research assistants so that appropriate precautions can be 
made.     
 
I confirm that I have completed this questionnaire honestly and agree to 
notify researchers within the ESNL of any change in the length of my 
menstrual cycle and/or pregnancy status. 
 
 
____________________________          _________________________ 
Name        Date  
 
_____________________________              ________________________ 
Staff Signature      Date 
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APPENDIX I 
 
FOOD LOG 
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APPENDIX J 
 
EATING SATISFACTION SURVEY 
 
 
Texas	A&M	University:	Exercise	&	Sport	Nutrition	Laboratory	Trial:	 	 Effects	 of	 Diet	 Type	 Selection	 Based	 on	 Response	 to	 a	 Carbohydrate	 Intolerance	Questionnaire	and	Genetic	Screening	on	Success	to	a	Weight	Loss	and	Exercise	Program									
     
Eating Satisfaction Survey 
	
NAME	________________________________	 Date	__________________________________	
	
INSTRUCTIONS		Circle	the	number	or	dot	between	numbers	that	best	indicates	the	degree	you	have	felt	the	following	symptoms	during	the	last	week:		
Appetite		None																														Low																												Moderate																										High																											Severe	0	.	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	2	.	.	.	.	.	.	.	.	.	3.	.	.	.	.	.	.	.	.4.	.	.	.	.	.	.	.	.5.	.	.	.	.	.	.	.	.6.	.	.	.	.	.	.	.	.7.	.	.	.	.	.	.	.	.8.	.	.	.	.	.	.	.	.9.	.	.	.	.	.	.	.	.10		
Hunger		None																														Low																												Moderate																										High																											Severe	0	.	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	2	.	.	.	.	.	.	.	.	.	3.	.	.	.	.	.	.	.	.4.	.	.	.	.	.	.	.	.5.	.	.	.	.	.	.	.	.6.	.	.	.	.	.	.	.	.7.	.	.	.	.	.	.	.	.8.	.	.	.	.	.	.	.	.9.	.	.	.	.	.	.	.	.10		
Satisfaction	from	Food		None																														Low																												Moderate																										High																											Severe	0	.	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	2	.	.	.	.	.	.	.	.	.	3.	.	.	.	.	.	.	.	.4.	.	.	.	.	.	.	.	.5.	.	.	.	.	.	.	.	.6.	.	.	.	.	.	.	.	.7.	.	.	.	.	.	.	.	.8.	.	.	.	.	.	.	.	.9.	.	.	.	.	.	.	.	.10		
Feeling	of	Fullness		None																														Low																												Moderate																										High																											Severe	0	.	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	2	.	.	.	.	.	.	.	.	.	3.	.	.	.	.	.	.	.	.4.	.	.	.	.	.	.	.	.5.	.	.	.	.	.	.	.	.6.	.	.	.	.	.	.	.	.7.	.	.	.	.	.	.	.	.8.	.	.	.	.	.	.	.	.9.	.	.	.	.	.	.	.	.10		
Amount	of	Energy		None																														Low																												Moderate																										High																											Severe	0	.	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	2	.	.	.	.	.	.	.	.	.	3.	.	.	.	.	.	.	.	.4.	.	.	.	.	.	.	.	.5.	.	.	.	.	.	.	.	.6.	.	.	.	.	.	.	.	.7.	.	.	.	.	.	.	.	.8.	.	.	.	.	.	.	.	.9.	.	.	.	.	.	.	.	.10		
Overall	Quality	of	Diet		None																														Low																												Moderate																										High																											Severe	0	.	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	2	.	.	.	.	.	.	.	.	.	3.	.	.	.	.	.	.	.	.4.	.	.	.	.	.	.	.	.5.	.	.	.	.	.	.	.	.6.	.	.	.	.	.	.	.	.7.	.	.	.	.	.	.	.	.8.	.	.	.	.	.	.	.	.9.	.	.	.	.	.	.	.	.10	
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APPENDIX K 
 
ROSENBERG SELF-ESTEEM SCALE 
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APPENDIX L 
 
SOCIAL PHYSICAL ANXIETY SCALE 
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APPENDIX M 
 
BODY IMAGE 
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APPENDIX N 
 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
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